---
document_datetime: 2023-09-21 18:53:16
document_pages: 90
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/trimbow-epar-public-assessment-report_en.pdf
document_name: trimbow-epar-public-assessment-report_en.pdf
version: success
processing_time: 51.5697647
conversion_datetime: 2025-12-19 22:59:28.108284
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

18 May 2017 EMA/CHMP/289952/2017 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Trimbow

International non-proprietary name: beclometasone / formoterol / glycopyrronium bromide

Procedure No. EMEA/H/C/004257/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                    | 7                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................7       |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                          | ........................................................8                                                 |
| 2. Scientific discussion................................................................................                    | 9                                                                                                         |
| 2.1. Introduction                                                                                                           | ........................................................................................................9 |
| Problem statement                                                                                                           | .....................................................................................................9    |
| 2.2. Quality aspects                                                                                                        | .................................................................................................. 12     |
| 2.2.1. Introduction....................................................................................................     | 12                                                                                                        |
| 2.2.2. Active Substance.............................................................................................        | 13                                                                                                        |
| 2.2.3. Finished Medicinal Product................................................................................           | 18                                                                                                        |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                          | 20                                                                                                        |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                   | ...................... 20                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................                        | 20                                                                                                        |
| 2.3. Non-clinical aspects............................................................................................       | 20                                                                                                        |
| 2.3.1. Introduction....................................................................................................     | 20                                                                                                        |
| 2.3.2. Pharmacology.................................................................................................        | 21                                                                                                        |
| 2.3.3. Pharmacokinetics ............................................................................................        | 24                                                                                                        |
| 2.3.4. Toxicology......................................................................................................     | 26                                                                                                        |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................                   | 35                                                                                                        |
| 2.3.6. Discussion on non-clinical aspects                                                                                   | ..................................................................... 36                                  |
| 2.3.7. Conclusion on non-clinical aspects.....................................................................              | 40                                                                                                        |
| 2.4. Clinical aspects                                                                                                       | .................................................................................................. 41     |
| 2.4.1. Introduction....................................................................................................     | 41                                                                                                        |
| 2.4.2. Pharmacokinetics                                                                                                     | ............................................................................................ 45           |
| Dose proportionality and time dependencies                                                                                  | ................................................................ 47                                       |
| 2.4.3. Pharmacodynamics..........................................................................................           | 48                                                                                                        |
| 2.4.4. Discussion on clinical pharmacology...................................................................               | 48                                                                                                        |
| 2.4.5. Conclusions on clinical pharmacology.................................................................                | 49                                                                                                        |
| 2.5. Clinical efficacy                                                                                                      | .................................................................................................. 49     |
| 2.5.1. Dose-response studies .....................................................................................          | 49                                                                                                        |
| 2.5.2. Main clinical studies.........................................................................................       | 50                                                                                                        |
| Results.................................................................................................................... | 57                                                                                                        |
| Clinical studies in special populations ..........................................................................          | 68                                                                                                        |
| Supportive study(ies)................................................................................................       | 69                                                                                                        |
| 2.5.3. Discussion on clinical efficacy............................................................................          | 69                                                                                                        |
| 2.5.4. Conclusions on clinical efficacy..........................................................................           | 72                                                                                                        |
| 2.6. Clinical safety                                                                                                        | .................................................................................................... 72   |
| Patient exposure                                                                                                            | ...................................................................................................... 73 |

<div style=\"page-break-after: always\"></div>

| Serious adverse events and deaths.............................................................................           | 76                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Laboratory findings...................................................................................................   | 77                                                                                               |
| Safety in special populations......................................................................................      | 77                                                                                               |
| Immunological events ...............................................................................................     | 78                                                                                               |
| Safety related to drug-drug interactions and other interactions ......................................                   | 78                                                                                               |
| Discontinuation due to AES........................................................................................       | 78                                                                                               |
| 2.6.1. Discussion on clinical safety..............................................................................       | 79                                                                                               |
| 2.6.2. Conclusions on the clinical safety ......................................................................         | 80                                                                                               |
| 2.7. Risk Management Plan........................................................................................        | 80                                                                                               |
| 2.8. Pharmacovigilance                                                                                                   | ............................................................................................. 82 |
| 3. Benefit-Risk Balance.............................................................................                     | 82                                                                                               |
| 3.1. Therapeutic Context .......................................................................................         | 82                                                                                               |
| 3.1.1. Disease or condition ........................................................................................     | 82                                                                                               |
| 3.1.2. Available therapies and unmet medical need.......................................................                 | 82                                                                                               |
| 3.1.3. Main clinical studies.........................................................................................    | 83                                                                                               |
| 3.2. Favourable effects..............................................................................................    | 83                                                                                               |
| 3.3. Uncertainties and limitations about favourable effects.............................................                 | 84                                                                                               |
| 3.4. Unfavourable effects...........................................................................................     | 84                                                                                               |
| 3.5. Uncertainties and limitations about unfavourable effects .........................................                  | 85                                                                                               |
| 3.6. Effects Table...................................................................................................... | 85                                                                                               |
| 3.7. Benefit-risk assessment and discussion.................................................................             | 87                                                                                               |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                   | 87                                                                                               |
| 3.7.2. Balance of benefits and risks ............................................................................        | 88                                                                                               |
| 3.7.3. Additional considerations on the benefit-risk balance ...........................................                 | 89                                                                                               |
| 3.8. Conclusions.......................................................................................................  | 89                                                                                               |
| 4. Recommendations.................................................................................                      | 89                                                                                               |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

Adverse drug reaction

AE

Adverse event

AEMPS

Spanish Agencia Española de Medicamentos y Productos Sanitarios

ANCOVA

Analysis of covariance

ANOVA

Analysis of variance

AUC

Area under the concentration-time curve

AUC0-∞

Area under the curve extrapolated to infinity

AUC0-t

Area under the curve calculated between time 0 and the last quantifiable time point

AUC0-t,ss

Area under the curve calculated between time 0 and the last quantifiable time point at steady-state

B17MP

Beclometasone-17-monopropionate

B21MP

Beclometasone-21-monopropionate

BDI

Baseline dyspnoea index

BDP

Beclometasone dipropionate

BfArM

Bundesinstitut für Arzneimittel und Medizinprodukte

bid

Twice daily

BMI

Body mass index

BP

Blood pressure

bpm

Beats per minute

CAT

COPD assessment test

CHMP

CEP

CCS

Committee for Medicinal Products for Human Use

Certificate of Suitability

Container Closure System

CI

Confidence interval

CL

Total clearance

CL/F

Total systemic clearance

CLr

Renal clearance

CLrss

Renal clearance at steady-state

Cmax

Maximum plasma concentration

Cmax,ss

Maximum plasma concentration at steady-state

Cmin

Minimum plasma concentration

COPD

Chronic obstructive pulmonary disease

CRF

Case report form

CS

Clinically significant

CSR

Clinical study report

DBP

Diastolic blood pressure

DD

Delivered dose

DDI

Drug-drug interaction

DPI

Dry powder inhaler

ECG

Electrocardiogram

eCRF

EC

Electronic case report form

European Community

EMA

European Medicines Agency

E-RS

EDQM

Exacerbations of chronic pulmonary disease tool-respiratory symptoms

European Directorate for the Quality of Medicines

EU

European Union

F

Bioavailability

F2

Fraction of the dose absorbed by a zero-order process

FDC

Fixed dose combination

FEV1

Forced expiratory volume in 1 second

FF

Formoterol fumarate

FPM

Fine particle mass

FVC

Forced vital capacity

GB

GC

Glycopyrronium bromide

Gas chromatography

GCP

Good Clinical Practice

GFR

Glomerular filtration rate

GOLD

Global Initiative for Chronic Obstructive Lung Disease

γGT

HCl

Gamma-glutamyltransferase

Hydrochloric acid

HFA

HPLC

Hydroxyfluoroalkane

High Performance Liquid Chromatography

HR

Heart rate

IC

Inspiratory capacity

IC50

Half maximal inhibitory concentration

ICH

International Conference on Harmonisation

ICS

IR

Inhaled corticosteroid

Infra-red

IRS

Interactive response system

ITT

Intent-to-treat

i.v.

Intravenous

Ka

Absorption rate constant

KF

KF

Formation rate constant

Karl Fisher

LABA

Long-acting β2-agonist

LAMA

Long-acting muscarinic antagonist

LC-MS/MS

Liquid chromatography-mass spectrometry/mass spectrometry

LLOQ

Lower limit of quantification

LOCF

Last observation carried forward

MAA

Marketing authorisation application

MACE

Major adverse cardiovascular event

MATE1

Multidrug and toxin extrusion protein 1

MCID

Minimal clinically important difference

MD

Metered dose

MEB

Medicines Evaluation Board

MHRA

Medicines and Healthcare products Regulatory Agency

MMAD

Mass median aerodynamic diameter

MMRM

Mixed model for repeated measures

NA

Not applicable

NCS

Non-clinically significant

NGI

NIRS

Next generation impactor

Near infra-red spectroscopy

OCT1

Organic cationic transporter 1

OCT2

Organic cationic transporter 2

od

Once daily

<div style=\"page-break-after: always\"></div>

OIP

pMDI

Orally inhaled products

pressurised metered dose inhaler

PD

Pharmacodynamic

PE

Ph.Eur.

Point estimate

European Pharmacopoeia

PK

Pharmacokinetic

pMDI

Pressurised metered dose inhaler

PP

PQRI

Per protocol

Product Quality Research Institute

PT

QbD

Preferred term

Quality by Design

QoL

Quality of life

QTcF

Fridericia-corrected QT interval

QTcP

Population-corrected QT interval

Rac

Accumulation ratio

RI

Renal impairment

SABA

Short-acting β 2-agonist

SAE

Serious Adverse Event

SBP

Systolic blood pressure

SD

Standard deviation

sGaw

Specific airway conductance

SGRQ

St George's Respiratory Questionnaire

SmPC

Summary of Product Characteristics

SOC

System organ class

SS

Steady-state

TDI

Transition dyspnoea index

TEAE

Treatment-emergent adverse event

tmax

Time corresponding to Cmax

t max,ss

Time corresponding to Cmax at steady-state

TQT

Thorough QT

ULOQ

Upper limit of quantification

vs.

Versus

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Chiesi Farmaceutici S.p.A. submitted on 30 September 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for TRIMBOW, through the centralised procedure under Article 3 (2)(b) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 19 November 2015. The eligibility to the centralised procedure under Article 3(2)(b) of Regulation (EC) No 726/2004 was based on demonstration of interest of patients at Community level.

The applicant applied for the following indication:

Trimbow is indicated for the symptomatic treatment and reduction of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD) with airflow limitation (FEV1 &lt; 50% predicted normal) and who are at risk of exacerbations

-despite regular therapy with both inhaled corticosteroids and bronchodilators, or with bronchodilators alone; or

-eligible for treatment with inhaled corticosteroids, long-acting beta2-agonists and long-acting muscarinic antagonists triple therapy.

## The legal basis for this application refers to:

Article 10(b) of Directive 2001/83/EC - relating to applications for new fixed combination products.

The application submitted is for a new fixed combination medicinal product and is composed of administrative information, complete quality data  and with appropriate own applicant's non-clinical and clinical data.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/0001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific Advice

The applicant received Scientific Advice from the CHMP on 21 February 2013 and 10 April 2013. The Scientific Advice pertained to non-clinical and clinical aspects of the development and on the Phase III studies' design as part of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Harald Enzmann Co-Rapporteur:   David Lyons

- The application was received by the EMA on 30 September 2016.
- The procedure started on 27 October 2016.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 15 January 2017. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 13 January 2017. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 19 January 2017.
- During the meeting on 23 February 2017, the CHMP agreed on the consolidated List of Questions to be sent to the applicant.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 15 March 2017.
- The following GCP inspections were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product:
- -A GCP inspection at one clinical investigator site in Italy between 06 February 2017 and 10 February 2017.
- -A GCP inspection at one clinical investigator site in Czech Republic between 20 February 2017 and 24 February 2017.
- -A GCP inspection at the Sponsor site between 20 March 2017 and 24 March 2017.
- The outcome of the inspections carried out was issued on 8 May 2017 (Integrated Inspection Report).The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 26 April 2017.
- During the PRAC meeting on 5 May 2017, the PRAC agreed on the PRAC Assessment Overview and Advice to CHMP.
- During the meeting on 15-18 May 2017, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Trimbow on 18 May 2017.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## Problem statement

This application is in adult patients with chronic obstructive pulmonary disease (COPD) with specific risk factors.

COPD is defined as 'a common preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases'  according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) document (updated in 2017) (GOLD 2017).

COPD is a major public health problem and is the fourth leading cause of death in the world, with increasing prevalence and mortality predicted in the coming decades. COPD is projected to be the third leading cause of death by 2020.

The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airway disease (e.g.  obstructive  bronchiolitis)  and  parenchymal  destruction  (emphysema).  The  relative  contributions  vary from  person  to  person  and  evolve  at  different  rates  over  time.  Chronic  inflammation  causes  structural changes,  narrowing  of  the  small  airways  and  destruction  of  the  lung  parenchyma  leading  to  the  loss  of alveolar attachments to the small airways and decreased lung elastic recoil.

The main risk factor for COPD is tobacco smoking. However, other environmental exposures such as biomass fuel exposure and air pollution may also contribute. Host factors (e.g. genetic abnormalities, abnormal lung function and accelerated aging) predispose individuals to develop COPD.

COPD  is  characterised  by  cough,  dyspnoea  on  exertion  or  even  at  rest,  with  a  consequent  reduction  of physical  activity  and  deterioration  of  quality  of  life  (QoL)  (GOLD  2016).  The  inflammatory  response contributes to small airways disease (e.g. obliterative bronchiolitis) and emphysema, which in turn reduce the elastic recoil of the lungs leading to collapse and obstruction of the small airways during exhalation. Systemic features  of  COPD  are  very  common  (Barnes  PJ  and  Celli  BR  2009)  and  their  evaluation  allows  a  more accurate prediction of mortality risk and comorbidity risk than lung function alone ( Cote CG et al. 2007, De Torres JP et al. 2009, Puhan MA et al. 2009 ).

During  the  natural  course  of  COPD,  the  majority  of  patients  develop  acute  episodes  of  worsening  of symptoms that differ from the day to day variations, and may require modifications in therapy ( GOLD 2016). These  episodes  are  referred  to  as  exacerbations.  COPD  exacerbations  are  important  because  they  are associated with accelerated FEV1 decline ( Donaldson GC et al. 2002 ), significant morbidity, healthcare cost and mortality ( Celli BR and Barnes PJ 2007 ).

According to the GOLD document, the assessment of the disease severity should take into account various aspects of the disease such as symptoms, degree of airflow limitation, exacerbation risk and comorbidities. Based on the overall disease severity, COPD patients can be divided into the following four groups:

<div style=\"page-break-after: always\"></div>

- Group A (i.e. patients with low risk [of future events such as exacerbations, hospital admissions or death] and less symptoms);
- Group B (i.e. patients with low risk and more symptoms);
- Group C (i.e. patients with high risk and less symptoms);
- Group D (i.e. patients with high risk and more symptoms).

In COPD, the therapeutic goal is to reduce symptoms, reduce the frequency and severity of exacerbations and improve health status and exercise tolerance (GOLD 2016). The mainstay of treatment for symptomatic relief  in  stable  COPD  are  bronchodilators  and,  as  the  disease  worsens,  ICS  and  phosphodiesterase  4inhibitors as anti-inflammatory agents are recommended in combination with long acting bronchodilators.

The main classes of bronchodilators used in COPD are β2 agonist and anticholinergic agents. β2 agonists lead to relaxation and bronchodilation by stimulating the β2-adrenoreceptor on the airway smooth muscle. Short acting β2 agonists (SABAs; e.g. salbutamol and fenoterol) are used for acute bronchodilation and relief of symptoms. LABAs (e.g. salmeterol, FF and indacaterol) exhibit a prolonged duration of effect of 12 hours or more,  and  are  used  to  achieve  more  sustained  symptom  control.  Anti  cholinergics  (e.g.  the  short-acting ipratropium  bromide,  and  the  long-acting  GB  and  Tiotropium)  exert  their  effect  by  blocking  the  effect  of acetylcholine on the muscarinic receptors on the airway smooth muscles.

ICS treatment reduces the inflammation associated with COPD. When compared to placebo, long term use of ICS reduces the mean rate of exacerbations and slows the decline in QoL, as measured by the St George's Respiratory  Questionnaire  (SGRQ).  Response  to  ICS  is  not  predicted  by  bronchodilator  reversibility  or bronchial hyper-responsiveness.

Although up to 20% of patients with moderate airflow limitation may experience frequent exacerbations, the risk  of  exacerbations  significantly  increases  in  patients  with  severe  and  very  severe  airflow  limitation.  In COPD patients from Groups C and D (i.e. with high risk of exacerbation and with less or more symptoms, respectively), a fixed combination of ICS with a LABA or a LAMA alone is recommended as first choice of treatment (GOLD 2016).

When patients remain symptomatic with these therapies, the combination of all three classes (ICS, LABA and LAMA)  is  recommended.  Furthermore,  several  studies  have  shown  that  triple  therapies  consisting  of  two bronchodilators (such as a combination LABA and LAMA) and an ICS resulted in better efficacy in terms of lung  function  improvement  and  symptom  control  compared  to  bronchodilator  monotherapies  or  ICS/LABA FDC (Singh D et al. 2008, Aaron SD et al. 2007, Welte T et al. 2009, Short PM et al. 2012). This enhanced effect is due to the fact that ICS, LABA and LAMA work together either synergistically or additively.

The mechanism of action of CHF 5993 pMDI includes both the bronchodilatory and anti inflammatory action mentioned  above.  In  CHF  5993  pMDI,  both  FF  and  GB  induce  bronchodilation,  which  is  central  for  the symptomatic  treatment  of  COPD.  Alongside  airflow  limitation,  inflammation  also  plays  a  role  in  the pathophysiology of COPD. The effects of corticosteroids on the inflammatory pathway of COPD are subject of ongoing debate. However, when used in combination, ICSs such as BDP may increase the number of β2adrenoceptors  while  β2-agonists  may  induce  glucocorticoid  receptor  nuclear  translocation  and  therefore provide an additive/synergistic effect.

International documents and guidelines (e.g. GOLD2016) recommend the use of free (i.e. extemporary using different inhalers) triple combinations of ICS, LABA and LAMA for the treatment of severe and symptomatic COPD patients.

<div style=\"page-break-after: always\"></div>

## About the product

TRIMBOW (hereafter referred to as CHF 5993) is a novel triple combination of an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). The product is a fixed dose combination  of  beclometasone  dipropionate  (BDP),  formoterol  fumarate  (FF)  and  glycopyrronium  bromide (GB)  intended  for  oral  inhalation.  Trimbow  is  formulated  as  a  hydroxyfluoroalkane  (HFA)  solution  to  be delivered via a pressurised metered dose inhaler (pMDI) with a nominal dose per actuation of BDP, FF and GB of 100 µg, 6 µg and 12.5 µg, respectively.

A FDC consisting of BDP 100 µg and FF 6 µg (Foster and related names, also referred to as CHF 1535) has been developed by the applicant. CHF 1535 pMDI has been nationally approved in Europe first in asthma in 2006 and then, in 2014 via a Type II variation in COPD.

The inhalers used for CHF 5993 pMDI and for CHF 1535 pMDI are similar.

The formulation of CHF 5993 pMDI was developed with a high extrafine inhaled particle fraction (i.e. mass median aerodynamic diameter [MMAD] around 1.1 µm), similar to that of CHF 1535 pMDI. The extrafine formulation allows a reduction to about half the equivalent dose of a conventional BDP aerosol.

GB inhalation  powder  has  been  approved  in  2012  in  Europe  for  maintenance  bronchodilator  treatment  to relieve symptoms in adult patients with COPD. To support the development of CHF 5993 pMDI, the applicant has developed a GB pMDI as a single agent, although the applicant does not intend to seek a marketing authorisation for this product in COPD and therefore did not perform a full clinical development. The proposed indication is:

Trimbow is indicated for the symptomatic treatment and reduction of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD) with airflow limitation (FEV1 &lt; 50% predicted normal) and who are at risk of exacerbations

-despite regular therapy with both inhaled corticosteroids and bronchodilators, or with bronchodilators alone; or

-eligible for treatment with inhaled corticosteroids, long-acting beta2-agonists and long-acting muscarinic antagonists triple therapy.

The approved indication is:

Maintenance  treatment  in  adult  patients  with  moderate  to  severe  chronic  obstructive  pulmonary  disease (COPD)  who  are  not  adequately  treated  by  a  combination  of  an  inhaled  corticosteroid  and  a  long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1)

The posology requested is two inhalations of CHF 5993 pMDI 100/6/12.5 micrograms twice daily (i.e. total daily dose: 400 µg BDP, 24 µg FF, 50 µg GB).

## Type of Application and aspects on development

This application is submitted as a new fixed dose combination referring to Article 10b of Directive 2001/83/EC via  the  optional  scope  of  the  Centralised  Procedure  according  to  Article  3(2)(b)  (significant  innovation  or interest of patients at Community level) of Regulation (EC) No. 726/2004.

<div style=\"page-break-after: always\"></div>

The  clinical  development  programme  of  CHF  5993  pMDI  was  conducted  according  to  the  following  CHMP guidelines:

- -CHMP/EWP/240/95 Rev. 1, February 2009: Guideline on clinical development of fixed combination medicinal products;
- -EMA/CHMP/483572/2012, 21 June 2012: Guideline on clinical investigations of medicinal products in the treatment of Chronic Obstructive Pulmonary Disease (COPD);
- -CPMP/EWP/4151/00 Rev. 1, January 2009: Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled  products  for  use  in  the  treatment  of  Asthma  and  Chronic  Obstructive  Pulmonary  Disease (COPD) in adults and for use in the treatment of asthma in children and adolescents.

Advice was received from three National Agencies (AEMPS [2010], MHRA [2011, 2012] and MEB [2012]) in the clinical development of CHF 5993 pMDI in COPD.

In  addition,  in  November 2012 the  applicant  sought  advice  from  the  EMA  (EMA/CHMP/SAWP/65480/2013, Clarification letter EMA/226787 /2013), mainly on clinical/clinical pharmacology aspects of the development and on the Phase III study designs. In addition, the following development aspects were discussed: clinical package for GB and duration of the GB dose finding studies; wording of the target indication; cardiac safety monitoring in Phase III and waiver from a Thorough QT (TQT) study; clinical approach to address special populations; drug-drug interaction (DDI) studies; interpretation of in vivo data regarding the characterisation of a spacer device.

Germany and Ireland  have  given  advices  in  their  position  as  appointed  Rapporteur/Co-Rapporteur  in  July 2016.

In summary, in line with the FDC guidelines, the development of TRIMBOW pMDI in COPD is based on the potential advantage of obtaining the following:

- An improvement of the benefit/risk profile by demonstration of better efficacy of CHF 5993 pMDI vs. Foster pMDI with a similar acceptable safety profile (step-up-indication);
- A  simplification  of  the  therapy,  as  the  three  active  components  are  administered  with  one  dose regimen in a single inhaler, whereas the current triple therapy for COPD is often achieved with two different inhalers usually at two different dose regimens (twice daily for the ICS/LABA combination and once daily for the LAMA component) (substitution indication).

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product, Trimbow (also referred to as CHF 5993), is presented as a pressurised inhalation solution containing beclometasone dipropionate anhydrous (BDP), formoterol fumarate dihydrate (FF) and glycopyrronium bromide (GB) as active substances.

Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms of glycopyrronium bromide).

<div style=\"page-break-after: always\"></div>

Each metered dose (the dose leaving the valve of the inhaler) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms glycopyrronium bromide).

Other ingredients are: ethanol anhydrous, hydrochloric acid and norflurane (propellant).

The product is available in a pressurised container (coated aluminium), with a metering valve. The pressurized container is inserted in a plastic inhaler which incorporates a mouthpiece and a dose counter (60 actuations or 120 actuations per pressurised container) or dose indicator (180 actuations per pressurised container) and is provided with a polypropylene mouthpiece cap, as described in Section 6.5 of the SmPC.

## 2.2.2. Active Substance

## Beclometasone dipropionate, anhydrous

## General information

The chemical name of beclometasone dipropionate is [2-[(6 S ,9 R ,16 R )-9-chloro-6-fluoro-11-hydroxy10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6 H -cyclopenta[a]phenanthren-17-yl]-2oxoethyl] 2,2-dimethylpropanoate corresponding to the molecular formula C28H37ClO7. It has a relative molecular mass of 521.1 g/mol and the following structure:

<!-- image -->

## Figure 1 Molecular structure of beclometasone dipropionate, anhydrous.

The active substance is a white or almost white, crystalline powder, practically insoluble in water, freely soluble in acetone, sparingly soluble in 96% ethanol. The active substance exhibits stereoisomerism due to the presence of eight asymmetric carbon atoms.

Since the starting material has a fixed stereochemistry (natural configuration), there are hindrance effects and the relevant reactions are stereospecific, it has been demonstrated that the process gives BDP with a fixed stereochemistry.

Enantiomeric purity is controlled routinely by specific optical rotation.

Limited information on polymorphism has been provided for beclometasone dipropionate. This is acceptable as the active substance is in solution in the finished product.

As there is a monograph of beclometasone dipropionate in the European Pharmacopoeia, the proposed manufacturers of the active substance have been granted a Certificate of Suitability of the European

<div style=\"page-break-after: always\"></div>

Pharmacopoeia (CEP) for beclometasone dipropionate which have been provided within the current Marketing Authorisation Application.

## Manufacture, characterisation and process controls

The information regarding manufacturing process steps and in-process controls, characterisation, control of materials and of critical steps and intermediates, manufacturing process development and packaging material is covered by the CEPs. The relevant information has been assessed by the EDQM before issuing the Certificates of Suitability.

## Specification

The active substance specification includes tests for appearance, identity (IR, chlorides reaction, loss on drying, NIRS), specific optical rotation, loss on drying (Ph.Eur.), related substances (HPLC), assay (HPLC.), residual solvents (dichlorometane and ethyl acetate) (GC), density (Ph.Eur.) and particle size (laser diffraction).

The proposed specification for beclometasone dipropionate complies with the specification and test methods of its Ph. Eur. monograph.

Batch analyses of three representative batches of beclometasone dipropionate anhydrous from each of the proposed active substance manufacturers have been provided. The results are within the specifications and consistent from batch to batch.

The holders of the CEPs have declared the absence of the use of material of human or animal origin in the manufacture of beclometasone dipropionate, anhydrous.

## Stability

A re-test period of 5 years at 25 ºC / 60% RH if stored, protected from light, in a double polyethylene bag placed into an aluminium box is stated on the CEP for the active substance sourced from one supplier.

Primary packaging material and a re-test period have not been stated on the CEP from the alternative supplier.

The following parameters were tested: appearance, identification, loss on drying, impurities, assay and microbiological tests. All tested parameters were within the specification. No trends were observed.

The stability results indicate that the active substance manufactured by the alternative supplier is sufficiently stable. The stability results justify the proposed retest period of 5 years at 25 ºC / 60% RH in the proposed container.

<div style=\"page-break-after: always\"></div>

## Formoterol fumarate dihydrate

## General information

The chemical name of formoterol fumarate dihydrate is N -[2-Hydroxy-5-[(1 RS )-1-hydroxy-2-[[(1 RS -2-(4methoxy-phenyl)-1-methylethyl] amino]ethyl]phenyl] formamide (E)-butenedioate dihydrate corresponding to the molecular formula C42H56N4O14. It has a relative molecular mass 840.91 g/mol and the following structure:

Figure 2 Molecular structure of formoterol fumarate, dihydrate

<!-- image -->

The active substance is a white, almost-white or slightly yellow crystalline powder. It is slightly soluble in water and in isopropyl alcohol; soluble in methyl alcohol; freely soluble in dimethyl sulphoxide and acetic acid.

Formoterol presents two asymmetric carbons, so four possible isomers exist, forming two racemates. The commercial formoterol is a racemic mixture of R , R (-) and S , S (+) enantiomers which is routinely ensured by a test for specific optical rotation. The content of diastereoisomers R*S* is controlled in the active substance specification in line with the Ph. Eur. monograph.

Limited information on polymorphism has been provided for formoterol fumarate dihydrate. This is acceptable as the active substance is in solution in the finished product.

As there is a monograph of formoterol fumarate dihydrate in the European Pharmacopoeia, the manufacturers of the active substance have been granted a Certificate of Suitability of the European Pharmacopoeia (CEP) for formoterol fumarate dihydrate which have been provided within the current Marketing Authorisation Application.

## Manufacture, characterisation and process controls

The information regarding manufacturing process steps and in-process controls, characterisation, control of materials and of critical steps and intermediates, manufacturing process development and packaging material is covered by the CEPs. The relevant information has been assessed by the EDQM before issuing the Certificates of Suitability.

<div style=\"page-break-after: always\"></div>

## Specification

The active substance specification includes tests for appearance, identity (IR, NIRS), specific optical rotation (Ph.Eur.), pH (Ph.Eur.), water content (KF), Impurity I (HPLC), related substances (HPLC), residual solvents (GC), particle size distribution (laser diffraction) and palladium (plasma emission).

The proposed specification for formoterol fumarate, as presented in Table 2 below, complies with the specifications and test methods of its Ph. Eur. monograph.

Batch analyses of three representative batches of formoterol fumarate dihydrate from each of the proposed active substance manufacturers have been provided. The results are within the specifications and consistent from batch to batch.

The holders of the CEPs have declared the absence of the use of material of human or animal origin in the manufacture of formoterol fumarate dihydrate.

## Stability

For formoterol fumarate dihydrate sourced from one supplier a re-test period of 48 months is stated on the CEP.

Neither a re-test period nor packaging materials are mentioned on the CEP for FF sourced from the alternative supplier.

For the alternative supplier, stability results on appearance, water, assay and related substances justify the proposed retest period of 5 years at 25°C/ RH 60% in the proposed container.

## Glycopyrronium bromide

## General information

The chemical name of glycopyrronium bromide is (3 RS )-3-[(2 RS )-(2-cyclopentyl-2-hydroxy-2phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide corresponding to the molecular formula C19H28BrNO3. It has a relative molecular mass 398.33 g/mol and the following structure:

<!-- image -->

## Figure 3 Molecular structure of glycopyrronium bromide

The active substance is a white or almost white, crystalline powder; freely soluble in water, soluble in ethanol (96%), very slightly soluble in methylene chloride. There are two asymmetric carbons in the molecule. The

<div style=\"page-break-after: always\"></div>

product is a 50/50% mixture of the enantiomers. Thus, the product is not optically active. The diastereoisomers purity is controlled in the active substance specification in line with the Ph. Eur. monograph.

Limited information on polymorphism has been provided for glycopyrronium bromide. This is acceptable as the active substance is in solution in the finished product.

As there is a monograph of glycopyrronium bromide in the European Pharmacopoeia, the manufacturers of the active substance have been granted a Certificate of Suitability of the European Pharmacopoeia (CEP) for glycopyrronium bromide which have been provided within the current Marketing Authorisation Application.

## Manufacture, characterisation and process controls

The information regarding manufacturing process steps and in-process controls, characterisation, control of materials and of critical steps and intermediates, manufacturing process development and packaging material is covered by the CEPs. The relevant information has been assessed by the EDQM before issuing the Certificates of Suitability.

## Specification

The active substance specification includes tests for: appearance, appearance of the solution, identity (IR, bromide reaction and NIRS), loss on drying (Ph.Eur.), acidity or alkalinity, sulphated ash (Ph.Eur.), assay (HPLC), diastereomer purity, organic impurities (HPLC), residual solvents (GC), related substances (HPLC), and residual methylbromide (GC-HS).

The proposed specification for glycopyrronium bromide, as presented in Table 3 below, complies with the specifications and test methods of its Ph. Eur. monograph.

Batch analyses of three representative batches of glycopyrronium bromide from each active substance manufacturer have been provided. The results are within the specifications and consistent from batch to batch.

The holders of the CEPs have declared the absence of the use of material of human or animal origin in the manufacture of glycopyrronium bromide.

## Stability

A re-test period of 60 months if stored at 25°C/ RH 60% in double polyethylene bags placed in a fibre drum is stated on the CEP from one supplier.

A re-test period of 5 years if stored at 25°C/ RH 60% in double polyethylene bags placed in a cardboard drum is stated on the CEP from the alternative supplier.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is a pressurised inhalation solution, also referred as pressurised metered dose inhaler (pMDI), containing three active substances (beclometasone dipropionate anhydrous, formoterol fumarate dihydrate and glycopyrronium bromide) dissolved in a medium consisting of norflurane (propellant) ethanol (co-solvent), hydrochloric acid (formulation stabiliser). Each nominal metered actuation supplies 100 µg BDP, 6 µg, FF and 12.5 µg GB corresponding to 87.4 µg, 5.2 µg and 10.9 µg, as delivered dose, respectively.

Three presentations are proposed, namely: 60, 120 and 180 actuations/container (also referred as can or canister).

The aim of the pharmaceutical development was to develop a solution formulation containing beclometasone dipropionate anhydrous, formoterol fumarate dihydrate and glycopyrronium bromide. Considering the low active content per actuation for all the active substances and the technical difficulties of the development of a stable suspension formulation, a solution formulation was chosen in order to provide good intra-inhaler performance and physical stability. Additionally, since the active substances are dissolved, their particle size distribution is not critical to product performance. Hence, the quality of the aerosol cloud is determined by the physical properties of the solution, especially its vapour pressure, the conduit provided by the valve and the orifice of the actuator.

The quality aspects described in the 'Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products' (EMEA/CHMP/QWP/49313/2005 Corr) were met. As reference for setting the in vitro equivalence criteria with Foster, the following guideline was followed: 'Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of the therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents' (CPMP/EWP/4151/00 Rev.1). For the container closure system and the excipients, the following guidelines were followed: 'Guideline on plastic immediate packaging materials' CPMP/QWP/4359/03EMEA/CVMP/205/04 and 'Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product' CHMP/QWP/396951/2006.

Solubility studies of each of the active substances in the solvent system, consisting of norflurane, ethanol anhydrous, and hydrochloric acid, at different temperatures were conducted. The BDP, FF and GB solubility studies confirmed that all active substances remain in solution at target concentrations in the selected formulation.

Compatibility of all active substances with the excipients and the container closure system has been verified during the development studies on laboratory and pilot batches and by the stability studies carried out up to now on the finished product at production scale.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation.

The material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

<div style=\"page-break-after: always\"></div>

A traditional filling manufacturing method is used to manufacture the finished product. The process used for the production of the clinical batches was the same as the proposed commercial process. Sufficient information on manufacturing process development using a QbD approach has been provided.

Robustness assessment during development of the finished product and of the related manufacturing process took into consideration QbD principles (such as prior knowledge and a risk assessment process).

## Manufacture of the product and process controls

The manufacturing process and the in-process controls performed have been sufficiently described. Process validation studies have been conducted on production scale batches and are acceptable. All validation data were within specification.

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form and it is in line with the requirements of the 'Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products' (EMEA/CHMP/QWP/49313/2005 Corr). The parameters refer to description (product and primary packaging), identification of each active substance (HPLC and HPLC/UV), assay of each active substance (HPLC and HPLC/UV), related substances of each active substance (HPLC), moisture content (KF), fine particle massbeginning of can (new generation impactor (NGI)/HPLC), mean delivered dose intra-can and inter-cans (HPLC) and uniformity of delivered dose intra-can and inter-cans (HPLC), microbiological limits (Ph.Eur.), leak rate, number of actuations per container.

The analytical methods used, including the compendial ones, have been described in detail and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the working and reference standards used for assay and impurities testing has been presented.

Adequate specification has been provided for the canister, the metering valves and the actuators.

Batch analytical data for 12 commercial scale batches (manufactured in 2014 &amp; 2015) of the finished product (3 x 60, 7 x 120 and 2 x 180 actuations/can presentations), fully equivalent to the finished product proposed for the market has been presented confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability studies have been conducted on several batches manufactured at the intended site of manufacture, at the intended production scale and packaged in the proposed container closure system.

The stability studies have been carried out according to ICH requirements. Batches of the three presentations of the finished product were stored under the long term conditions (5°C), and in use conditions (25°C/60% RH and 30°C/75% RH).

Samples were tested for all the parameters listed in the release specification (apart from the identification test). The analytical procedures used are stability indicating.

All the results were within the limits set in the shelf-life specification. A photo-stability study was not completed as it is not considered relevant since a protective primary packaging was used.

<div style=\"page-break-after: always\"></div>

The stability data provided is representative of all the proposed active substance suppliers as the finished product batches used during the stability testing have been manufactured using at least two different batches of active substance from all the proposed suppliers and no differences were observed between the different suppliers.

Based on available stability data, the proposed shelf-life for the 60 actuations presentation is 21months at +5 °C, including a maximum in-use period of 2 months below 25 °C. The proposed shelf life for the 120 and 180 actuations presentations is 22 months at +5 °C, including a maximum in-use period of 4 months below 25 °C. The proposed shelf-life as stated in the SmPC (section 6.3) is justified.

## Adventitious agents

No excipients derived from animal or human origin have been used. Sufficient information on the declaration regarding BSE-free material used for the actuator system has been provided.

Satisfactory supplier's declarations for BSE/TSE risk, OGM and latex absence for the canister material and the metering valve have been provided.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substances and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. The quality aspects of the finished product have been addressed by ensuring adherence with the relevant CHMP guidelines for inhalation products and with the Ph.Eur. general chapter 'Preparations for Inhalation'.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation(s) for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The non-clinical package was performed according to EU guidelines as detailed below.

Safety pharmacology studies were conducted in compliance with the GLP regulations and according to the international guidelines. Studies on primary pharmacology used experimental models usually not fully in accordance with GLP regulations, however, based on valid scientific principles.

<div style=\"page-break-after: always\"></div>

The toxicokinetic studies provided by the Applicant for CHF 5993 and GB as well as most of the other ADME studies submitted for CHF 5993 and GB were conducted in accordance with GLP principles.

The Applicant has investigated the toxicological profile of the CHF 5993 combination product through single and repeated dose toxicity and reproductive toxicity studies. In addition, the Applicant has provided a set of toxicological studies for the single component GB. These studies were conducted in compliance with the GLP regulations (exception: single dose toxicity studies for CHF 5993) but as this was performed according to the relevant international guidelines, this was considered acceptable.

The  analytical  methods  used  for  determining  analyte  concentrations  in  GLP  pharmacokinetic/toxicokinetic studies were, with a few exceptions, validated according to the EMEA Guideline EMEA/CHMP/EWP/192217/2009 and to the FDA Guidance (May 2001) on bioanalytical method validation and in compliance with the GLP regulations. In all validation, toxicokinetic and pharmacokinetic studies, analyte concentrations were expressed as concentration of free compound.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## CHF 5993

The non-clinical pharmacological studies conducted with the combination of GB and CHF 1535 (BDP+formoterol) provide support for the concept that the FDC of GB and CHF 1535 (CHF 5993) displays increased efficacy/potency versus bronchoconstriction and airway hyper-responsiveness induced by different challenges  (including  bronchoconstriction  induced  by  acetaldehyde  and  Ach  in  anaesthetised  guinea  pigs, airway hyper-responsiveness induced by ovalbumine and histamine in ovalbumine-sensitised guinea pigs and airway hyper-responsiveness induced by substance P in acetaldehyde-sensitised guinea pigs). BDP and FF coadministration  also  potentiated  the  inhibitory  effect  of  GB  on  histamine  and  TXB2  release  following ovalbumine  challenge  in  sensitised  animals.  Taken  together,  these  studies  support  the  concept  that  the application of the LAMA GB in combination with the established, clinically efficacious BDP+FF (ICS + LABA) combination  may  have  the  potential  to  provide  an  additional  benefit  for  the  treatment  of  COPD  patients, when compared with the single components (an hypothesis to be verified by clinical data).

## Glycopyrronium bromide

The non-clinical pharmacological studies provided showed that GB is a potent, efficacious and long-lasting bronchodilatating  compound  in  isolated  preparations  from  guinea-pigs  and  human  lung  specimens  and  in anaesthetised guinea-pigs. Compared with the muscarinic receptor antagonists tiotropium and ipratropium, GB is as potent or even more potent than both compounds in isolated human bronchial preparations, while in anaesthetised guinea-pigs it is as potent as ipratropium but about 3 times less potent than tiotropium. GB's duration of action is intermediate between that of tiotropium and that of ipratropium in both in vitro and in vivo bioassays.

## Additional data (CHF 1535)

According  to  available  data,  the  combination  of  inhalable  BDP  and  FF  has  been  shown  to  be  an  effective bronchodilator  following  Ach  induced  bronchoconstriction  in  anaesthetised  guinea  pigs  and  ovalbumin challenge in sensitised anaesthetised guinea pigs. Furthermore the BDP+FF combination was effective when administered i.t. at reducing inflammation in a sephadex-induced lung oedema model in rats.

## Secondary pharmacodynamics

<div style=\"page-break-after: always\"></div>

Non-clinical data concerning secondary pharmacodynamics of the active substances BDP, FF and GB have not been provided by the Applicant. Taking into account that such effects have been evaluated clinically and are well-documented in published literature, this is considered acceptable.

## Safety pharmacology

## CHF 5993

Cardiovascular  and  respiratory  system :  In in  vitro studies,  CHF  5993  had  no  effects  on  cardiac  sodium (hNaV1.5) and L-type calcium (hCaV1.2) channels expressed in human embryonic kidney (HEK-293) cells and on duration of action potential in isolated guinea pig myocytes. However, CHF 5993 inhibited potassium current  via  hERG  channels  (which  physiologically  play  an  important  role  in  myocardial  repolarisation) expressed  in  HEK-293  cells  and  its  potency  for  this  effect  increased  with  prolonged  incubation  (IC50  378 ng/ml).

In a telemetry study in conscious dogs treated with CHF 5993 via inhalation, effects consistent with the ß2adrenergic  respectively  anti-muscarinic  pharmacological  activity  of  the  single  components  formoterol  and glycopyrronium  were  observed.  Heart  rate  increase  and  blood  pressure  decrease  were  seen  at  all  doses (including the low dose of 33+2+7 µg/kg BDP+FF+GB). Furthermore, at mid and high doses (134+8+35 and 460+29+107  µg/kg  BDP+FF+GB,  respectively),  the  P-wave  amplitude  was  increased  and  the  duration decreased  and  the  P-Q  and  QRS  intervals  were  shortened.  Additional  ECG  changes  included  a  dosedependent increase of sinus and ventricular tachycardia, ventricular premature contractions and 1st to 2nd degree atrio-ventricular block at the mid and high doses. Respiratory rate was increased at the high dose, tidal volume and minute volume were increased at all doses.

A safety factor calculation for the low CHF 5993 dose, based on either allometric dose conversion or systemic exposure to the active components of the CHF 5993 triple combination in dogs and in humans is provided in the tables below, respectively

Table 1 Safety factor calculations using allometric dose conversion

|            | DOG TELEMETRY - CARDIAC AND RESPIRATORY FUNCTION STUDY   | HUMAN EQUIVALENT DOSE $   | HUMAN DAILY DOSE #   | SAFETY FACTOR   |
|------------|----------------------------------------------------------|---------------------------|----------------------|-----------------|
| TEST ITEMS | µg/kg/day                                                | µg/kg                     | µg/kg/day            |                 |
| BDP        | 33                                                       | 18.3                      | 6.67                 | 3               |
| FF         | 2                                                        | 1.11                      | 0.4                  | 3               |
| GB         | 7                                                        | 3.89                      | 0.83                 | 5               |

$ Allometric conversion from dog to human based on body surface area (conversion factor = 1.8)

# Proposed human dose: 400/24/50 µ g day of BDP/FF/GB (6.67/0.4/0.83 µ g/kg/day of BDP/FF/GB)

<div style=\"page-break-after: always\"></div>

Table 2 Safety factor calculations based on systemic exposure

| TEST   | C MAX IN MALE DOGS OF THE 4 WEEK INHALATION STUDY AFTER A SINGLE DOSE OF 23+1.4+5.4 µG/KG   | C MAX IN HUMAN COPD PATIENTS   | SAFETY MARGIN TO HUMAN ON C MAX   | AUC 0-24 IN MALE DOGS OF THE 4 WEEK INHALATION STUDY AFTER A SINGLE DOSE OF 23+1.4+5.4 µG/KG   | AUC 0-24 IN HUMAN COPD PATIENTS $   | SAFETY MARGIN TO HUMAN ON AUC 0-24   |
|--------|---------------------------------------------------------------------------------------------|--------------------------------|-----------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------|
| ITEMS  | ng/mL                                                                                       | ng/mL                          | -                                 | ng.hr/mL                                                                                       | ng.hr/mL                            | -                                    |
| BDP    | 1.67                                                                                        | 0.367                          | 4.6                               | Nq                                                                                             | 0.139                               | nd                                   |
| B17MP  | 3.90                                                                                        | 0.678                          | 5.8                               | 2.29                                                                                           | 4.65                                | 0.49                                 |
| FF     | 0.0986                                                                                      | 0.017                          | 5.8                               | 0.195                                                                                          | 0.161                               | 1.2                                  |
| GB     | 0.208                                                                                       | 0.046                          | 4.5                               | 0.972                                                                                          | 0.320                               | 3.0                                  |

nq   AUC not quantifiable nd   not determined

$ AUC0-24h extrapolated from the AUC0-12h at steady state in the CARSAF study given 400/24/50 µ g day ( b.i.d .)

No adverse effects on cardiac or respiratory systems were evident following intraduodenal administration to rats.

CNS: No  additional  safety  pharmacology  studies  of  the  effects  of  the  CHF  5993  combination  on  CNS parameters were carried out. Considering the reported lack of relevant effects of the individual components on CNS parameters tested, this approach is considered acceptable.

## Glycopyrronium bromide

Cardiovascular and respiratory system : In in vitro studies, GB had no effect on duration of action potential of isolated guinea-pig myocytes, however, inhibited potassium current via hERG channels expressed in HEK-293 cells with an IC50-value of 399 µM (158 µg/ml).

In an in  vivo inhalation study in telemetered conscious dogs, GB resulted in CV effects expected for a M3 muscarinic antagonist, e.g. increase in heart rate, slight decrease in systolic and slight increase in diastolic blood pressure, slight but significant shortening of PQ, QRST, QT and QTc intervals and 1 st  or 2 nd  degree atrio-ventricular  block.  Taking  into  account  that  a  1 st   degree  atrio-ventricular  block  is  considered  to  be clinically not relevant, the NOAEL level was deemed to be 82 μg/kg in this study, providing a 44 fold safety margin assuming a 50 μg/day therapeutic dose.

Intraduodenal  administration  of  GB  at  doses  up  to  150  mg/kg  had  no  effect  on  cardiac  or  respiratory parameters in Wistar rats.

CNS :  Orally  applied  GB  resulted  in  a  slight  decrease  in  spontaneous  locomotor  activity  of  rats  at  higher doses, however, did not induce any behavioural change in the Irwin test, did not affect performance time in the rotarod test and had no effect on hexobarbital-induced sleeping time.

<div style=\"page-break-after: always\"></div>

Others : In pylorus-ligated rats, intraduodenally applied GB (in doses ≥ 20 mg/kg) induced an inhibition of gastric  secretion  and  (at  a  dose  of  320  mg/kg)  mortality.  Reported  GI  toxicity  associated  with  GB administration  is  not  considered  clinically  relevant  given  the  high  dose  and  the  intraduodenal  route  of administration. Orally applied GB inhibited GI charcoal propulsion and induced a decrease in urine output and significant increases in electrolyte (potassium, chloride) and protein excretion.

## Additional data (CHF 1535)

Orally applied CHF 1535 was not associated with any adverse CNS effects (except for a minor reduction in spontaneous locomotor activity and increase in sleeping time at higher doses). CHF 1535 was associated with a decrease in gastric motility (100 mg/kg orally) and a decrease in urine output ( ≥ 4mg/kg orally) at higher doses.

## Pharmacodynamic drug interactions

Non-clinical data concerning pharmacodynamic drug interactions of the active ingredients BDP, FF and GB have not been provided by the Applicant. Taking into account that such effects have been evaluated clinically and are well-documented for these therapeutic classes in published literature this is considered acceptable.

## 2.3.3. Pharmacokinetics

Pharmacokinetics and disposition of BDP and FF are well-known.

In  vitro pharmacokinetic studies were performed to investigate potential drug-drug interactions of GB and CHF 1535. No new in vivo PK studies are presented for CHF 1535. A more extensive package of PK studies has been provided concerning the absorption, distribution, metabolism and excretion of GB.

## Substance specific data

## - CHF 5993

A  possible  pharmacokinetic  interaction  between  GB  and  CHF  1535  (FF  +  BDP)  was  investigated  in  male catheterized  rats  after  separate  and  concomitant  i.v.  administration  of  the  components:  for  all  CHF  5993 components (BDP, FF; GB) and for B17MP (main metabolite of BDP) no statistically significant difference was observed in plasma AUC and systemic clearance, indicating no modification in the elimination mechanism due to co-administration of the single components.

No dedicated oral or pulmonary absorption studies were performed with CHF 5993. The systemic exposure to the CHF 5993 components and to B17MP was evaluated in toxicokinetic studies during the 4- and 13-week repeat-dose toxicity studies: the individual components of CHF 5993 are rapidly absorbed following inhalation administration  with  Tmax  reached  in ≈ 1  hour  and  elimination  half-lives  of  the  components  between  1-10 hours with little evidence of accumulation in rats and only slight accumulation in dogs (AUC week 13/day 1 ratios ranged 0.57-1.9). Following inhalation, exposure to BDP, its metabolite B17MP, FF and GB increased with dose. In rats, BDP was quantified in too few samples to allow the determination of AUCt and t½, only Cmax was used for comparison between groups. There was no significant change in drug exposure following combination administration relative to administration of CHF 1535 or GB (GB exposure was slightly lower in combination relative to single administration in rats, but this effect was not seen in dog).

## - Glycopyrronium bromide

<div style=\"page-break-after: always\"></div>

Glycopyrronium  pharmacokinetics  in  dogs  and  rats  was  characterized  by  a  low  oral  bioavailability  (in particular in rats), a high  systemic  clearance,  a  moderate volume  of  distribution  and  a  terminal  half-life lower than 13 hours.

Absorption:  The  submitted  toxicokinetic  data  indicate  systemic  exposure  to  glycopyrronium  following inhalation administration. Systemic  bioavailability of glycopyrronium after  oral  administration  was  20-30% in  dogs,  but  lower  than  1%  in  rats,  suggesting  that  the  contribution  of  glycopyrronium swallowed after inhalation to systemic glycopyrronium exposure is likely to be moderate in dogs and limited in rats. Due to the low intestinal absorption, high glycopyrronium doses are required to obtain a relevant systemic exposure in oral toxicity studies.

Distribution: Steady state volume of distribution of glycopyrronium, as determined after i.v. administration, was 2.4-6.7 L/kg in dogs and 1.2-6.8 L/kg in rats. No radiolabelled GB distribution studies are presented.

Glycopyrronium´s binding to rat, dog and mouse plasma proteins was in the range of 30-47% compared with a value of about 70% in humans and was not concentration dependent. The blood to plasma concentration ratio  was  lower  than  1,  indicating  no  significant  uptake  into  red  blood  cells.  For  the  glycopyrronium metabolite CHF 6006, plasma protein binding amounted to 88% in rats, 76% in dogs, 89% in humans and 73% in mice.

As expected for a quaternary ammonium compound, glycopyrronium showed low penetration through  the blood-brain barrier (in mongrel dogs and mice) and a limited placental transfer (in pregnant mice, dogs and ewes).

Metabolism: Glycopyrronium´s metabolic pattern, determined in vitro using liver microsomes and hepatocytes from humans, dogs, rats, rabbits and mice, was similar among species, supporting the choice of animal species (rat, dog) used for the toxicological evaluation.

The  main  metabolic  reaction  was  the  hydroxylation  of  the  phenyl-  or  cyclopentyl-rings.  Glycopyrronium ester hydrolysis (to generate the products CHF6006 and CHF6009) was shown to be a minor metabolic route. However, systemic exposure to CHF6006 was observed in rats after oral and inhalation application, which can be  explained  by  glycopyrronium  hydrolysis  in  the  gut  followed  by  CHF6006  absorption  into  the  systemic circulation. Systemic exposure to CHF6009 instead, due to a higher systemic clearance, is much lower than to CHF6006.

The  role  of  CYP450  isoforms  in  glycopyrronium metabolism was investigated  with  recombinant human CYP450 enzymes: CYP2D6 was found to be  the only isoform relevant for the metabolism, with a Km of 3.9 µM.

Excretion: After i.v. administration to bile duct catheterized rats, glycopyrronium excretion in bile accounted for less than 1% of the dose, whereas about 25% and 19% of the dose was excreted as unchanged drug into urine in males and females rats, respectively. The percentage of the dose that is not excreted unchanged is likely to be eliminated via metabolism.

The renal clearance was greater than the glomerular filtration rate, indicating that glycopyrronium is actively secreted into urine.

Pharmacokinetic drug interactions: Concerning the pharmacokinetic interaction between CHF 1535 (BDP+FF) and GB, see information on CHF 5993, above.

In vitro studies with transfected cells showed that glycopyrronium is a substrate of OCT1, OCT2 and MATE1 but  not  of  MDR1  and  BCRP  transporters.  The  ability  of  glycopyrronium  to  inhibit  the  human  transporters

<div style=\"page-break-after: always\"></div>

OCT1,  OCT2,  OCT3,  OCTN1,  OCTN2,  MATE1,  OAT1,  OAT3,  OATP1B1,  OATP1B3,  MDR1  and  BCRP  was investigated in  vitro. Since  the  observed  IC50-values  were  always  more  than  50-times  higher  than  the maximum plasma glycopyrronium concentration observed in clinical studies, drug-drug interactions due to inhibition of the transport of other drugs by glycopyrronium appear unlikely.

In in vitro studies with human liver microsomes and recombinant human UGTs neither the UGT (1A1, 1A3, 1A4, 1A6, 1A9, 2B7, 2B15) nor the CYP-450 (1A2, 2A6, 2B6, 2E1, 2C9, 2C19, 2D6, 3A4) linked activities were  significantly  affected  by  glycopyrronium.  Furthermore,  as  determined  in  cultured  hepatocytes,  no induction  of  enzyme  expression  (CYP3A4  and  CYP1A2)  was  observed.  Therefore,  glycopyrronium  is  not expected to modify plasma concentrations of co-administered substrates of the UGT- and CYP450-enzymes.

Other pharmacokinetic studies: Since glycopyrronium represents the (R,S)-(S,R) racemic pair of enantiomers,  corresponding  to  the  threo  diastereoisomeric  structure,  a  possible  difference  in  systemic exposure  to  the  single  enantiomers  was  investigated  in  rats  and  dogs  after  CHF  5993  inhalation.  The (S,R)/(R,S) ratios of enantiomers for Cmax and AUClast were in  the  range  1.0  -  1.2 in rats (indicating no relevant difference in  exposure to the enantiomers) and 0.7 - 1.6 in dogs (suggesting a limited difference in exposure).

Since CHF 6006 was not detectable in plasma after i.v. glycopyrronium administration, but was detectable after inhalation,  it  was  hypothesized  that  the  amount  of  the  inhaled  dose  that  is  swallowed  may  undergo chemical  hydrolysis  in  the  gut  to  generate  CHF  6006  and  CHF  6009,  which  are  then  absorbed  in  the systemic  circulation.  Pharmacokinetics  of  CHF 6006  and  CHF 6009, investigated in male rats showed that they have opposite pharmacokinetic properties, with low clearance and a low volume of distribution for the former and  high  clearance  and  a   high  volume  of  distribution for  the  latter.  Therefore,  although  only  a small  percentage  of  the  amount  swallowed  is  hydrolyzed,  the  opposite  pharmacokinetic  properties  of  the compounds explain the significant systemic exposure to CHF 6006 and the negligible systemic exposure to CHF 6009.

## - Additional data (CHF 1535)

According to available data, BDP is rapidly cleared from lung and bronchi and after 24 h less than 1% of the administered  dose  remained  in  these  tissues.  The  metabolism  of  BDP  in  rats  and  dogs  is  similar  to  that observed in man. BDP is rapidly hydrolysed into its main active metabolite B17MP and the minor metabolite 21-monopropionate (B21MP), that are subsequently transformed into the pharmacologically inactive alcohol derivatives (BOH).

For radiolabelled FF, the radioactivity distributed mainly in kidney and liver, followed by plasma, trachea and the lung. FF plasma protein binding was similar between rat, dog and human plasma and ranged from 50 to 65%. Metabolism of FF occurs via O-glucuronidation, with the phenolic glucuronide as primary metabolite in rats, dogs and humans.

B17MP was a substrate for MDR1, however the relevant IC50 values are well in excess of the reported clinical Cmax. Data are not presented assessing the interaction of BDP or FF with human organic anionic transporters or inhibition of UGT or CYP450 isoforms. Considering that BDP and FF have previously been licensed and that there is clinical experience using them in combination, it is accepted that additional in vitro tests are unlikely to provide data which will significantly add to the safety assessment at this time.

## 2.3.4. Toxicology

<div style=\"page-break-after: always\"></div>

## Overview of the toxicological development program

## Toxicological studies performed with CHF 5993

The  non-clinical  toxicology  package  for  CHF  5993  is  based  on  the  completed  toxicology  program  and  a comprehensive set of toxicology studies for GB. In addition bridging studies with the CHF 5993 combination have been performed. These include, single dose oral toxicity studies in rats of the combination in the ratio of 100:6:25 (dissolved in 0.5% carboxymethylcellulose), 4-week repeat dose inhalation toxicity studies in rats and  dogs  of  the  free  combination  of  CHF  1535  pMDI  and  GB  pMDI,  and  13-week  repeat  dose  inhalation toxicity studies in rats and dogs of the fixed combination of CHF 5993 pMDI (100μg BDP/6μg FF/25μg GB). Although this ratio is different than that of the proposed clinical product (GB dose is 12.5μg in the clinical product,  25μg  in  toxicological  studies),  this  design  is  considered  adequate  to  support  the  present  MAA. Furthermore, reproductive oral toxicity studies were carried out in rats to assess the effect of the combination on embryo-foetal development, fertility and pre &amp; post-natal development. All studies except the single dose toxicity studies were GLP compliant.

## Selection of species for toxicological studies

Rat and dog were the animal species used for single and repeat-dose toxicological evaluation of CHF 5993, as inter-species comparison  of metabolism  and  of pharmacokinetic properties of formoterol,  BDP  and glycopyrronium supported the selection of these species.

## Characterization of the toxicological profile of inhaled glycopyrronium bromide

Glycopyrronium is already in clinical use by the i.v. route (as pre- and intra-operative antimuscarinic agent), by the oral route (for the treatment of peptic ulcer) and, as recently approved, by inhalation (in combination with a ß2-agonist for treatment of COPD). To further characterize the toxicological profile of inhaled GB, the Applicant has conducted a number of additional toxicity and safety pharmacology studies with GB or the GBHFA formulation, including, as recommended in a scientific advice given by the EMA in 2013, the evaluation of  the  carcinogenic  potential  of  GB  in  a  104-week  rat  inhalation  study  and  an  oral  26-week  study  in transgenic  Tg.rasH2  mice.  These  studies  were  carried  out  in  compliance  with  the  GLP  regulations  and  in accordance with the relevant international GLs.

## Single dose toxicity

## CHF 5993

When  administered  by  the  oral  or  i.p.  route  to  rats,  CHF  5993  (BDP:FF:GB,100:6:25  dissolved  in  0.5% carboxymethylcellulose)  showed  a  low  acute  toxicity, with a maximum tolerated dose of 500 mg/kg and 100 mg/kg,  respectively.  At  an  oral  dose  of  800  mg/kg,  piloerection,  hunched  posture,  ataxia,  salivation, lachrymation,  reduced  activity  and  semi  closed  eyes  were  observed.  At  this  dose,  3/10  animals  died. Following i.p. administration of 200 mg/kg, 1/10 animals died.

## Glycopyrronium bromide

According to published literature, GB showed low toxicity after single dose application by different routes of administration in rodent and non-rodent species.

## Repeat dose toxicity

## CHF 5993

In  repeat  dose  inhalation  studies  with  CHF  5993  in  rats  and  dogs  of  up  to  13  weeks  duration,  the  main

<div style=\"page-break-after: always\"></div>

observed  alterations  were  related  to  the  immuno-suppressive  activity  of  BDP/B17MP  (observed  in  both species) and cardiovascular effects (e.g. increase in heart rate) due to the pharmacological activity of FF and GB (mainly observed in dogs).

Toxicokinetic determinations  evidenced  the systemic  exposure  of  the study animals  to formoterol, glycopyrronium and BDP/B17MP following inhalative application of CHF 5993.

In the repeat dose toxicity studies with CHF 5993, groups given FF doses in the dog studies in excess of 2 μg/kg/day  underwent  a  2-5  day  dose  escalation  phase  prior  to  starting  the  studies  to  ameliorate  the  CV effects of high dose FF.

4-week studies: 4-week repeat dose inhalation toxicity studies with a 4 week recovery period were performed in rat and dog using a combination of the existing CHF 1535 (BDP+FF) pMDI and a GB pMDI, compared to the single components and to controls (air and/or vehicle). Thymus, heart, liver, and adrenals were identified as the primary target organs. Reductions in thymus and adrenal weights were evident in groups exposed to CHF  1535  and  CHF  5993.  These  were  reversible following recovery and are consistent with the pharmacological activity of BDP. Changes in CV parameters in beagle dogs (increase in HR and decrease in QT in CHF 1535 group and groups exposed to doses of CHF 5993 ≥ 127+8+32 µg/kg/day BDP+FF+GB) are consistent with the pharmacological activity of FF and GB. There did not appear to be a significant additive effect concerning toxicity for the combination product relative to the single components.

Safety  margins  with  regard  to  clinical  application  of  CHF  5993,  as  derived  from  the  4-week  repeat  dose toxicity studies in rats and dogs, are depicted in the following tables, respectively.

Table 3 Safety factor calculations for the 4-week rat repeat dose toxicity study based on systemic exposure

| TEST ITEMS   | RAT 4 WEEK INHALATION C MAX AT LOAEL 1   | RAT 4 WEEK INHALATION C MAX AT LOAEL 1   | HUMAN COPD PATIENTS C MAX   | SAFETY MARGIN TO HUMAN ON C MAX   | SAFETY MARGIN TO HUMAN ON C MAX   | RAT 4 WEEK INHALATION AUC 0-24 AT   | RAT 4 WEEK INHALATION AUC 0-24 AT   | HUMAN COPD PATIENTS AUC 0-24 $   | SAFETY MARGIN TO HUMAN ON AUC 0-24   | SAFETY MARGIN TO HUMAN ON AUC 0-24   |
|--------------|------------------------------------------|------------------------------------------|-----------------------------|-----------------------------------|-----------------------------------|-------------------------------------|-------------------------------------|----------------------------------|--------------------------------------|--------------------------------------|
|              | ng/mL                                    | ng/mL                                    | ng/mL                       | -                                 | -                                 | ng.hr/mL                            | ng.hr/mL                            | ng.hr/mL                         | -                                    | -                                    |
|              | Male                                     | Female                                   |                             | Male                              | Female                            | Male                                | Female                              |                                  | Male                                 | Female                               |
| BDP          | 0.347                                    | 1.75                                     | 0.367                       | 0.95                              | 4.8                               | 0.188                               | 1.29                                | 0.139                            | 1.4                                  | 9.3                                  |
| B17MP        | 9.78                                     | 23.9                                     | 0.678                       | 14                                | 35                                | 17.5                                | 89.5                                | 4.65                             | 3.8                                  | 19                                   |
| FF           | 0.134                                    | 0.126                                    | 0.017                       | 7.9                               | 7.4                               | 0.185                               | 0.223                               | 0.161                            | 1.1                                  | 1.4                                  |
| GB           | 0.543                                    | 0.545                                    | 0.046                       | 12                                | 12                                | 2.43                                | 2.94                                | 0.320                            | 7.6                                  | 9.2                                  |

$ AUC0-24h extrapolated from the AUC0-12h at steady state in the CARSAF study given 400/24/50 µ g day ( b.i.d .)

1 LOAEL proposed by the Reviewer (95+6+23 µ g/kg/day of BDP/FF/GB).

<div style=\"page-break-after: always\"></div>

Table 4 Safety factor calculations for the 4-week dog repeat dose toxicity study based on systemic exposure

| TEST ITEMS   | DOG 4 WEEK INHALATION C MAX AT NOAEL 1   | DOG 4 WEEK INHALATION C MAX AT NOAEL 1   | HUMAN COPD PATIENTS C MAX   | SAFETY MARGIN TO HUMAN ON C MAX   | SAFETY MARGIN TO HUMAN ON C MAX   | DOG 4 WEEK INHALATION AUC 0-24 AT   | DOG 4 WEEK INHALATION AUC 0-24 AT   | HUMAN COPD PATIENTS AUC 0-24 $   | SAFETY MARGIN TO HUMAN ON AUC 0-24   | SAFETY MARGIN TO HUMAN ON AUC 0-24   |
|--------------|------------------------------------------|------------------------------------------|-----------------------------|-----------------------------------|-----------------------------------|-------------------------------------|-------------------------------------|----------------------------------|--------------------------------------|--------------------------------------|
|              | ng/mL                                    | ng/mL                                    | ng/mL                       | -                                 | -                                 | ng.hr/mL                            | ng.hr/mL                            | ng.hr/mL                         | -                                    | -                                    |
|              | Male                                     | Female                                   |                             | Male                              | Female                            | Male                                | Female                              |                                  | Male                                 | Female                               |
| BDP          | 1.49                                     | 1.37                                     | 0.367                       | 4.1                               | 3.7                               | nq                                  | 3.25                                | 0.139                            | nq                                   | 23                                   |
| B17MP        | 3.99                                     | 3.99                                     | 0.678                       | 5.9                               | 5.9                               | 2.73                                | 3.49                                | 4.65                             | 0.59                                 | 0.75                                 |
| FF           | 0.0776                                   | 0.0928                                   | 0.017                       | 4.6                               | 5.5                               | 0.373                               | 0.355                               | 0.161                            | 2.3                                  | 2.2                                  |
| GB           | 0.317                                    | 0.943                                    | 0.046                       | 6.9                               | 21                                | 1.92                                | 3.35                                | 0.320                            | 6.0                                  | 10                                   |

$   AUC0-24h extrapolated from the AUC0-12h at steady state in the CARSAF study given 400/24/50 µ g day ( b.i.d .)

1 NOAEL proposed by the Reviewer (31+2+7 µ g/kg/day of BDP/FF/GB).

nq  AUC not quantifiable

13-week  studies :  13-week  repeat  dose  inhalation  toxicity  studies  with  a  6  week  recovery  period  were performed in rat and dog using a 100+6+25 μg (BDP+FF+GB) combination pMDI, compared to the single components and to controls. The CHF 5993 formulation is different from that proposed for clinical application in  this  MAA,  but  this  is  considered  acceptable  for  safety  studies  as  the  GB  dose  exceeds  the  dose  in  the proposed clinical formulation (25 vs 12.5 μg GB). Thymus, liver, heart and adrenals were again identified as target organs in these studies.

In rat, thymus atrophy and reduction in weight was evident in the CHF 1535 group and all CHF 5993 groups examined, effects which were reversible following the 6 week recovery period. Decreased lymphocytes were evident in the CHF 1535 group and in females in all CHF 5993 groups and males at the highest dose only (883+55+207 μg/kg/day BDP+FF+GB), effects  that  are   likely  related  to  the  pharmacological  activity    of BDP.

In dogs, cardiovascular effects (e.g. an increase in heart rate), likely related to the pharmacological activity of FF and/or GB, represented prominent findings.

Safety  margins  with  regard  to  clinical  application  of  CHF  5993,  as  derived  from  the  13-week  repeat  dose toxicity studies in rats and dogs, are depicted in the following tables, respectively.

<div style=\"page-break-after: always\"></div>

Table  5  Safety  factor  calculations  for  the  13-week  rat  repeat  dose  toxicity  study  based  on systemic exposure

| TEST ITEMS   | RAT 13 WEEK INHALATION C MAX AT LOAEL 1   | RAT 13 WEEK INHALATION C MAX AT LOAEL 1   | HUMAN COPD PATIENTS C MAX   | SAFETY MARGIN TO HUMAN ON C MAX   | SAFETY MARGIN TO HUMAN ON C MAX   | RAT 13 WEEK INHALATION AUC 0-24 AT   | RAT 13 WEEK INHALATION AUC 0-24 AT   | HUMAN COPD PATIENTS AUC 0-24 $ SAFETY TO AUC 0-24   | MARGIN HUMAN ON   | MARGIN HUMAN ON   |
|--------------|-------------------------------------------|-------------------------------------------|-----------------------------|-----------------------------------|-----------------------------------|--------------------------------------|--------------------------------------|-----------------------------------------------------|-------------------|-------------------|
|              | ng/mL                                     | ng/mL                                     | ng/mL                       | -                                 | -                                 | ng.hr/mL                             | ng.hr/mL                             | ng.hr/mL                                            | -                 | -                 |
|              | Male                                      | Female                                    |                             | Male                              | Female                            | Male                                 | Female                               |                                                     | Male              | Female            |
| BDP          | 1.35                                      | 0.735                                     | 0.367                       | 3.7                               | 2.0                               | 1.57                                 | 0.904                                | 0.139                                               | 11                | 6.5               |
| B17MP        | 18.9                                      | 33.0                                      | 0.678                       | 28                                | 49                                | 27.8                                 | 153                                  | 4.65                                                | 6.0               | 33                |
| FF           | 0.287                                     | 0.204                                     | 0.017                       | 17                                | 12                                | 0.503                                | 0.400                                | 0.161                                               | 3.1               | 2.5               |
| GB           | 0.978                                     | 0.607                                     | 0.046                       | 21                                | 13                                | 7.63                                 | 2.65                                 | 0.320                                               | 24                | 8.3               |

$ AUC0-24h extrapolated from the AUC0-12h at steady state in the CARSAF study given 400/24/50 µ g day ( b.i.d .) 1 LOAEL proposed by the Reviewer (110+6+24 µ g/kg/day of BDP/FF/GB)

Table  6  Safety  factor  calculations  for  the  13-week  dog  repeat  dose  toxicity  study  based  on systemic exposure

| TEST ITEMS   | DOG 13 WEEK INHALATION C MAX AT NOAEL 1   | DOG 13 WEEK INHALATION C MAX AT NOAEL 1   | HUMAN COPD PATIENTS C MAX C MAX   | HUMAN COPD PATIENTS C MAX C MAX   | SAFETY MARGIN TO HUMAN ON DOG 13 AUC 0-24 NOAEL 1   | SAFETY MARGIN TO HUMAN ON DOG 13 AUC 0-24 NOAEL 1   | WEEK INHALATION AT HUMAN COPD PATIENTS AUC 0-24   | WEEK INHALATION AT HUMAN COPD PATIENTS AUC 0-24   | SAFETY MARGIN TO HUMAN ON AUC 0-24   | SAFETY MARGIN TO HUMAN ON AUC 0-24   |
|--------------|-------------------------------------------|-------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------------------------|-----------------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------|--------------------------------------|
|              | ng/mL                                     | ng/mL                                     | ng/mL                             | -                                 | -                                                   | ng.hr/mL                                            | ng.hr/mL                                          | ng.hr/mL                                          | -                                    | -                                    |
|              | Male                                      | Female                                    |                                   | Male                              | Female                                              | Male                                                | Female                                            |                                                   | Male                                 | Female                               |
| BDP          | 0.923                                     | 0.954                                     | 0.367                             | 2.5                               | 2.6                                                 | 0.231                                               | 0.239                                             | 0.139                                             | 1.7                                  | 1.7                                  |
| B17MP        | 3.95                                      | 3.81                                      | 0.678                             | 5.8                               | 5.6                                                 | 2.85                                                | 2.62                                              | 4.65                                              | 0.61                                 | 0.56                                 |
| FF           | 0.0545                                    | 0.0525                                    | 0.017                             | 3.2                               | 3.1                                                 | 0.170                                               | 0.167                                             | 0.161                                             | 1.1                                  | 1.0                                  |
| GB           | 0.208                                     | 0.179                                     | 0.046                             | 4.5                               | 3.9                                                 | 0.570                                               | 0.739                                             | 0.320                                             | 1.8                                  | 2.3                                  |

$ AUC0-24h extrapolated from the AUC0-12h at steady state in the CARSAF study given 400/24/50 µ g day ( b.i.d .)

1 NOAEL proposed by the Reviewer (36+2+8 µ g/kg/day of BDP/FF/GB).

## Glycopyrronium bromide

Repeat-dose toxicity of inhaled GB was evaluated in dogs (study duration up to 13 weeks) and rats (study duration up to 26 weeks). Toxicokinetic determinations performed in these studies showed systemic exposure to  glycopyrronium  and  its  metabolite  without  evidence  of  accumulation.  The  main  observed  effects  were related  to  the  known  antimuscarinic  activity  of  GB  (e.g.  increase  in  heart  rate,  mydriasis).  In  addition, decreases in body weight gain/food consumption were consistently observed.

<div style=\"page-break-after: always\"></div>

## Genotoxicity

A standard battery of in vitro and in vivo genotoxicity tests was performed with GB. In addition, genotoxicity studies  of  the  already  approved  combination  CHF  1535  were  presented.  In  studies  performed  in  line with option 1 from ICH S2(R1), GB and CHF 1535 were negative for mutagenicity in a bacterial Ames test, did not produce chromosomal damage in an in vitro chromosome aberration test in human lymphocyte cells with and without metabolic activation, and were negative in in vivo micronucleus assays performed in rats with doses up to 80 mg/kg for GB and 1500 mg/kg for CHF 1535. No genotoxicity studies were performed with the triple combination CHF 5993. Based on the provided studies, GB and CHF 1535 are not considered to be genotoxic in  vitro and in  vivo .  The  lack  of  genotoxicity  studies  with  the  triple  combination  CHF  5993  is  therefore considered acceptable.

## Carcinogenicity

According to the CHMP 'GL on the Non-clinical Development of Fixed Combinations of Medicinal Products' (EMEA/CHMP/SWP/258498/2005),  CHF  5993  corresponds  to  the  co-development  of  three  known  active substances as a fixed dose combination. For FF and BDP extensive non-clinical and clinical data are available and  therefore  the  applicant's  view  that  additional  carcinogenicity  studies  for  these  compounds  are  not considered necessary is acceptable to the CHMP. Although high doses of FF were reported to be associated with an increase in the incidence of mesovarial leiomyoma and granulosa/theca cell tumours in rats, these tumours  are  thought  to  represent  specific  effects  of  β-adrenergic  agonists  in  rodents,  not  linked  to  a genotoxic mechanism given that all the different mutagenicity tests are negative. For GB no long-term data via  the  inhalation  route  were  available,  therefore  the  Applicant  performed  a  104-week  rat  inhalation carcinogenicity  study  with  GB  alone.  GB  showed  no  carcinogenic  potential  after  inhalation  in  rats  at sufficiently high safety margins towards the anticipated human  exposure.  In addition,  a  26-week carcinogenicity  study  with  GB  in  transgenic  Tg.rasH2  mice  was  performed,  which  showed  no  carcinogenic potential of GB after oral administration.

## Reproduction toxicity

## CHF 5993

The effects of CHF 5993 on fertility and early embryonic development, embryo-foetal development and on the pre- and post-natal development were studied in rats following oral administration of BDP, FF and GB in the  ratio  of  100+6+25  in  0.5%  carboxymethylcellulose.  Reported  doses  of  CHF  5993  when  formulated  in solutions for oral gavage always reflect the sum of the doses of each respective single agent (BDP+FF+GB)

Toxicokinetic data for CHF 5993 were not collected concomitantly with the reproduction toxicity studies, but were obtained from a separate dose-range finding and toxicokinetic study with CHF 5993. The toxicokinetic data  show  that  the  exposure  to  B17MP  (metabolite  of  BMP)  is  sufficiently  high  at  the  NOAELs  of  the reproduction  toxicity  studies  compared  to  human  exposure  at  the  therapeutic  dose.  The  exposure  to formoterol is  lower  or even  2-fold  higher  at  the  NOAELs  compared  to  human  exposure  at  the  therapeutic dose. For glycopyrronium, the exposure tends to be similar or even lower than the human exposure at the therapeutic dose.

In the fertility study with CHF 5993, all females mated. However, a dose-dependent decrease in pregnant females was observed leading to a reduction of conception rate and fertility index. In females, treatmentrelated effects included a slightly increased mean precoital time and reduction in mean body weight gain and number  of  corpora  lutea.  Pre-  and  post-implantation  loss  was  also  significantly  increased,  leading  to  a reduced number of implantation sites and live embryos. Treatment was not associated with any macroscopic

<div style=\"page-break-after: always\"></div>

change related to male fertility at any dose level tested. The increased pre-implantation loss and reduced number of implantations may be due to treatment with BDP. As the exposure to glycopyrrolate at this dose level  seems  to  be  similar  to  the  exposure  in  humans,  no  safety  margin  would  exist  for  this  effect.  The parental NOAEL was considered to be 2 mg/kg/day and the NOEL for reproduction was considered to be 0.2 mg/kg/day.

In  the  embryo-foetal  development  study  in  rats,  treatment-related  findings  were  recorded  in  the  foeti including significantly lower foetal weights and a slight disturbance in development, characterized by a slight delay in ossification, an increased incidence of visceral variations such as left-sided umbilical artery, dilated ureter/renal pelvis or distended urinary bladder and thymus long cranial. Such effects have been reported for glucocorticoids and are therefore attributed to the treatment with BDP. The exposure to B17MP at the NOEL was 20-fold higher than the human exposure at the therapeutic dose, suggesting a sufficiently high safety margin.

The NOAEL for maternal effects was 20 mg/kg/day and the NOEL for fetal developmental toxicity was 0.2 mg/kg/day.

In  the  pre-and  post-natal  development  study  with  CHF  5993  in  rats  an  unexpected  high  mortality  was observed  in  the  high  dose  group  of  2  mg/kg/day  of  the  dams  and  also  of  the  litters,  leading  to  early termination of this dose group. Ruffled fur was observed in some individuals at the end of the gestation and the start of the lactation period, with associated reduction in food intake and bodyweight gain. The females appeared to  have  difficulties  with  the  birth  and  several  were  losing  weight.  In  addition,  only  7  out  of  22 females gave birth to live pups and on Day 4 of lactation only 2 litters remained.

The high mortality and the difficulties with birth seen in the 2 mg/kg dose group are probably linked to the known effects of the β2-sympathomimetic FF and is consistent with that previously seen with Foster (BDP+FF - ratio 100+6) in the rat pre-postnatal development study. Also, it cannot be excluded that antimuscarinic effects  of  GB  such  as  dry  mouth  or  tachycardia  could  have  compounded  the  tocolytic  effects  of  FF  and contributed to worsening the general health of the dams.

Other treatment-related effects in the dams included lower food consumption and bodyweight, increase in post-implantation loss and number of dead pups and reduction in litter size. The increase in post-implantation loss is considered to be related to treatment with BDP, since this is a known effect of glucocorticoids.

In F1 pups bodyweight was reduced, probably due to a lack of maternal care/availability of milk, which are likely to be related to the observed reduction of food consumption and body weight in the dams at this time due to the pharmacological activity of glycopyrronium.

In the F1 generation, the number of pregnant females, number of corpora lutea, implantation and litter size was reduced and post-implantation loss was increased.

The NOEL for the parent F0 generation was considered to be 0.02 mg/kg/day and the NOEL for the F1 generation was established at 0.02 mg/kg/day. The exposure levels at the NOAEL for FF and GB were below the human exposure levels at the recommended therapeutic dose of Trimbow in COPD patients and thus the effects seen in this study may be of clinical relevance.

## GB

The  applicant  also  submitted  embryo-foetal  developmental  studies  with  GB  alone  in  rats  and  Himalayan rabbits  as  second  mammalian  species  together  with  dose-range-findings  and  toxicokinetic  studies  in  both species.

<div style=\"page-break-after: always\"></div>

The toxicokinetic dose ranging study in rats confirmed that GB was detectable at all dosages tested, while in rabbit  it  was  only  detectable  at  the  higher  dose,  this  informed  the  choice  of  dosages  to  be  used  in  the embryo/foetal  development  study.  It  is  acceptable  to  use  data  from  oral  gavage  studies  despite  the  low bioavailability  of  GB  via  the  oral  route  (&lt;1%(PRECLI-RP-0365)),  as  exposure  values  in  the  dosage  range used in these studies still provide exposures with adequate safety margins relative to human Cmax and AUC values  (63  and  14  respectively  @  5mg/kg/day).  In  rats,  GB  was  well  tolerated,  with  none  of  the  doses examined  producing  any  effect  on  the  reproductive  parameters  measured,  the  foetal  NOAEL  was  set  at 125mg/kg/day, the highest dose tested.  Doses  of 25mg/kg/day and  above were  however  associated with decreased maternal food consumption and weight gain, hence the maternal NOAEL was set at 5mg/kg/day. No evidence of teratogenic potential was observed at any dose level tested. In rabbits, doses of 30mg/kg/day and above were associated with abortions and a reduction in maternal weight gain. The 60mg/kg/day high dose  was  associated  with  a  decrease  in  placental  weight.  The  foetal  NOEL  was  set  at  60  mg/kg/day  but maternal NOAEL was set at 15mg/kg/day due to the incidence of abortions and reductions in maternal weight gain at higher doses. There was no evidence of teratogenic effects up to the highest dose level tested. These data  do  not  indicate  that  GB  is  associated  with  teratogenic  potential,  they  do  suggest  the  potential contribution of GB to the reductions in weight gain and food consumption observed in animals administered the combination product.

## Local tolerance

In  repeat  dose  inhalation  toxicity  studies  with  CHF  5993,  no  signs  of  lung  irritation  were  seen  up  to  the highest  dose  administered  to  rats  and  dogs  for  13  consecutive  weeks  (see  subsection  'Repeat  dose toxicity'),  and  no  local  irritancy  or  systemic  toxicity  were  seen  following  administration  of  vehicle  (HFA, ethanol, HCl).

A calculation of safety margins for CHF 5993 with regard to clinical application, based on the local exposure of the alveolar epithelium to the active components BDP, FF and GB in 13-week inhalation toxicity studies in animal studies and in the clinical situation is presented in the following tables.

Table 7 Safety margin calculations concerning lung dose for the rat 13-week repeat dose toxicity study

|            | RAT - 13 WEEK TOX STUDY              | RAT - 13 WEEK TOX STUDY                             | HUMAN DAILY DOSE   | HUMAN DAILY DOSE                                    | SAFETY MARGIN   |
|------------|--------------------------------------|-----------------------------------------------------|--------------------|-----------------------------------------------------|-----------------|
| TEST ITEMS | NOAEL for local toxicity (µg/kg/day) | Corresponding Lung dose (µg/m 2 alveolar surface) $ | µg/day #           | Corresponding Lung dose (µg/m 2 alveolar surface) $ |                 |
| BDP        | 883                                  | 65                                                  | 400                | 7.4                                                 | 9               |
| FF         | 55                                   | 4                                                   | 24                 | 0.4                                                 | 10              |
| GB         | 207                                  | 15                                                  | 50                 | 0.9                                                 | 17              |

$ Calculations considered an alveolar surface areas of 0.34 m 2 for a 250g rat and 54 m 2  for a 60 kg human, and include a lung deposition factor of 10% of the inhaled dose in rat and 100% in human.

# Proposed human dose: 400/24/50 µ g/day of BDP/FF/GB

<div style=\"page-break-after: always\"></div>

Table 8 Safety margin calculations concerning lung dose for the dog 13-week repeat dose toxicity study

|            | DOG - 13 WEEK TOX STUDY              | DOG - 13 WEEK TOX STUDY                             | HUMAN DAILY DOSE   | HUMAN DAILY DOSE                                    | SAFETY MARGIN   |
|------------|--------------------------------------|-----------------------------------------------------|--------------------|-----------------------------------------------------|-----------------|
| TEST ITEMS | NOAEL for local toxicity (µg/kg/day) | Corresponding Lung dose (µg/m 2 alveolar surface) $ | µg/kg/day #        | Corresponding Lung dose (µg/m 2 alveolar surface) $ |                 |
| BDP        | 514                                  | 32                                                  | 400                | 7.4                                                 | 4               |
| FF         | 32                                   | 2                                                   | 24                 | 0.4                                                 | 5               |
| GB         | 130                                  | 8                                                   | 50                 | 0.9                                                 | 9               |

$ Calculations considered an alveolar surface areas of 40.7 m 2 for a 10kg dog and 54 m 2  for a 60 kg human, and include a lung deposition factor of 25% of the inhaled dose in dog and 100% in human.

# Proposed human dose: 400/24/50 µ g/day of BDP/FF/GB

## Other toxicity studies

## - Antigenicity

There is  no  specific  antigenic  concern  with  regard  to  the  single  active  components  (BDP,  FF,  GB)  of  CHF 5993. Nevertheless, an assessment of the leucocyte populations (immunophenotyping) was performed during the  4-week  repeat  dose  inhalation  toxicity  study  with  CHF  5993  in  rats.  A  relevant  effect  on  the  relative proportion of leukocyte subpopulations was not detected.

## -  Immunotoxicity

There is no specific immunotoxic alert for the single components (BDP, FF, GB) of CHF 5993. Nevertheless, a measurement  of  anti-sheep  red  blood  cell  (anti-SRBC)  IgM  titers  (as  an  indicator  of  primary  immune response)  was  performed  during  the  4-week  repeat-dose  inhalation  study  in  rats  to  assess  potential immunotoxicity. Unexpectedly, there was a statistically significant increase (to 433% of the placebo value) in  the  mean  anti-SRBC  IgM  titers of  male  rats treated  with  GB  alone  at  a  dose of 238  µg/kg/day.   The Applicant clarified that the high anti-SRBC IgM titers seen in male rats treated with GB alone were mainly due to the inclusion of 2 males (possible outliers) with titers substantially higher than the other males evaluated in this group, which had IgM titers similar to the females. Since there were no other findings in the 4 week study in rats as well as in published literature correlating high doses of GB (administered alone or as part of CHF 5993) with an effect on primary immune response, the Applicant concluded that the apparent effect on anti-SRBC IgM titers, observed in males only, was fortuitous. This conclusion is considered acceptable.

## - Excipients

The  CHF  5993  pMDI  formulation  contains  the  propellant  HFA-134a  and  low  quantities  of  the  excipients ethanol  and  hydrochloric  acid,  ingredients  commonly  and  safely  used  in  inhaled  pharmaceutical  products. Although  not  necessarily  required,  their  possible  adverse  effects  have  been  evaluated  during  inhalation toxicity studies where the vehicle alone was also tested.

## - Impurities

<div style=\"page-break-after: always\"></div>

From a toxicological point of view, the specifications of the BDP-, FF- and GB-related impurities have been adequately justified by the Applicant.

BDP-related :  The  Applicant  has  assessed  16-β-methylepoxide-17,21-dipropionate  (BDP  epoxide  or  CHF 4119),  a  degradation  product  that  the  Applicant  states  is  related  to  beclometasone  21-propionate,  for genotoxicity in a GLP-compliant Ames test, for its ability to cause chromosomal damage in vitro in cultured human lymphocytes, and in vivo in a test for micronuclei in polychromatic erythrocytes (PCEs) in mouse bone marrow. CHF 4119 was shown to be negative in these tests. CHF 4119 was found to cause no mortality following a single administration to CD-1 mice at doses of 5000mg/kg via oral gavage and 2000mg/kg i.p. As CHF 4119 is contained in any other impurities and hence ≤ 1.0% in the final product, this qualification  is sufficient to comply with the requirements of ICH Q3B.

FF related : FF related impurity CHF 4278 is present above the ICH Q3B qualification threshold in the finished product. An animal  group in the 13-week rat repeat dose toxicity study that received CHF 5993 containing 1% CHF 4278 did not exhibit any additional toxicity to that observed in the CHF 5993 group. In addition CHF 4278 was shown to be negative for genotoxicity in a bacterial Ames test.

A dedicated repeat dose toxicity study showed no difference in toxicological parameters in rats treated with CHF 1535 enriched with 2% formoterol ethanolate (CHF 4484) or PMA. The addition of a CHF 1535 control group in this experiment would have provided a more useful comparator to establish the effects of PMA and CHF4484 on toxicological parameters (rather than placebo/air control group). However, as treatment related toxicity was similar to that previously reported in the 13-week rat repeat dose toxicity studies, the approach is considered acceptable. Both PMA and CHF4484 were negative in a bacterial Ames test and did not induce chromosomal  aberrations  in  human  lymphocytes.  Therefore,  these  impurities  are  considered  sufficiently qualified.

GB-related : GB related impurity CHF 5463 was not mutagenic in an in vitro Ames test. It was not associated with any toxicity additional to that observed by GB when tested in a two-week repeat dose inhalation toxicity study in rats.

## 2.3.5. Ecotoxicity/environmental risk assessment

The  Applicant  provided  an  environmental  risk  assessment  in  accordance  with  the  'Guideline  on  the environmental  risk  assessment  of  medicinal  products  for  human  use'  (EMEA/CHMP/SWP/4447/00  corr  2). The PEC values in Phase I for all active ingredients (beclometasone dipropionate (BDP), formoterol fumarate dihydrate  (FF),  and  glycopyrronium  bromide  (GB))  are  below  the  action  limit  of  0.01  µg/l.  For  the  active substances  FF  and  GB  no  assessment  in  Phase  II  Tier  A  is  required.  BDP  and  its  active  metabolite beclometasone monopropionate (B17MP) are glucocorticoids. Glucocorticoids play a role in many physiological  processes  and  act  as  endocrine  disruptors.  Therefore,  according  to  the  EMA  guideline (EMEA/CHMP/SWP/4447/00),  a  tailored  environmental  risk  assessment  strategy  should  be  followed  to address its specific mechanism of action irrespective of the action limit of 0.01 µg/l.

The  Applicant  provided  acceptable  experimental  values  on  log  KOW  of  -0.02  and  -1.35  for  FF  and  GB, respectively. No further PBT assessment is required. For B17MP an experimental value of 3.49 is available and accepted by the assessor. The potential to bioaccumulate should be considered in Phase II Tier B for this active ingredient (see below).

<div style=\"page-break-after: always\"></div>

## Revised Summary of main study results

| Substance (INN/Invented Name): Formoterol fumarate dihydrate   | Substance (INN/Invented Name): Formoterol fumarate dihydrate   | Substance (INN/Invented Name): Formoterol fumarate dihydrate   | Substance (INN/Invented Name): Formoterol fumarate dihydrate   |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| CAS-number (if available): 183814-30-4                         | CAS-number (if available): 183814-30-4                         | CAS-number (if available): 183814-30-4                         | CAS-number (if available): 183814-30-4                         |
| PBT screening                                                  |                                                                | Result                                                         | Conclusion                                                     |
| Bioaccumulation potential- log K ow                            | OECD 107                                                       | -0.02                                                          | Potential PBT (N)                                              |
| PBT-assessment                                                 | PBT-assessment                                                 | PBT-assessment                                                 | PBT-assessment                                                 |
| Parameter                                                      | Result relevant for conclusion                                 |                                                                | Conclusion                                                     |
| Bioaccumulation                                                | log K ow                                                       | -0.02                                                          | not B                                                          |
| Persistence                                                    | DT50 or ready biodegradability                                 | not available                                                  |                                                                |
| Toxicity                                                       | NOEC or CMR                                                    | not available                                                  |                                                                |
| PBT-statement :                                                | The compound is not considered as PBT nor vPvB                 | The compound is not considered as PBT nor vPvB                 | The compound is not considered as PBT nor vPvB                 |
| Phase I                                                        | Phase I                                                        | Phase I                                                        | Phase I                                                        |
| Calculation                                                    | Value                                                          | Unit                                                           | Conclusion                                                     |
| PEC surfacewater , default                                     | 0.00012                                                        | µ g/L                                                          | > 0.01 threshold (N)                                           |

| Substance (INN/Invented Name): glycopyrronium bromide   | Substance (INN/Invented Name): glycopyrronium bromide   | Substance (INN/Invented Name): glycopyrronium bromide   | Substance (INN/Invented Name): glycopyrronium bromide   |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| CAS-number (if available): 51186-83-5                   | CAS-number (if available): 51186-83-5                   | CAS-number (if available): 51186-83-5                   | CAS-number (if available): 51186-83-5                   |
| PBT screening                                           |                                                         | Result                                                  | Conclusion                                              |
| Bioaccumulation potential- log K ow                     | OECD 107                                                | -1.35                                                   | Potential PBT (N)                                       |
| PBT-assessment                                          | PBT-assessment                                          | PBT-assessment                                          | PBT-assessment                                          |
| Parameter                                               | Result relevant for conclusion                          |                                                         | Conclusion                                              |
| Bioaccumulation                                         | log K ow                                                | -1.35                                                   | not B                                                   |
|                                                         | BCF                                                     | not available                                           |                                                         |
| Persistence                                             | DT50 or ready biodegradability                          | not available                                           |                                                         |
| Toxicity                                                | NOEC or CMR                                             | not available                                           |                                                         |
| PBT-statement :                                         | The compound is not considered as PBT nor vPvB          | The compound is not considered as PBT nor vPvB          | The compound is not considered as PBT nor vPvB          |
| Phase I                                                 | Phase I                                                 | Phase I                                                 | Phase I                                                 |
| Calculation                                             | Value                                                   | Unit                                                    | Conclusion                                              |
| PEC surfacewater , default                              | 0.00025                                                 | µ g/L                                                   | > 0.01 threshold (N)                                    |

## 2.3.6. Discussion on non-clinical aspects

## Pharmacology

## Primary pharmacodynamics

The  non-clinical  pharmacological  studies  conducted  by  the  Applicant  with  the  combination  of  GB  and  CHF 1535  (BDP+formoterol)  provide  support  for  the  concept  that  the  triple  combination  CHF  5993  displays increased efficacy/potency versus bronchoconstriction and airway hyper-responsiveness induced by different challenges.  Taken  together,  these  studies  support  the  concept  that  the  application  of  the  LAMA  GB  in combination  with  the  established,  clinically  efficacious  BDP+FF  (ICS  +  LABA)  combination  may  have  the

<div style=\"page-break-after: always\"></div>

potential to provide an additional benefit for the treatment of COPD patients, when compared with the single components (as to be verified by clinical data).

## Secondary pharmacodynamics

The Applicant has not provided any data. Taking into account that secondary pharmacodynamic effects of BDP,  FF  and  GB  have  been  evaluated  clinically  and  are  well-documented  in  published  literature,  this  is considered acceptable.

## Safety pharmacology

## Effects of CHF 5993 on cardiovascular and respiratory function in telemetered dogs

In  accordance  with  the  known  systemic  pharmacodynamic  effects  of  ß-adrenoceptor  agonists  (LABA)  and muscarinic antagonists (LAMA), in a safety pharmacology inhalation study in telemetered Beagle dogs, the cardiovascular system was the major target system for acute effects of CHF 5993. A significant increase in heart  rate  and  a  significant  decrease  in  blood  pressure  was  observed  for  all  CHF  5993  treated  groups, including the low-dose group (33+2+7 µg/kg BDP+FF+GB), and additional ECG changes, including a dosedependent increase of sinus and ventricular tachycardia, ventricular premature contractions and 1st to 2nd degree atrio-ventricular block were observed for the mid and high doses.

According to a safety margin calculation, based either on an allometric dose conversion (see Table 6) or on systemic  exposure  to  the  active  components  of  CHF  5993  (see  Table  7),  the  low  CHF  5993  dose  would correspond to about 3 to 5 times respectively 1.2 to 3 times the proposed human daily dose of CHF 5993, when considering the margins for FF and GB only (acute CV effects of CHF 5993 are expected to be mainly due to the pharmacological activity of the β2-adrenergic and/or anti-muscarinic components).

## Other data

No additional safety studies of the effects of the CHF 5993 combination on CNS parameters were carried out. Since  the  Applicant  provided  results  from  safety  pharmacology  studies  on  GB  and  CHF  1535  (BDP+FF), demonstrating no adverse CNS effects, this approach is considered acceptable.

## Pharmacokinetics

In  vitro pharmacokinetic studies were performed to investigate potential drug-drug interactions of GB and CHF  1535,  no  new in  vivo PK  studies  are  presented  for  CHF  1535,  but  a  more  extensive  PK  package  is presented for GB.

The individual components of CHF 5993 are rapidly absorbed following inhalation administration with Tmax reached in ≈ 1 hour and elimination half-lives of the components between 1-10 hours with little evidence of accumulation in rats and only slight accumulation in dogs (AUC week 13/day 1 ratios ranged 0.57-1.9). There was no significant change to drug exposure following combination administration relative to administration of CHF 1535 or GB alone (GB exposure was slightly lower in combination relative to single administration in rats, but this effect was not seen in dogs).

No human specific metabolite was found following incubation of GB with liver microsomes and hepatocytes from different  species.  The  main  metabolic  pathway  for  GB  is  cyclopentyl  ring  hydroxylation  and  hydroxyl group oxidation on the mandelic acid moiety with simultaneous cyclopentyl ring elimination.

BDP  is  rapidly  hydrolysed  to  its  main  active  metabolite  B17MP  and  to  B21MP  that  are  subsequently transformed into the pharmacologically inactive alcohol derivatives (BOH).

<div style=\"page-break-after: always\"></div>

FF metabolism involves O-glucuronidation, with the phenolic glucuronide as primary metabolite in rats, dogs and humans.

In vitro studies  suggest  that  GB  has  low  potential  for  drug-drug  interactions  at  clinically  relevant concentrations.

## Toxicology

The safety program for CHF 5993 is based on the toxicology program for the previously approved CHF 1535 (BDP+FF) combination and a full set of toxicology studies for GB. In addition, bridging studies with the CHF 5993 combination have been performed. All pivotal studies (with the exception of the single dose toxicity studies) were GLP compliant. It should be noted that bridging studies conducted with CHF 5993 use a higher GB dose (25 μg) than the proposed clinical product (12.5 μg). This is considered adequate to support this MAA.

## Repeat dose toxicity

## 4- and 13-week inhalation toxicity studies with CHF 5993 in dogs and rats

Thymus, heart, liver and adrenals were identified as primary target organs in both rats and dogs in the 13week  inhalation  repeat  dose  toxicity  studies  with  a  6  week  recovery  period.  Rats  appeared  to  be  highly sensitive to systemic pharmacological (corticosteroid) effects of BDP/B17MP in consequence a NOAEL could not  be  established  in  this  species.  In  dogs,  cardiovascular  effects  (e.g.  an  increase  in  heart  rate),  likely related  to  the  systemic  pharmacological  activity  of  FF  (ß2-adrenergic)  and/or  GB  (anti-muscarinic), represented prominent findings.

Overall, the toxicological profile of the triple combination reflected that of the single components without a relevant  quantitative  increase  in  toxicity  and  without  unexpected  findings.  For  this  reason,  chronic  toxicity studies of longer duration were not conducted by the Applicant, which is considered acceptable.

For  the  rat  repeat  dose  toxicity  studies,  exposure-based  safety  margins  for  the  designated  LOAELs  are generally covering the proposed human dose (i.e. safety margins are &gt; 1) for all the active components of CHF 5993 (see Tables 8 and 10).

Similarly,  for  the  dog  repeat  dose  toxicity  studies,  the  designated  NOAELs  provide  safety  margins  that generally  cover  the  proposed  human  dose  for  the  active  components  of  CHF  5993,  only  the  systemic exposure for B17MP was lower than the expected exposure in man at the proposed clinical dose (see Tables 9 and 11).

## Repeat-dose toxicity studies with GB

When administered alone, GB appears to be well tolerated in rats and dogs with mydriasis, a slight increase in HR (both directly related to its anti-muscarinic mechanism of action) and a slight decrease in body weight gain, being the only reported effects following inhalation dosing for up to 13 weeks in repeat-dose toxicity studies and for up to 104 weeks in the long-term carcinogenicity study conducted with GB in rats.

## Genotoxicity

Both  GB  and  CHF  1535  were  negative  for  mutagenicity  in  the  bacterial  Ames  test,  and  did  not  produce chromosomal damage in in  vitro chromosome  aberration  tests  performed  in  human  lymphocyte  cells  and were negative in in vivo micronucleus assays performed in rats. The lack of any genotoxicity data for the CHF 5993  combination  product  is  acceptable  given  the  lack  of  genotoxic  activity  exhibited  by  the  single components.

<div style=\"page-break-after: always\"></div>

## Carcinogenicity

No long term carcinogenicity studies were conducted on the CHF 5993 combination. However, in a 104-week rat  inhalation  carcinogenicity  study  and  an  oral  26-week  carcinogenicity  in  transgenic  Tg.rasH2  mice performed by the Applicant, GB showed no carcinogenic potential and published data concerning long term studies conducted with BDP and FF in rats do also not indicate a clinically relevant carcinogenic potential.

## Reproductive toxicity

Only  one  species  was  used  to  investigate  the  effect  of  CHF  5993  administration  on  embryo/foetal development.  This  is  considered  acceptable  as  the  effects  of  the  individual  components  of  CHF  5993  on embryo/foetal  development  have  previously  been  characterised,  and  the  potential  corticosteroid  related foetal toxicity has been previously reported.

The effects of CHF 5993 on fertility and early embryonic development, embryo-foetal development and on the  pre-  and  post-natal  development  were  studied  in  rats  following  oral  administration.  Toxicokinetic evaluation for CHF 5993 was performed in a separate dose-range finding and toxicokinetic study with CHF 5993.  Furthermore,  embryo-foetal  developmental  studies  with  glycopyrronium  alone  in  rats  and  rabbits together with dose-range-findings and toxicokinetic studies in both species were also submitted.

The effects seen in reproduction toxicity studies for CHF 5993 were generally similar to those reported for the single agents. However some effects occurred at exposure levels of the single components which were similar or even lower than the human exposure at the therapeutic dose and should be regarded as clinical relevant. At higher doses, CHF 5993 was shown to exhibit a slight disturbance in development in the embryo-foetal development study; this is most likely a corticosteroid-related effect.

The  high  mortality  and  the  difficulties  with  birth  seen  in  the  pre-postnatal  developmental  study  with  CHF 5993 in the 2 mg/kg dose group is probably linked to the known effects of the β2-sympathomimetic FF and is consistent  with  that  previously  seen  with  Foster  (BDP+FF  -  ratio  100+6)  in  the  rat  pre-postnatal development  study.  Also,  it  cannot  be  excluded  that  antimuscarinic  effects  of  GB  such  as  dry  mouth  or tachycardia  could  have  compounded  the  tocolytic  effects  of  FF  and  contributed  to  worsening  the  general health of the dams. The exposure levels at the NOAEL for FF and GB were below the human exposure levels at the recommended therapeutic dose of Trimbow in COPD patients and thus these effects may be of clinical relevance. Adequate information has been introduced in sections 4.6 and 5.3 of the SmPC to mention that also the anti-muscarinic effects of GB may contribute to the effects seen in pregnant rats in the late phase of gestation and early phase of lactation and the loss of pups.

## Local tolerance

In  repeat  dose inhalation toxicity studies with CHF 5993 in rats and dogs of up to 13 weeks duration, no signs of lung irritation were seen up to the highest doses administered. A calculation of safety margins for CHF 5993, based on the local exposure of the alveolar epithelium in the animal studies and in the clinical situation, provided values &gt; 1 for all active components of CHF 5993, indicating an adequate exposure of the animals in the repeat dose toxicity studies to BDP, FF and GB (see Tables 12 and 13).

## Other studies

## Immunotoxicity

There is no specific immunotoxic alert on the single components of CHF 5993 (BDP, FF, GB). Nevertheless, a measurement  of anti-sheep  red  blood  cell  (anti-SRBC)  IgM titers (primary  immune  response) was performed during the 4-week inhalation repeat dose study in rats to assess potential immunotoxicity. Besides

<div style=\"page-break-after: always\"></div>

an increase in the mean anti-SRBC IgM titers of male rats treated with a GB dose of 238 µg/kg/day no relevant findings were observed.

## Impurities

The Applicant conducted an additional toxicological qualification for the BDP metabolite BDP epoxide, which was shown to be negative for mutagenicity in a bacterial Ames test, does not induce chromosomal aberrations in vitro in human lymphocytes and does not induce chromosomal damage as assessed in an in vivo test for micronuclei in polychromatic erythrocytes (PCEs) in mouse bone marrow.

FF related impurities PMA, formoterol ethanolate and deformilate at 2%, 2% and 1% of FF dose respectively were not found to alter toxicological parameters following 13 week inhalation in rats. Furthermore, none of these impurities was associated with mutagenicity as assessed in a bacterial Ames test and neither PMA nor formoterol ethanolate were found to produce chromosomal aberrations in human lymphocytes.

GB related impurity CHF5463 was not mutagenic in an in vitro Ames test. It was not associated with any toxicity additional to that observed by GB when tested in the two-week repeat dose inhalation toxicity study in rat.

## Environmental risk assessment

Regarding the specific mode of action of B17MP, the Applicant provided a chronic Fish Full Life-Cycle study covering development and reproduction of Fathead Minnows (Pimephales promelas). The performance of the test is acceptable and valid. In conclusion, a PEC/PNEC risk quotient of 0.14 can be derived considering a NOEC of 0.13 µgl-1 and a PEC value for B17MP of 0.0018 µgl-1. It is considered that caused by the specific mechanism of action an Algae Toxicity Test (OECD 201) and a Daphnids Reproduction Test (OECD 211) as well as a Sediment Organism Test with invertebrates (e.g. OECD 218) can be waived as the Fish Full LifeCycle Test is considered the appropriate effect study for ERA.

However, a fate assessment should also be included to conclude on the behaviour of the active substance in the natural environment. Thus the Applicant agreed with the CHMP request to commit to provide a test on transformation  in  water  -  sediment  systems  (OECD  308)  if  the  substance  is  not  readily  biodegradable  in accordance with OECD 301.

Furthermore,  the  log  KOW  of  B17MP  is  above  3,  which  requires  the  consideration  of  the  bioconcentration factor in fish. The Applicant committed also to provide an experimental study of BCF in fish according to TG OECD 305 in the post approval setting.

For GB and FF no detailed environmental risk assessment is considered necessary because the action limit in Phase  I  is  not  exceeded.  Further  PBT  assessment  is  not  necessary.  The  ERA  for  these  two  ingredients  is completed.

As a result of the above considerations for the active ingredient, the available data do not allow to conclude definitively on the potential risk of BDP. Upon request of CHMP, the Applicant commits to provide the missing data  on  fate  and  bioconcentration  by  the  end  of  the  year  2018.  This  is  accepted.  A  respective  letter  of agreement has been provided, including an expected time schedule.

## 2.3.7. Conclusion on non-clinical aspects

In accordance with the EMA 'GL on the non-clinical development of fixed combinations of medicinal products' (EMEA/CHMP/SWP//258498/2005), the Applicant has submitted nonclinical pharmacological, pharmacokinetic

<div style=\"page-break-after: always\"></div>

and toxicological study data for the CHF 5993 triple combination as applicable. In addition, the Applicant has provided additional nonclinical studies for GB, including a long-term and a short-term carcinogenicity study, as recommended by the EMA in a scientific advice given in 2013.

Overall, the primary pharmacodynamic studies provided adequate evidence to support the concept that the combination  of  the  LAMA  GB  with  the  established  BDP+FF  (ICS  +  LABA)  combination  (CHF  1535)  may provide  an  additional  benefit  for  the  treatment  of  COPD  patients,  when  compared  with  the  single components.

From the pharmacokinetic point of view, both rat and dog were identified as relevant species for non-clinical testing.

Overall,  the  toxicology  programme  for  CHF  5993  revealed  no  unexpected  toxicity  based  on  conventional studies of safety pharmacology and repeat dose toxicity and this information was included in SmPC section 5.3. The reproductive toxicity studies suggest that CHF 5993 may be associated with reproductive toxicity and administration to pregnant women should only be considered when the potential benefits outweigh the risks to the foetus. Appropriate warnings have been included in section 4.6 of the SmPC.

The non-clinical data provided is considered acceptable.

The  CHMP  recommended  that  tests  for  fate  assessment  and  for  the  study  on  bioconcentration  of  BDP  in accordance with TG OECD 305 should be conducted post-approval.

## 2.4. Clinical aspects

## 2.4.1. Introduction

The clinical programme of CHF 5993 pMDI in COPD included:

- Studies of the single GB entity, which has been developed as two different strengths (i.e. GB 12.5 pMDI and GB 25 pMDI) to mirror the GB component and formulation in CHF 5993 pMDI and to appropriately evaluate the LAMA component of the triple FDC (see Table below);
- Studies conducted on the TRIPLE combination CHF 5993 pMDI in healthy subjects (Table below) and in COPD patients (Table below).

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant.

A routine GCP inspection of the clinical study Triple 5 was to verify compliance with ICH GCP and applicable regulations (GCP/2016/036). The sites selected for the inspection were: site 38503 - PI Francesco Mazza Italy; site 203511 - PI Ilona Pavlislova - Czech Republic and the Sponsor Chiesi Farmaceutici SpA. Based on the  inspection  and  the  findings  observed  it  can  be  concluded  that  study  TRIPLE  5  has  generally  been conducted  by  the  two  sites  in  compliance  with  GCP  and  internationally  accepted  ethical  standards.  The deficiencies observed do not pose a risk for patients or data quality (Integrated Inspection Report, dated 8 May 2017).

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 9 Overview of the clinical development - GB single agent

|                                        | Study GLYCO 1 CCD-0915-CSR- 0048                                                                                                                  | Study TRIPLE 1 CCD-1101-                                                                                                                                                         | Study GLYCO 2 CCD-0916-CSR-0054                                                                                                      | Study GLYCO 2 CCD-0916-CSR-0054                                                                                                                                                                                                               | Study TRIPLE 9 CCD-                                                                                   |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
|                                        |                                                                                                                                                   | CSR-0049                                                                                                                                                                         | Part 1                                                                                                                               | Part 2                                                                                                                                                                                                                                        | 05993AA1-09                                                                                           |
| Study type                             | PK                                                                                                                                                | PK                                                                                                                                                                               | Efficacy and safety                                                                                                                  | Efficacy and safety                                                                                                                                                                                                                           | Efficacy and safety                                                                                   |
| Design                                 | Phase I, randomised, open-label, single-dose, 3 way cross-over, single centre                                                                     | Phase I, randomised, open label, single dose, placebo controlled, 4 way cross-over, single centre                                                                                | Phase II, randomised, double blind, placebo controlled, single dose escalation, alternating cross over, single centre                | Phase II, randomised, double blind, placebo controlled, repeated dose 4-way cross over followed by an open label period with Tiotropium, single centre                                                                                        | Phase IIb, randomised, double blind, placebo controlled, 2 way cross over, multicentre, multinational |
| Primary objective                      | To investigate the pharmacokinetics, the absolute availability and the lung bioavailability of inhaled GB 25 pMDI with and without charcoal block | To evaluate the PK interaction between GB and FF by comparing systemic exposure after a single dose of free combination of GB 25 µg pMDI and FF 12 µg pMDI to that of the single | To assess the safety/tolerability of single administration of GB pMDI at 5 dose levels                                               | To assess the bronchodilator efficacy of GB pMDI at 3 dose levels by comparison with GB placebo pMDI after repeated administrations                                                                                                           | To demonstrate the superiority of GB 12.5 pMDI vs. GB placebo pMDI in terms of lung function          |
| Study treatment and total (daily) dose | Inhaled GB 25 pMDI with or without charcoal block, 4 puffs (total dose: 100 µg GB)                                                                | components GB 25 pMDI + FF 12 pMDI, 4 and 2 puffs, respectively (total dose: 100 µg GB + 24 µg FF)                                                                               | GB 12.5 pMDI, 1 puff (total dose: 12.5 µg GB), GB 25 pMDI, 1, 2, 4 and 8 puffs (total dose: 25, 50, 100 and 200 µg GB, respectively) | GB 12.5 pMDI, 1 puff bid (total daily dose: 25 µg GB), GB 25 pMDI, 1 and 2 puffs bid (total daily dose: 50 and 100 µg GB), Tiotropium, 1 inhalation daily of 18 µg. On Day 8 of each treatment period: FF 12 µg on top of GB pMDI, placebo or | GB 12.5 pMDI, 2 puffs bid (total daily dose: 50 µg GB)                                                |
| Subjects/patients                      | Healthy subjects                                                                                                                                  | Healthy subjects                                                                                                                                                                 | Tiotropium Moderate to severe COPD patients                                                                                          | Tiotropium Moderate to severe COPD patients                                                                                                                                                                                                   | Moderate to very severe COPD patients                                                                 |
| Number of                              | 20                                                                                                                                                | 44                                                                                                                                                                               | 27 38                                                                                                                                | 27 38                                                                                                                                                                                                                                         | 100                                                                                                   |

<div style=\"page-break-after: always\"></div>

| randomised subjects/patients       |                                                                                                        |                                                                                                          |                                                             |                                                                                                        |                              |
|------------------------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|------------------------------|
| Comparators and total (daily) dose | Intravenous injection of a 200 µg/mL GB solution (Robinul; 1x 0.5 mL injection, total dose: 100 µg GB) | GB 25 pMDI, 4 puffs (total dose: 100 µg) FF 12 pMDI, 2 puffs (total dose: 24 µg FF) Placebo pMDI, 1 puff | GB placebo pMDI, number of puffs to match GB pMDI treatment | GB placebo pMDI, number of puffs to match GB pMDI treatment with administration of FF 12 pMDI on Day 8 | GB placebo pMDI, 2 puffs bid |
| Treatment duration                 | Single-dose                                                                                            | Single-dose                                                                                              | Single-dose                                                 | 8 days with an add-on single dose of FF 12 pMDI on Day 8                                               | 4 weeks                      |

## Table 10 Overview of the clinical development - CHF 5993 pMDI TRIPLE combination in healthy subjects

|                                        | Study TRIPLE 2 CCD-1102-CSR-0056                                                                                                                                                 | Study TRIPLE 10 CCD-05993AA1-10                                                                                                                                                   | Study TRIPLE 12 CCD-05993AA1-12                                                                                                                                                                                                               |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study type                             | PK                                                                                                                                                                               | PK                                                                                                                                                                                | PK                                                                                                                                                                                                                                            |
| Design                                 | Phase I, randomised, open-label, single-dose, 4-way cross-over                                                                                                                   | Phase I, non-randomised, open-label, parallel-group                                                                                                                               | Phase I, randomised, open-label, single-dose, 2-way cross-over                                                                                                                                                                                |
| Primary objective                      | To evaluate the PK and biopharmaceutical interactions between GB 25 pMDI and Foster 100/6 pMDI administered separately, in free combination or in the FDC CHF 5993 100/6/25 pMDI | To characterise the pharmacokinetics of the GB component of CHF 5993 100/6/25 pMDI in subjects with renal impairment in comparison with demographically-matching healthy subjects | To evaluate the PK interaction when CHF 5993 100/6/25 pMDI is administered with cimetidine by comparing the systemic exposure of GB after a single dose of the FDC CHF 5993 100/6/25 pMDI administered alone or at steady-state of cimetidine |
| Study treatment and total (daily) dose | CHF 5993 100/6/25 pMDI, 4 puffs (total dose: 400/24/100 µg CHF 5993)                                                                                                             | CHF 5993 100/6/25 pMDI, 4 puffs (total dose: 400/24/100 µg CHF 5993)                                                                                                              | Cimetidine + CHF 5993 100/6/25 pMDI, 800 mg bid and 4 puffs, respectively (total daily dose: 1600 mg cimetidine + 400/24/100 µg CHF 5993)                                                                                                     |
| Subjects                               | Healthy subjects                                                                                                                                                                 | Subjects with mild, moderate and severe renal impairment vs. demographically-matching healthy subjects                                                                            | Healthy subjects                                                                                                                                                                                                                              |
| Number of randomised subjects          | 44                                                                                                                                                                               | 42                                                                                                                                                                                | 26                                                                                                                                                                                                                                            |
| Comparators and total (daily) dose     | Foster 100/6 pMDI + GB 25 pMDI, 4 puffs of each (total dose: 400/24 µg Foster + 100 µg GB) GB 25 pMDI, 4 puffs (total dose: 100 µg GB)                                           | -                                                                                                                                                                                 | CHF 5993 100/6/25 pMDI, 4 puffs (total dose: 400/24/100 µg CHF 5993)                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                    | Foster 100/6 pMDI, 4 puffs (total dose: 400/24 µg Foster)   |             |                                                                                                                                                         |
|--------------------|-------------------------------------------------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment duration | Single-dose                                                 | Single-dose | Repeated doses of cimetidine for 6 days + single dose of CHF 5993 100/6/25 pMDI on the 4 th day (Day 1); Single dose of CHF 5993 100/6/25 pMDI on Day 1 |

## Table 11 Overview of the clinical development plan - CHF 5993 pMDI TRIPLE combination in COPD patients

|                                        | Study TRIPLE 4 CCD-05993AA1-04                                                                                             | Study TRIPLE 3 CCD-1106-PR- 0066                                                                                                                | Study TRIPLE 5 CCD-1207-PR-0091 PIVOTAL                                                                                 | Study TRIPLE 6 CCD-1208-PR-0090 PIVOTAL                                                                                                                          | Study CARSAF CCD-1107-CSR- 0067                                                                                              |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Study type                             | PK/PD                                                                                                                      | Efficacy and safety                                                                                                                             | Efficacy and safety                                                                                                     | Efficacy and safety                                                                                                                                              | Safety                                                                                                                       |
| Design                                 | Phase I, randomised, open-label, single-dose, placebo-controlled, 3-way cross-over, single centre                          | Phase II, randomised, double-blind, active-controlled, 4-way cross-over, multicentre, multinational                                             | Phase III, randomised, double-blind, active-controlled, 2-arm parallel group, multicentre, multinational                | Phase III, randomised, double-blind, double-dummy, active-controlled, 3-arm parallel group, multicentre, multinational                                           | Phase II, randomised, double-blind, active-controlled, 3-arm parallel group, multicentre, multinational                      |
| Primary objective                      | To investigate the effect of AeroChamber Plus ™ spacer on PK of CHF 5993 100/6/25 pMDI active ingredients                  | To assess the efficacy of Foster 100/6 pMDI + GB pMDI (3 dose-level) vs. Foster 100/6 pMDI in terms of lung function                            | To demonstrate the superiority of CHF 5993 100/6/12.5 pMDI vs. Foster 100/6 pMDI in terms of lung function and dyspnoea | To demonstrate the superiority of CHF 5993 100/6/12.5 pMDI vs. Tiotropium in terms of moderate/severe COPD exacerbation rate                                     | To assess the effects of Foster 100/6 pMDI + GB pMDI (2 dose-levels) vs. Foster 100/6 pMDI in terms of cardiovascular safety |
| Study treatment and total (daily) dose | CHF 5993 100/6/25 pMDI with AeroChamber Plus ™ , 4 puffs (total dose: 400/24/100 µg CHF 5993)                              | Foster 100/6 pMDI, 2 puffs bid + GB 12.5, 1 puff bid or GB 25 pMDI, 1 or 2 puffs bid (total daily dose: 400/24 µg Foster + 25, 50 or 100 µg GB) | CHF 5993 100/6/12.5 pMDI, 2 puffs bid (total daily dose: 400/24/50 µg CHF 5993)                                         | CHF 5993 100/6/12.5 pMDI, 2 puffs bid (total daily dose: 400/24/50 µg CHF 5993)                                                                                  | Foster 100/6 pMDI, 2 puffs bid + GB 12.5 or 25 pMDI, 2 puffs bid (total daily dose: 400/24 µg Foster + 50 or 100 µg GB)      |
| Patients                               | Moderate to severe COPD patients                                                                                           | Moderate to severe COPD patients                                                                                                                | Severe to very severe COPD patients                                                                                     | Severe to very severe COPD patients                                                                                                                              | Moderate to severe COPD patients                                                                                             |
| Number of randomised patients          | 36                                                                                                                         | 178                                                                                                                                             | 1368                                                                                                                    | 2691                                                                                                                                                             | 191                                                                                                                          |
| Comparators and total (daily) dose     | CHF 5993 100/6/25 pMDI with standard actuator, 4 puffs (total dose: 400/24/100 µg CHF 5993) CHF 5993 Placebo pMDI, 4 puffs | Foster 100/6 pMDI, 2 puffs bid (total daily dose: 400/24 µg Foster)                                                                             | Foster 100/6 pMDI, 2 puffs bid (total daily dose: 400/24 µg Foster)                                                     | Foster 100/6 pMDI, 2 puffs bid + Tiotropium, 1 capsule od (total daily dose: 400/24 µg Foster + 18 µg Tiotropium) Tiotropium, 1 capsule od (total daily dose: 18 | Foster 100/6 pMDI, 2 puffs bid + GB placebo pMDI, 2 puffs bid (total daily dose: 400/24 µg Foster)                           |

<div style=\"page-break-after: always\"></div>

|                    |             |        |          | µg Tiotropium)   |         |
|--------------------|-------------|--------|----------|------------------|---------|
| Treatment duration | Single-dose | 1 week | 52 weeks | 52 weeks         | 14 days |

## 2.4.2. Pharmacokinetics

## · Introduction

As the pharmacokinetics of BDP and FF is known, the primary purpose of the clinical PK programme was to characterise the PK profiles of GB as single monotherapy and to rule out any PK interactions between the individual components of CHF 5993.

Six clinical pharmacology studies were conducted to characterise the PK profiles of BDP/B17MP, FF and GB. In addition, two Phase II studies (studies GLYCO 2 and CARSAF) and one Phase III study (study TRIPLE 6) also assessed the PK of the active components of CHF 5993 pMDI. PK data from study TRIPLE 6 were pooled with those from study CARSAF and subjected to a population PK analysis.

The formulation CHF 5993 100/6/25 pMDI with a higher GB dose (25 µg/actuation) was used as a treatment to allow a more reliable estimation of GB plasma concentration vs. time in four PK studies (study TRIPLE 2, study TRIPLE 4, study TRIPLE 10 and study TRIPLE 12).

In  addition,  the  applicant  has  developed  CHF  5259,  a  GB  pMDI  formulation,  as  a  single  agent.  This formulation was developed at two GB strengths: 12.5 µg/actuation (referred to as GB 12.5 pMDI) and 25 µg/actuation (also referred to as GB 25 pMDI). These two GB strengths allowed single-dose administration of GB at total dose of 100 µg in studies GLYCO 1, TRIPLE 1 and TRIPLE 2 as well as a total GB dose range up to 100 µg in studies CARSAF and TRIPLE 3, and up to 200 µg in study GLYCO 2.

## · Absorption

Study GLYCO 1 was conducted to investigate the pharmacokinetics, the absolute bioavailability and the lung bioavailability  of  single  dose  GB  in  healthy  subjects.  GB  Cmax  and  AUC0-30min  were  similar  following administration with or without charcoal block with 90% CI of the ratio of geometric means of 85 - 123% and 92  -  124%,  respectively,  indicating  that  the  rate  of  lung  absorption  of  GB  was  comparable  with  the  two treatment  procedures.  The  overall  systemic  exposure  was  slightly  decreased  using  the  charcoal  block  as indicated by the 90% CI of the ratio of geometric means of 104-149% for AUC0-t and 99-153% for AUC024h.  The  mean  lung  bioavailability  of  GB  was  10.5%  (with  activated  charcoal  blockage)  while  the  mean absolute bioavailability was 12.8% (without activated charcoal blockage).

The mean elimination half-life of GB in healthy volunteers was approximately 6 hours after a GB single i.v. injection. 40% of the dose was excreted in the urine within 24 hours (study GLYCO 1).

Study GLYCO 2 (part 2) was conducted to investigate the pharmacokinetics of repeated inhalation of doses ranging  from  12.5  to  50  µg  twice  daily  in  COPD  patients.  GB  showed  linear  pharmacokinetics  with  little systemic  accumulation  at  steady-state  (median  accumulation  ratio  was  2.2  to  2.5).  Steady  state  plasma concentrations were reached within 6 days of treatment, as indicated by similar pre-dose levels on Days 6 and 7.

Study TRIPLE 2 was conducted to evaluate the PK and biopharmaceutical interactions between GB 25 pMDI and Foster pMDI, administered as free combination, and as CHF 5993 pMDI in healthy subjects. Absence of biopharmaceutical interaction between CHF 5993 pMDI components was demonstrated for BDP/B17MP and FF since the 90% confidence intervals (CIs) for the ratio of adjusted geometric means for Cmax and AUC0-t

<div style=\"page-break-after: always\"></div>

were  within  the  bioequivalence  limits  of  80-125%.  Only  GB  systemic  exposure  (AUC0-t)  was  slightly increased (by 13%, 90% CI 98.60 - 130.48%) after administration of CHF 5993 100/6/25 pMDI compared to the free combination.

The  effects  of  the  AeroChamber  Plus  Flow-Vu  VHC  spacer  on  the  pharmacokinetics  of  CHF  5993  pMDI  in COPD  patients  was  investigated  in  study  TRIPLE  4.  The  use  of  spacer  and  holding  chamber  devices  can eliminate the issues associated with inadequate inhalation technique by minimizing coordination difficulties, reducing oropharyngeal deposition and increasing lung deposition. This is most important in pMDIs containing corticosteroids  since  oropharyngeal  deposition  of  inhaled  corticosteroids  may  lead  to  oral  absorption  and contribute to local side effects, including pharyngeal candidiasis, dysphonia as well as systemic side effects such as hypothalamic pituitary adrenal suppression.

Inhalation  of  CHF  5993  pMDI  with  the  spacer  AeroChamber  Plus™  resulted  in  an  increase  in  GB  lung exposure (Cmax and AUC0-30min) and total exposure (AUC0-t). GB Cmax, AUC 0-30min and AUC0-t were higher  after  inhalation  of  CHF  5993  pMDI  with  spacer  compared  to  inhalation  without  spacer,  with  point estimates (90% CI) of the ratios of 160.4% (131.5-195.7%), 160.0% (133.9-191.1%) and 144.8% (127.4164.6%), respectively.

For FF and B17MP an increase in lung exposure (Cmax and AUC0-30min) and in a decrease in total exposure (AUC0-t)  were  observed.  The  effects  of  the  AeroChamber  Plus™  spacer  on  B17MP  and  formoterol  PK observed in study TRIPLE 4 are in line with previous PK data obtained after inhalation of Foster 100/6µg pMDI with the same spacer. The spacer AeroChamber Plus™ is already approved for use with Foster 100/6µg pMDI.

## · Distribution

In  study  GLYCO  1,  the  apparent  volume  of  distribution  (Vz)  of  inhaled  GB  was  increased  compared  to intravenous (i.v.) infusion (6420 L versus 323 L), reflecting the slower elimination after inhalation.

## · Metabolism

In vitro metabolism studies showed GB hydrolysis to be a minor and negligible metabolic route. CYP2D6 was found  to  be  the  only  enzyme  responsible  for  GB  metabolism.  After  intra-tracheal  administration,  oral administration and inhalation of GB in male rats, CHF 6006, an acidic metabolite arising from ester hydrolysis of GB, was detected in the systemic circulation.

The PK profile of CHF 6006 was assessed in study TRIPLE 12 in healthy volunteers. CHF 6006 was detected in plasma, with a systemic exposure of the same order of magnitude as GB.

CHF 6006 is devoid of any activity against muscarinic receptors.

## · Elimination

The mean elimination half-life of GB in healthy volunteers was approximately 6 hours after a GB single i.v. injection. 40% of the dose was excreted in the urine within 24 hours (study GLYCO 1).

In  COPD  patients  receiving  repeated  twice  daily  administration  of  inhaled  GB  mean  elimination  half-life ranged from 5 to 12 hours at steady state. The fraction of the dose excreted in urine ranged from 13.0% to 14.5% at steady state (study GLYCO 2 Part 2).

Mean renal clearance was similar across the range of doses tested and after single and repeated inhalation (range 281-396 mL/min).

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

Dose proportionality of GB has been investigated in study GLYCO 2 Part 2 Time dependency of GB has been investigated in study GLYCO 1 and GLYCO 2 Part 2.

## · Special populations

PK, safety and tolerability of CHF 5993 pMDI in subjects with impaired renal function has been investigated in study TRIPLE 10. Systemic exposure (AUC0-t) to B17MP and FF was not affected by mild to severe renal impairment. For GB, there was no impact in patients with mild and moderate renal impairment. However, an increase in total systemic exposure of up to 2.5-fold was observed in subjects with severe renal impairment (GFR below 30 mL/min/1.73 m2), as a consequence of a significant reduction of the amount excreted in urine (approximately 90% reduction of GB renal clearance). Results from study TRIPLE 10 supports the conclusion and the recommendations made in the SmPC regarding the fact that use of CHF 5993 in patients with severe renal  impairment  or  end-stage  renal  disease  requiring  dialysis  be  considered  only  if  the  expected  benefit outweighs the potential risk (see SmPC section 4.2).

Specific  clinical  studies  have  not  been  conducted  for  CHF  5993  pMDI  in  patients  with  impaired  hepatic function  since  GB  is  predominantly  cleared  by  renal  excretion.  Thus,  mild  or  moderate  impairment  of  the hepatic metabolism of GB is not thought to result in a clinically relevant increase of its systemic exposure. Nevertheless, since no relevant data on the use of CHF 5993 in patients with severe hepatic impairment are available, CHF 5993 should be used with caution in these patients and potential adverse reactions should be monitored. Appropriate recommendations and warnings have been incorporated into the SmPC (see section 4.2 and section 4.4).

A  specific  PK  study  to  evaluate  a  difference  in  PK  due  to  gender,  body  weight  and  age  has  not  been conducted.

In the population PK analysis with PK data from studies TRIPLE 6 and CARSAF, gender and age was not found to be a significant covariate of B17MP, FF and GB. No dosage adjustment is required in elderly patients (65 years of age and older). Body weight, however, was found to be a significant covariate of B17MP, FF and GB. In  COPD  patients  with  very  low  body  weight  (i.e.  less  than  40  kg)  and  with  concomitant  severe  renal impairment (i.e. GFR below 27 mL/min/1.73 m²), a dose adjustment would be indicated.

## · Interactions

Study  TRIPLE  1  investigated  the  pharmacokinetic  interaction  of  GB  and  FF  by  comparing  the  systemic exposure  after  a  single  dose  of  the  free  combination  of  CHF  5259  and  Atimos  to  that  of  the  single components. Study TRIPLE 2 was conducted to evaluate the PK interactions between GB 25 pMDI and Foster pMDI, administered separately, and as free combination. The PK interaction was investigated by comparing the systemic exposure in terms of Cmax and AUC0-t, between FosterFoster + GB and Foster and between Foster + GB and GB. Both studies have demonstrated a similar plasma concentration profile for GB and FF as well as for BDP/B17MP, FF and GB.

Study TRIPLE 12 evaluated the extent of the drug-drug interaction between CHF 5993 and the OCT2/MATE1 inhibitor cimetidine. Co-administration of CHF 5993 pMDI with Cimetidine resulted in a slight increase of the total GB AUC0-t by 16% and of Cmax by 26% compared with the administration of CHF 5993 pMDI alone. FF AUC0-t showed also an increase after co-administration of CHF 5993 pMDI with Cimetidine by 21%, while Cmax  as  well  as  tmax  were  not  influenced  by  Cimetidine.  Based  on  the  magnitude  of  the  observed  PK

<div style=\"page-break-after: always\"></div>

changes  for  GB  and  FF,  no  clinically  relevant  drug  interaction  is  expected  when  CHF  5993  pMDI  is  coadministered with cimetidine.

Appropriate information has been included in the SmPC section 4.5.

## 2.4.3. Pharmacodynamics

## · Primary and secondary pharmacology

No new studies investigating the pharmacodynamics of BDP, a synthetic corticosteroid, and FF, a long-acting beta2 receptor agonist, have been conducted as the PD of these actives are well known.

GB  is  a  high-affinity,  long-acting  muscarinic  receptor  antagonist  (anticholinergic)  used  for  inhalation  as bronchodilator  treatment  of  COPD.  A  greater  than  4-fold  selectivity  for  the  human  M3  receptors  over  the human  M2  receptor  has  been  demonstrated.  Parasympathetic  nerves  are  the  major  bronchoconstrictive neural pathway in airways, and cholinergic tone is a key reversible component of airflow obstruction in COPD. GB works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.

The applicant has conducted a cardiac safety study (CARSAF) in COPD patients to investigate the effects of GB on other PD parameters (e.g. heart rate, QT interval, and blood pressure). The aim of the study was to evaluate the variation of a selected set of cardiovascular parameters induced by Foster plus two dosages of GB (daily dose 50 or 100μg) compared to Foster alone (daily dose 400/24) in moderate to severe patients with COPD. The mean 24-hour heart rate slightly decreased from baseline to day 14 in all treatment groups. ECG parameters (including QTcF interval) were comparable in the three groups at both the first and the last day  of  study  treatment.  The  mean  heart  rate,  systolic  and  diastolic  blood  pressure  did  not  substantially change from pre- to post-dose at baseline, day 7 and day 14 in the three treatment groups.

Six clinical pharmacology studies were conducted to characterise the profiles of BDP/FF/GB delivered by CHF 5993 pMDI. The design and methodology of these studies were considered appropriate.

## 2.4.4. Discussion on clinical pharmacology

The  studies  investigated  the  PK  and  the  absolute  and  lung  bioavailability  of  inhaled  GB  25  pMDI  with  or without charcoal block in healthy subjects (study GLYCO 1) and demonstrated low oral bioavailability of the GB component of CHF 5993. There was little or no interaction between GB and FF after administration of single doses of the free combination GB 25 pMDI + FF 12 µg pMDI or single dose of the single components in healthy subjects (study TRIPLE 1). The PK and biopharmaceutical interactions between GB 25 pMDI and CHF 1535 pMDI, administered separately, as a free combination or as the FDC CHF 5993 pMDI in healthy subjects (study TRIPLE 2) did not suggest a clinically meaningful interaction.

The PK of CHF 5993 was investigated with special focus on GB, after a single dose in subjects with renal impairment  compared  to  healthy  subjects  and  showed  increasing  exposure  with  decline  in  renal  function (study TRIPLE 10). Use of CHF 5993 in patients with severe renal impairment or end-stage renal disease requiring  dialysis  should  be  considered  only  if  the  expected  benefit  outweighs  the  potential  risk.  Since  no relevant data on the use of CHF 5993 in patients with severe hepatic impairment are available, CHF 5993 should be used with caution in these patients and potential adverse reactions should be monitored. In COPD patients with very low body weight (i.e. less than 40 kg) and with severe renal impairment (i.e. GFR below 27 mL/min/1.73 m²), a dose adjustment would be indicated.

<div style=\"page-break-after: always\"></div>

There was no substantial PK interaction between CHF 5993 active components and cimetidine (an inhibitor of the  organic  cation  transport  in  kidneys),  with  special  focus  on  GB  (study  TRIPLE  12).  In  addition,  the population PK analysis performed on PK data from studies CARSAF and TRIPLE 6 showed no DDI between GB and  the  medications  most  frequently  taken  by  COPD  patients  (enalapril,  lisinopril,  ramipril,  bisoprolol, amlodipine, losartan, valsartan and atorvastatin).

The  effect  of  the  AeroChamber  spacer  on  the  PK  of  the  CHF  5993  active  components  after  a  single  dose administered using the standard actuator with or without AeroChamber in patients with moderate to severe COPD (study TRIPLE 4) showed greater exposure to GB with use of the spacing device. However, for GB, no safety signals have been observed in studies GLYCO 2 and CARSAF in which GB was administered at supratherapeutic doses (i.e. up to 200 µg in study GLYCO 2 and at 100 µg in study CARSAF), suggesting that a 2fold increase in GB exposure is unlikely to result in (cardiovascular) safety concerns.

Study CARSAF was the principal evaluation of the secondary pharmacology on Trimbow. The PK profiles of CHF  5993  active  components  were  evaluated  after  administration  of  CHF  1535  (Foster)  alone  and  in combination with GB pMDI at total daily dose of 50 µg (therapeutic dose) or 100 µg (supra-therapeutic dose) in  moderate  to  severe  COPD  patients.  Co-administration  was  well  tolerated  and  did  not  raise  any cardiovascular signals of concern.

The pharmacodynamics properties of GB are adequately explored. No further studies to evaluate the potential for corrected QT interval (QTc) are considered to be necessary.

## 2.4.5. Conclusions on clinical pharmacology

The pharmacokinetics and pharmacodynamics of CHF 5993 has been sufficiently characterised to support this application.

## 2.5. Clinical efficacy

## · Introduction

The clinical programme of CHF 5993 pMDI in COPD included three Phase II (studies GLYCO 2, TRIPLE 3 and CARSAF), one Phase IIb (study TRIPLE 9) and two Phase III clinical studies (studies TRIPLE 5 and 6). Studies GLYCO 2 and TRIPLE 3 were dose finding studies which assessed the efficacy and safety of different GB doses alone or in combination with Foster. Study TRIPLE 9 further investigated the longer term (4 weeks) efficacy and safety of GB in the target population at the selected dose. Studies TRIPLE 5 and TRIPLE 6 were pivotal efficacy and safety studies for the FDC.

## 2.5.1. Dose-response studies

The proposed daily dosing for the ICS + LABA component (i.e. 400 µg BDP + 24 µg FF) corresponds to the dosing of Foster currently approved for use in patients with moderate to severe COPD who have significant symptoms despite regular bronchodilator therapy. The proposed daily dosing for the LAMA component (i.e. 50 µg GB) has been chosen based on the results of studies GLYCO 2 (Part 2) and TRIPLE 3.

In study GLYCO 2 (Part 2) all doses of GB (25, 50, and 100 μg) were superior to placebo in terms of the primary efficacy variable, trough FEV1 at 12 h post-dose on Day 7, and for all secondary efficacy variables

<div style=\"page-break-after: always\"></div>

based on FEV1 evaluated on Days 1, 7, and 8 of  multiple  dose  administration.  There  was  no  statistically significant difference between the 50µg and the 100µg total daily dose for any efficacy variables.

Study TRIPLE 3 investigated the dose-response of GB 12.5, 25 and 50 mg BID (i.e., total daily doses of 25, 50 and 100 mg) when added to Foster compared with Foster alone in patients with COPD. The primary and secondary endpoint data for FEV1 AUC0-12h and trough values on Days 1 and 7 all show a numerical doseresponse  relationship,  with  12.5  mg  BID  having  the  lowest  numerical  effect  and  50  mg  BID  having  the highest numerical effect. The results suggest that the effects of 12.5 mg BID fall below the clinically relevant threshold, while the 25 mg BID dose may meet the criteria for the minimally effective dose. The 100µg dose of GB (total daily dose) did not show significant advantages versus 50µg dose of GB (total daily dose).

## 2.5.2. Main clinical studies

Studies TRIPLE 5 and TRIPLE 6 are the two main clinical studies and described below:

## · Study design

Study TRIPLE 5 was designed to compare the TRIPLE combination CHF 5993 to Foster, in order to fulfil the requirements of the FDC guideline for confirmatory clinical trials, i.e. to demonstrate the efficacy of the FDC by parallel group comparisons to a standard of care (SOC) (step-up), thereby demonstrating the contribution of the GB component.

Study TRIPLE 6 was designed to address the requirements of the CHMP COPD Guideline, which recommends the  use  of  the  test  product  (CHF  5993)  for  comparison  with  an  established  long-acting  antimuscarinic comparator (tiotropium) as per the GOLD guideline. In addition, the CHF 5993 was compared with the open combination of Foster plus Tiotropium.

## · Study participants

The main inclusion criteria were:

- Male or female adults aged ≥ 40 years with written informed consent obtained prior to any studyrelated procedure;
- Patients with a diagnosis of COPD (according to GOLD document, revised 2013) at least 12 months before screening;
- Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack-years (pack-years = [number of cigarettes per day x number of years]/20);
- A post-bronchodilator FEV1 &lt;50% of the predicted normal value and a post-bronchodilator FEV1/FVC &lt;0.7, within 30 minutes after 4 puffs (4 x 100 μg) of salbutamol pMDI. If this criterion was not met at screening, the test could be repeated once before randomisation visit;
- A documented history of at least one exacerbation in the 12 months preceding screening.

COPD exacerbation was defined according to the following: ' A sustained worsening of the patient's condition (dyspnoea, cough and/or sputum production/purulence), from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in  a  patient  with  underlying  COPD  that  includes  prescriptions  of  systemic  corticosteroids  and/or antibiotics or need for hospitalisation '.

<div style=\"page-break-after: always\"></div>

Also  documented  visits  to  an  emergency  department  due  to  COPD  exacerbation  were  considered acceptable to fulfil this criterion;

- Patients under double therapy for at least 2 months prior to screening with either:
- -ICS/inhaled LABA or;
- -ICS/inhaled LAMA or;
- -Inhaled LABA and inhaled LAMA or;
- -Patients under monotherapy with LAMA for at least 2 months prior to screening;
- Symptomatic patients at screening with a CAT score ≥ 10;
- In study TRIPLE 5 only: Symptomatic patients at screening with a BDI focal score ≤ 10. This criterion had to be confirmed at randomisation (V2, Week 0);

The main exclusion criteria were:

- Diagnosis of asthma or history of allergic rhinitis or atopy (atopy which may have risen contraindications or impacted the efficacy of the study treatment according to Investigator's judgement);
- Patients requiring use of the following medications:
- a. Systemic steroids for COPD exacerbation in the 4 weeks prior to screening;
- b. A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks prior to screening;
- c. Phosphodiesterase (PDE)-4 inhibitors in the 4 weeks prior to screening;
- d. Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) in the 4 weeks prior to screening;
- COPD exacerbation requiring prescriptions of systemic corticosteroids and/or antibiotics or hospitalisation during the run-in period;
- Patients treated with non-cardio-selective β-blockers in the month preceding screening or during the run-in period;
- Patients treated with long-acting anti-histamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as pro re nata (PRN, as needed);
- Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia;
- Patients who had clinically significant (CS) cardiovascular condition (such as but not limited to unstable ischemic heart disease, NYHA Class III/IV, left ventricular failure, acute myocardial infarction);
- An abnormal and CS 12-lead ECG that resulted in active medical problem which may have impacted the safety of the patient according to Investigator's judgement.
- Patients whose 12-lead ECG showed Fridericia's corrected QT interval (QTcF) &gt;450 ms for males or &gt;470 ms for females at screening or at randomisation were not eligible;

<div style=\"page-break-after: always\"></div>

- Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator would have prevented use of anti-cholinergic agents;

In  summary,  the  patient  population  selected  for  both  pivotal  studies  includes  symptomatic  COPD  patients with severe to very severe airflow limitation and with a history of at least one exacerbation in the previous year (Group D patients according to GOLD classification, update 2016). At least 20% of patients with very severe airflow limitation (i.e. post-bronchodilator FEV1 at screening &lt;30% of predicted normal value) were to be randomised in both studies.

## · Treatments

The treatments used for both studies can be summarised by the figures below.

## TRIPLE 5 study

<!-- image -->

## Figure 4 Study design and schedule of visits

In  study  TRIPLE  5,  Foster  pMDI  was  chosen  as  control  treatment,  as  it  is  currently  marketed  for  the treatment of severe COPD patients who have significant symptoms despite bronchodilator therapy.

<div style=\"page-break-after: always\"></div>

## TRIPLE 6 study

Figure 5 Study design and schedule of visits

<!-- image -->

In study TRIPLE 6, CHF 5993 pMDI was compared to the LAMA Tiotropium alone and to the free combination Foster pMDI + Tiotropium. Tiotropium is one of the current first choice treatments for Group D patients and therefore  considered  as  a  suitable  comparator  to  test  the  superiority  of  CHF  5993  pMDI  in  terms  of moderate/severe exacerbation rate in grade D COPD patients. In addition, the free combination Foster pMDI +  Tiotropium  represents  an  alternative  ICS/LABA/LAMA  combination  and  it  was  considered  a  suitable comparator to test the non-inferiority of CHF 5993 pMDI in terms of pulmonary function.

Patients who were used to taking COPD pMDI medications via a spacer had to use the AeroChamber Plus™ for  the  study  medication.  As  rescue  medication,  patients  were  permitted  to  use  salbutamol  (100  μg  per actuation by pressurised metered dose inhaler), although not within 6 h before a spirometry assessment.

## Objectives

In  study  TRIPLE  5,  the  triple  combination  CHF  5993  pMDI  was  tested  for  superiority  over  Foster  pMDI  in terms of pre-dose and 2-hour post-dose FEV1 at 26 weeks. CHF 5993 was also tested for superiority over Foster for symptomatic benefit using TDI focal score.

In  study  TRIPLE  6,  CHF  5993  pMDI  was  tested  for  superiority  over  Tiotropium  in  terms  of  moderate  and severe COPD exacerbation rate over 52 weeks of treatment. The key secondary objectives of the study were to demonstrate the superiority of CHF 5993 pMDI over Tiotropium and to demonstrate the non-inferiority of CHF 5993 pMDI relative to Foster pMDI +Tiotropium, both in terms of pulmonary function pre-dose FEV1 at Week 52.

## · Outcomes/endpoints

## Study TRIPLE 5

<div style=\"page-break-after: always\"></div>

Three co-primary endpoints were measured: change from baseline in predose morning FEV1, change from baseline in 2-h postdose FEV1, and TDI focal score, all assessed at week 26.

The  secondary  efficacy  variables  were  pre-dose  FEV1  at  all  the  other  clinic  visits  and  averaged  over  the treatment period; FEV1 response (change from baseline in pre-dose FEV1 ≥ 100 mL) at weeks 26 and 52; 2h post-dose FEV1 at all the other clinic visits; TDI focal score at all the other clinic visits and TDI response (a focal score of one or more was deemed the MCID) at weeks 26 and 52; SGRQ total score at all clinic visits, and SGRQ response (decrease from baseline in total score ≥ 4 was deemed the MCID) at weeks 26 and 52; percentage of days without rescue medication use and average number of puffs per day; moderate-to-severe COPD exacerbation frequency over 52 weeks of treatment; and the time to first moderate-to-severe COPD exacerbation.

## Study TRIPLE 6

The primary endpoint was the moderate-to-severe COPD exacerbation rate over 52 weeks of treatment. The change from baseline in pre-dose morning FEV1 at week 52 was defined as a key secondary endpoint.

The  secondary  efficacy  variables  were  pre-dose  FEV1  at  all  the  other  clinic  visits  and  averaged  over  the treatment period; FEV1 response (change from baseline in pre-dose FEV1 ≥ 100 mL) at weeks 26 and 52; pre-dose  IC  at  all  clinic  visits;  SGRQ  total  score  at  all  clinic  visits,  and  SGRQ  response  (decrease  from baseline in total score ≥ 4 was deemed the MCID) at weeks 26 and 52; moderate COPD exacerbation rate; severe COPD exacerbation rate; time to first moderate-to-severe and severe COPD exacerbation; percentage of days without rescue medication use and average number of puffs per day.

## · Sample size

## Study TRIPLE 5

A total of 1304 patients (652 patients per group) were planned to be randomised in order to reach a total of 1088 evaluable patients at Week 26 (544 patients per group), considering a non-evaluable rate of approximately 16.5% at this time point. Based on the considerations listed below, an overall study power of approximately 85% was assured; in particular:

- Approximately 97.7% power to detect a mean difference of 60 mL in favour of CHF 5993 pMDI in change from baseline in pre-dose morning FEV1 at a two-sided significance level of 0.05, assuming an SD of 250 mL;
- Approximately 99.6% power to detect a mean difference of 70 mL in favour of CHF 5993 pMDI in change from baseline in 2-hour post-dose FEV1 at a two-sided significance level of 0.05, assuming an SD of 250 mL;
- Approximately 87.1% power to detect a mean difference of 0.6 units in favour of CHF 5993 pMDI in TDI focal score at a two-sided significance level of 0.05, assuming an SD of 3.2 units.

## Study TRIPLE 6

A total of 2580 patients were planned to be randomised according to a 2:2:1 ratio to the CHF 5993 pMDI (1032 patients),  Tiotropium  (1032  patients)  and  Foster  pMDI  +  Tiotropium  groups  (516  patients).  A  lognormal distribution was assumed for drop-out times, with drop-out rates of approximately 13%, 16.5% and 20% at Week 12, Week 26 and Week 52, respectively. A percentage of completed and evaluable patients with major protocol deviations of 9% was assumed.

<div style=\"page-break-after: always\"></div>

Based  on  the  considerations  listed  below,  an  overall  study  power  of  approximately  80%  was  assured;  in particular:

- This sample size assured approximately 93.3% power to detect a rate ratio of 0.8 between the CHF 5993 pMDI and Tiotropium groups at a two-sided significance level of 0.05, using a negative binomial model and assuming a rate of 0.9 exacerbations per patient per year in the Tiotropium group and an over-dispersion parameter of the negative binomial distribution of 0.56;
- At Week 52, 825 evaluable patients per group in the CHF 5993 pMDI and Tiotropium groups provided approximately 99.7% power to detect a mean difference of 60 mL in terms of change from baseline in FEV1 at a two-sided significance level of 0.05,assuming a SD of 260 mL;
- At Week 52, 751 evaluable patients in the CHF 5993 pMDI group and 375 evaluable patients in the Foster  pMDI  +  Tiotropium  group  with  no  major  protocol  deviations  assured  approximately  86.0% power to demonstrate the non-inferiority of CHF 5993 pMDI relative to Foster pMDI + Tiotropium in terms  of  change  from  baseline  in  FEV1  at  a  one-sided  significance  level  of  0.025,  with  a  noninferiority margin of -50 mL and assuming no difference between treatments and a SD of 260 mL.

## · Randomisation

## Study TRIPLE 5

A balanced block randomisation scheme stratified by country and severity of airflow limitation (i.e. post-bronchodilator FEV1 at screening &lt;30% or ≥ 30% of predicted normal value) was prepared via a computerised  system.  At  least  20%  of  patients  with  very  severe  airflow  limitation  (i.e.  postbronchodilator FEV1 at screening &lt;30% of predicted normal value) were randomised in the study.

## Study TRIPLE 6

A balanced block randomisation scheme stratified by country and severity of airflow limitation (i.e. post-bronchodilator FEV1 at screening &lt; 30% or ≥ 30% of the predicted normal value) was prepared via  a  computerised system. At least 20% of patients with very severe airflow limitation (i.e. postbronchodilator FEV1 at screening &lt; 30% of predicted normal value) were to be randomised in the study. Patients were randomised according to a 2:2:1 ratio to the CHF 5993 pMDI, Tiotropium and Foster pMDI + Tiotropium groups.

## · Blinding

All study treatments taken during the trial period of both pivotal studies were administered in a double-blind manner.  Neither  the  subjects  nor  the  investigators  knew  the  study  medication  assigned  to  a  particular subject.

A double-dummy design was used in study TRIPLE 6. Patients randomised to receive CHF 5993 pMDI were administered Tiotropium matched placebo and patients randomised to receive Tiotropium were administered pMDI placebo as detailed here below:

| Treatment Administration scheme   | CHF 5993 pMDI group                                                             | Tiotropium group                                                      | Foster pMDI +Tiotropium group                                            |
|-----------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------|
| pMDI                              | Two puffs in the morning and two puffs in the evening of CHF 5993 100/6/12.5 μg | Two puffs in the morning and two puffs in the evening of pMDI placebo | Two puffs in the morning and two puffs in the evening of Foster 100/6 μg |

<div style=\"page-break-after: always\"></div>

| DPI   | One capsule containing Tiotropium matched placebo in the morning using the HandiHaler inhaler   | One capsule containing Tiotropium 18 μg in the morning using the HandiHaler inhaler   | One capsule containing Tiotropium 18 μg in the morning using the HandiHaler inhaler   |
|-------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|

Source: CSR study TRIPLE 6, page 42

## · Statistical methods

In study TRIPLE 5, the three co-primary endpoints were all assessed with a linear mixed model for repeated measures  (MMRM),  with  data  up  to  discontinuation  included  in  the  analysis  for  withdrawn  patients.  This model included treatment, visit, treatment by visit interaction, country, number of COPD exacerbations in the previous year, severity of airflow limitation and smoking status at screening as fixed effects, and baseline value and baseline by visit interaction as covariates. To deal with multiplicity, the primary efficacy variables were tested in the following pre-specified hierarchical order: (1) pre-dose FEV1; (2) 2-h post-dose FEV1; (3) TDI focal score. At each step of the procedure, no confirmatory claims were to be made unless the superiority of CHF 5993 over Foster was shown in the preceding steps. Multiplicity was not adjusted for in the analyses of the secondary endpoints. Subgroup analyses of the co-primary endpoints were pre-specified, with patients grouped according  to  severity  of  airflow  limitation,  smoking  status,  sex,  reversibility  to  salbutamol,  COPD phenotype (chronic bronchitis, emphysema, or mixed), blood eosinophil concentration at screening, and age, with TDI also analysed according to presence of cardiovascular comorbidities. Sensitivity analyses were done on the three co-primary endpoints to assess the potential effect of missing data.

The MMRM model targets the hypothetical treatment effect if all patients had adhered ignoring the effect of non-adherence. Discontinuing  patients  were  not  followed-up.  The  applicant  addresses  the  question  on  the potential  effect  of  non-adherence  by  using  a  copy  reference  model  and  multiple  imputation  in  addition  to BOCF  (baseline  observation  carried  forward,  using  multiple  imputation  for  pre-dose  FEV1  and  single imputation for 2-h post-dose FEV1 and TDI).

In study TRIPLE 6, the comparisons between CHF 5993 pMDI and Tiotropium in terms of the primary and the key secondary efficacy variables were performed in the ITT and PP (for sensitivity purposes) populations. Since  non-inferiority  was  tested,  in  the  comparison  between  CHF  5993  pMDI  and  CHF  1535  pMDI  + Tiotropium  in  terms  of  the  key  secondary  efficacy  variable  the  ITT  and  the  PP  populations  had  equal importance.

The  comparisons  between  treatments  were  conducted  according  to  a  hierarchical  testing  procedure.  The primary and the key secondary efficacy comparisons were considered in the following order: (1) Superiority testing of CHF 5993 pMDI vs. Tiotropium in terms of moderate and severe COPD exacerbation rate over 52 weeks of treatment (primary efficacy variable); (2) Superiority testing of CHF 5993 pMDI vs. Tiotropium in terms of change from baseline in pre-dose morning FEV1 at Week 52 (key secondary efficacy variable); (3) Non-inferiority testing of CHF 5993 pMDI vs. CHF 1535 pMDI + Tiotropium in terms of change from baseline in pre-dose morning FEV1 at Week 52 (key secondary efficacy variable). At each step of the procedure, no confirmatory claims were made unless the objectives were met in all the preceding steps.

The number of moderate and severe COPD exacerbations during the treatment period was analysed using a negative binomial model including treatment, country, number of COPD exacerbations in the previous year, severity of airflow limitation and smoking status at screening as fixed effects, and log-time on study as an offset.  Superiority  of  CHF  5993  pMDI  over  Tiotropium  was  demonstrated  by  a  statistically  significant  rate

<div style=\"page-break-after: always\"></div>

ratio (defined as p &lt; 0.05) favouring CHF 5993 pMDI. The comparison CHF 5993 pMDI vs. CHF 1535 pMDI + Tiotropium was considered as a secondary efficacy analysis.

In order to assess the potential impact of missing data on the results of the primary efficacy analysis, the following sensitivity analyses were performed on all randomised patients: missing at random (MAR) and copy reference (CHF 1535 pMDI + Tiotropium) multiple imputation (MI). A sensitivity analysis was also performed to assess the impact of the differences between severity of airflow limitation recorded in the electronic case report form (eCRF) and entered in the Interactive Response Technology (IRT) at randomisation.

The analysis of the primary efficacy variable was also performed in the ITT population stratifying by severity of  airflow  limitation,  smoking  status  at  screening,  gender,  degree  of  reversibility,  main  COPD  phenotype, blood eosinophil count at screening, age, number of COPD exacerbations in the 12 months before screening and presence/absence of relevant concomitant cardiovascular diseases.

## Results

## · Participant flow

Study TRIPLE 5 ran between March 21, 2014, and Jan 14, 2016. 1812 patients were recruited, of whom 1368 were randomly assigned to one of the treatment groups (687 to CHF 5993 and 681 to Foster), with 602 (87.6%) completing the study in the CHF 5993 group and 579 (85.0%) in the Foster group. Compliance to treatment was high, with a median of 95.6% of doses taken in the CHF 5993 group and 95.0% of doses taken in the Foster group.

Study TRIPLE 6 ran between Jan 21, 2014, and Mar 18, 2016. 3433 patients were recruited, of whom 2691 were randomly assigned to one of the treatment groups (1078 to CHF 5993, 1075 to Tiotropium, 538 to Foster + Tiotropium), with 986 (91.5%) completing the study in the CHF 5993 group, 914 (85,0%) in the Tiotropium group and 496 (92.2%) in the Foster + tiotropium group. Throughout the treatment duration, the probability of discontinuation was higher in the Tiotropium group than in the CHF 5993 pMDI and Foster pMDI + Tiotropium groups. Compliance to treatment was high, with a median of 94.6% of doses taken in the CHF 5993  group,  94.3%  of  doses  taken  in  the  Tiotropium  group  and  94.9%  of  doses  taken  in  the  Foster  + Tiotropium group.

The subject disposition in both pivotal studies is generally comparable across the treatment arms.

## Baseline data

Baseline characteristics of the recruited patients in the two Phase III studies were comparable in terms of demography, lung function and symptoms.

In study TRIPLE 5, the majority of patients were taking a double therapy of ICS/LABA at study entry: 73.7% in  the  CHF  5993  pMDI  group  and  71.6%  in  the  CHF  1535  pMDI  group.  Overall,  the  double  therapy LABA/LAMA was taken by 13.8% and 15.7% of patients in the CHF 5993 pMDI and CHF 1535 pMDI groups, respectively, LAMA monotherapy was taken by 11.1% and 11.2% of patients, respectively and only 1.5% of patients in each group were taking ICS/LAMA.

In study TRIPLE 6, the majority of patients were taking a double therapy of ICS/LABA at study entry: 74.5% in the CHF 5993 pMDI group, 74.7% in the Tiotropium group and 70.4% in the CHF 1535 pMDI + Tiotropium group. Overall, the double therapy LABA/LAMA was taken by 11.6%, 11.5% and 13.8% of patients in the

<div style=\"page-break-after: always\"></div>

CHF 5993 pMDI, Tiotropium and CHF 1535 pMDI + Tiotropium groups, respectively. LAMA monotherapy was taken by 10.5%, 11.0% and 12.5% of patients, respectively and only 3.4%, 2.8% and 3.4% of patients, respectively were taking ICS/LAMA.

In study TRIPLE 5 more than 80% of patients had at least one concomitant disease, with at least one cardiac disorder reported by 36% of patients in the CHF 5993 group and 35% in the Foster group. In study TRIPLE 6 more than 80% of patients had at least one concomitant disease, with at least one cardiac disorder reported by 41% of patients in the CHF 5993 group, 43% in the Tiotropium group and 40% in the Foster + Tiotropium group.

Overall,  the  population  studied  in  these  two  pivotal  studies  were  representative  of  the  general  COPD population.

## Study Outcomes

The study results are presented in tabulated tables for both studies below. The following common efficacy variables of the two pivotal Phase III studies TRIPLE 5 and TRIPLE 6 are compared:

## Moderate/severe COPD exacerbation rate (primary efficacy variable in study TRIPLE 6)

CHF 5993 was found to be superior to both Foster (study TRIPLE 5) and Tiotropium (study TRIPLE 6) in terms of the moderate/severe exacerbation rate (Table below). In study TRIPLE 5 there was a 23% reduction in the rate of moderate/severe exacerbations with CHF 5993 compared with Foster (adjusted rate ratio [95% CI] 0.773  [0.647;  0.924],  p=0.005)  while  in  study  TRIPLE  6  there  was  a  20%  reduction  with  CHF  5993 compared  with  Tiotropium  (0.801  [0.693;  0.925],  p=0.003).  The  moderate/severe  exacerbation  rate  was similar  with  the  fixed  combination  of  CHF  5993  and  the  free  combination  of  Foster  +  Tiotropium  in  study TRIPLE 6 (1.013 [0.846; 1.214], p=0.887). The moderate/severe exacerbation rate was similar in the CHF 5993 groups in both studies.

Table 12 Moderate and severe COPD exacerbation rate, ITT population - Studies TRIPLE 5 and TRIPLE 6

|                                                 |                                                 | Study TRIPLE 5              | Study TRIPLE 5              | Study TRIPLE 6              | Study TRIPLE 6              | Study TRIPLE 6              |
|-------------------------------------------------|-------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                 |                                                 | CHF 5993 N=687              | Foster N=680                | CHF 5993 N=1077             | Tiotropium N=1074           | Foster + Tiotropium N=538   |
| Number (%) of Patients with Exacerbations       | Number (%) of Patients with Exacerbations       | 214 (31.1)                  | 240 (35.3)                  | 351 (32.6)                  | 383 (35.7)                  | 167 (31.0)                  |
| Number of Exacerbations                         | Number of Exacerbations                         | 288                         | 353                         | 485                         | 569                         | 244                         |
| Exacerbation Rate per Patient per Year          | Exacerbation Rate per Patient per Year          | 0.448                       | 0.565                       | 0.472                       | 0.583                       | 0.474                       |
| Total follow-up duration, years                 | Total follow-up duration, years                 | 643.06                      | 625.06                      | 1026.64                     | 976.68                      | 515.19                      |
| Adjusted Exacerbation Rate per Patient per Year | Adjusted Exacerbation Rate per Patient per Year | 0.410                       | 0.530                       | 0.457                       | 0.571                       | 0.452                       |
| Adjusted rate ratio (95% CI), p-value           | CHF 5993 vs. Foster                             | 0.773 (0.647; 0.924), 0.005 | 0.773 (0.647; 0.924), 0.005 | -                           | -                           | -                           |
| Adjusted rate ratio (95% CI), p-value           | CHF 5993 vs. Tiotropium                         | -                           | -                           | 0.801 (0.693; 0.925), 0.003 | 0.801 (0.693; 0.925), 0.003 | 0.801 (0.693; 0.925), 0.003 |
| Adjusted rate ratio (95% CI), p-value           | CHF 5993 vs. Foster + Tiotropium                |                             |                             | 1.013 (0.846; 1.214), 0.887 | 1.013 (0.846; 1.214), 0.887 | 1.013 (0.846; 1.214), 0.887 |
| Adjusted rate ratio (95% CI), p-value           | Foster + Tiotropium vs. Tiotropium              |                             |                             | 0.790 (0.661; 0.944), 0.010 | 0.790 (0.661; 0.944), 0.010 | 0.790 (0.661; 0.944), 0.010 |

## · Time to first moderate/severe COPD exacerbation

<div style=\"page-break-after: always\"></div>

The  results  of  the  Cox  proportion  hazards  analyses  showed  that  the  time  to  first  moderate/severe exacerbation was significantly prolonged with CHF 5993 compared with Foster (study TRIPLE 5, hazard ratio [95%  CI]  of  0.803  [0.668;  0.967],  p=0.020)  and  Tiotropium  (study  TRIPLE  6,  0.836  [0.723;  0.966], p=0.015), with no difference between CHF 5993 and Foster + Tiotropium (1.055 [0.877; 1.269], p=0.569).

- Change from baseline in pre-dose morning FEV1 over time (at Weeks 4, 12, 26 [co primary efficacy variable  in  study  TRIPLE  5],  40  and  52  [key  secondary  efficacy  variable  in  study  TRIPLE  6])  and averaged over the entire treatment period

CHF 5993 was found to be superior to both Foster (study TRIPLE 5) and Tiotropium (study TRIPLE 6) and non-inferior  to  Foster  +  Tiotropium  (study  TRIPLE  6)  in  terms  of  the  change  from  baseline  in  pre-dose morning FEV1 to both Week 26 and Week 52 (Table below). The magnitude of the adjusted mean change from baseline was similar in the CHF 5993 groups in both studies. The magnitude of the difference between CHF 5993 vs. both Foster and Tiotropium after 52 weeks of treatment was similar (adjusted mean difference of 0.63 and 0.61, respectively).

Table 13 Change from baseline in pre-dose morning FEV1 at Weeks 26 and 52, ITT population Study TRIPLE 5 and Study TRIPLE 6

|                                    |                                    | Study TRIPLE 5                | Study TRIPLE 5                | Study TRIPLE 6                  | Study TRIPLE 6                  | Study TRIPLE 6                  |
|------------------------------------|------------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                    |                                    | CHF 5993 N=687                | Foster N=680                  | CHF 5993 N=1077                 | Tiotropium N=1074               | Foster + Tiotropium N=538       |
| Baseline                           | n                                  | 686                           | 679                           | 1077                            | 1074                            | 538                             |
| Baseline                           | Mean (SD)                          | 1.096 (0.381)                 | 1.094 (0.393)                 | 1.118 (0.384)                   | 1.130 (0.358)                   | 1.137 (0.391)                   |
| Change from baseline: Week 26      | Change from baseline: Week 26      | Change from baseline: Week 26 | Change from baseline: Week 26 | Change from baseline: Week 26   | Change from baseline: Week 26   | Change from baseline: Week 26   |
| n                                  | n                                  | 642                           | 616                           | 1027                            | 977                             | 510                             |
| Adjusted mean (95% CI)             | Adjusted mean (95% CI)             | 0.082 (0.062; 0.102)          | 0.001 (-0.019; 0.021)         | 0.075 (0.059; 0.092)            | 0.024 (0.007; 0.041)            | 0.086 (0.063; 0.109)            |
| p-value                            | p-value                            | ˂ 0.001                       | 0.922                         | <0.001                          | 0.005                           | <0.001                          |
| Adj. mean diff. (95% CI), p- value | CHF 5993 vs. Foster                | 0.081 (0.052; 0.109), ˂ 0.001 | 0.081 (0.052; 0.109), ˂ 0.001 | -                               | -                               | -                               |
|                                    | CHF 5993 vs. Tiotropium            | -                             | -                             | 0.051 (0.028; 0.075), <0.001    | 0.051 (0.028; 0.075), <0.001    | 0.051 (0.028; 0.075), <0.001    |
|                                    | CHF 5993 vs. Foster + Tiotropium   |                               |                               | -0.011 ( -0.039 ; 0.018), 0.461 | -0.011 ( -0.039 ; 0.018), 0.461 | -0.011 ( -0.039 ; 0.018), 0.461 |
|                                    | Foster + Tiotropium vs. Tiotropium |                               |                               | 0.062 (0.034; 0.091), <0.001    | 0.062 (0.034; 0.091), <0.001    | 0.062 (0.034; 0.091), <0.001    |
| Change from baseline: Week 52      | Change from baseline: Week 52      | Change from baseline: Week 52 | Change from baseline: Week 52 | Change from baseline: Week 52   | Change from baseline: Week 52   | Change from baseline: Week 52   |
| n                                  | n                                  | 606                           | 578                           | 985                             | 921                             | 495                             |
| Adjusted mean (95% CI)             | Adjusted mean (95% CI)             | 0.071 (0.050; 0.093)          | 0.008 (-0.014; 0.030)         | 0.082 (0.065; 0.100)            | 0.021 (0.003; 0.039)            | 0.085 (0.061; 0.110)            |
| p-value                            | p-value                            | ˂ 0.001                       | 0.474                         | <0.001                          | 0.019                           | <0.001                          |
| Adj. mean diff. (95% CI), p- value | CHF 5993 vs. Foster                | 0.063 (0.032; 0.094),         | 0.063 (0.032; 0.094),         |                                 |                                 |                                 |
|                                    | CHF 5993 vs. Tiotropium            | ˂ 0.001                       | ˂ 0.001                       | 0.061 (0.037; 0.086), <0.001    | 0.061 (0.037; 0.086), <0.001    | 0.061 (0.037; 0.086), <0.001    |
|                                    | CHF 5993 vs. Foster + Tiotropium   |                               |                               | -0.003 ( -0.033 ; 0.027), 0.852 | -0.003 ( -0.033 ; 0.027), 0.852 | -0.003 ( -0.033 ; 0.027), 0.852 |

<div style=\"page-break-after: always\"></div>

| Foster + Tiotropium vs. Tiotropium   | 0.064 (0.034; 0.094), <0.001   |
|--------------------------------------|--------------------------------|

- FEV1 response at Weeks 26 and 52

The  percentage  of  patients  who  were  FEV1  responders  at  Weeks  26  and  52  was  statistically  significantly greater with CHF 5993 than with Foster (study TRIPLE 5) and Tiotropium (study TRIPLE 6) (Table below). The percentage of responders was similar for the both fixed and free TRIPLE combination group at Weeks 26 and 52.

<div style=\"page-break-after: always\"></div>

Table 14 FEV1 responders at Week 26 and Week 52, ITT population - Study TRIPLE 5 and Study TRIPLE 6

|                               |                                    | Study TRIPLE 5                | Study TRIPLE 5                | Study TRIPLE 6            | Study TRIPLE 6            | Study TRIPLE 6            |
|-------------------------------|------------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|---------------------------|
|                               |                                    | CHF 5993 N=687                | Foster N=680                  | CHF 5993 N=1077           | Tiotropium N=1074         | Foster + Tiotropium N=538 |
| Week 26                       | Week 26                            |                               |                               |                           |                           |                           |
| Responder, n (%)              | Responder, n (%)                   | 287 (41.8)                    | 165 (24.3)                    | 421 (39.1)                | 306 (28.5)                | 204 (37.9)                |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster                | 2.299 (1.817; 2.910), ˂ 0.001 | 2.299 (1.817; 2.910), ˂ 0.001 |                           |                           |                           |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Tiotropium            |                               |                               | 1.61 (1.34; 1.93), <0.001 | 1.61 (1.34; 1.93), <0.001 | 1.61 (1.34; 1.93), <0.001 |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster + Tiotropium   |                               |                               | 1.04 (0.84; 1.30), 0.694  | 1.04 (0.84; 1.30), 0.694  | 1.04 (0.84; 1.30), 0.694  |
| Odds ratio (95% CI), p- value | Foster + Tiotropium vs. Tiotropium |                               |                               | 1.54 (1.23; 1.92), <0.001 | 1.54 (1.23; 1.92), <0.001 | 1.54 (1.23; 1.92), <0.001 |
| Week 52                       | Week 52                            |                               |                               |                           |                           |                           |
| Responder, n (%)              |                                    | 259 (37.7)                    | 158 (23.2)                    | 408 (37.9)                | 295 (27.5)                | 210 (39.0)                |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster                | 2.061 (1.621; 2.620), ˂ 0.001 | 2.061 (1.621; 2.620), ˂ 0.001 |                           |                           |                           |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Tiotropium            |                               |                               | 1.62 (1.35; 1.95), <0.001 | 1.62 (1.35; 1.95), <0.001 | 1.62 (1.35; 1.95), <0.001 |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster + Tiotropium   |                               |                               | 0.95 (0.76; 1.18), 0.627  | 0.95 (0.76; 1.18), 0.627  | 0.95 (0.76; 1.18), 0.627  |
| Odds ratio (95% CI), p- value | Foster + Tiotropium vs. Tiotropium |                               |                               | 1.71 (1.37; 2.13), <0.001 | 1.71 (1.37; 2.13), <0.001 | 1.71 (1.37; 2.13), <0.001 |

- Change from baseline in SGRQ total score over time

CHF 5993 was found to be superior to both Foster (study TRIPLE 5) and Tiotropium (study TRIPLE 6) in terms of the change from baseline in SGRQ total score at Week 52 (Table below). The difference between CHF 5993 and Foster + Tiotropium in study TRIPLE 6 reached statistical significance in favour of Foster + Tiotropium at Weeks 26 and 52. The magnitude of the difference between CHF 5993 vs. both Foster and Tiotropium was similar (adjusted mean difference of -1.69 and -1.60, respectively).

Table 15 Change from baseline in SGRQ total score at Week 26 and Week 52, ITT population Study TRIPLE 5 and Study TRIPLE 6

|                                    |                                  | Study TRIPLE 5                | Study TRIPLE 5                | Study TRIPLE 6                | Study TRIPLE 6                | Study TRIPLE 6                |
|------------------------------------|----------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                                    |                                  | CHF 5993 N=687                | Foster N=680                  | CHF 5993 N=1077               | Tiotropium N=1074             | Foster + Tiotropium N=538     |
| Baseline                           | n                                | 658                           | 644                           | 1026                          | 1039                          | 521                           |
|                                    | Mean (SD)                        | 52.29 (16.84)                 | 50.32 (16.50)                 | 54.42 (16.65)                 | 54.49 (16.77)                 | 53.02 (16.32)                 |
| Change from baseline: Week 26      | Change from baseline: Week 26    | Change from baseline: Week 26 | Change from baseline: Week 26 | Change from baseline: Week 26 | Change from baseline: Week 26 | Change from baseline: Week 26 |
| n                                  | n                                | 594                           | 558                           | 944                           | 919                           | 474                           |
| Adjusted mean (95% CI)             | Adjusted mean (95% CI)           | -4.76 (-5.69; -3.83)          | -3.43 (-4.38; -2.47)          | -5.44 (-6.26; -4.62)          | -4.41 (-5.24; -3.59)          | -7.20 (-8.35; -6.05)          |
| p-value                            | p-value                          | ˂ 0.001                       | ˂ 0.001                       | <0.001                        | <0.001                        | <0.001                        |
| Adj. mean diff. (95% CI), p- value | CHF 5993 vs. Foster              | -1.33 (-2.66; 0.01), 0.051    | -1.33 (-2.66; 0.01), 0.051    | -                             | -                             | -                             |
| Adj. mean diff. (95% CI), p- value | CHF 5993 vs. Tiotropium          |                               |                               | -1.03 (-2.19; 0.14), 0.083    | -1.03 (-2.19; 0.14), 0.083    | -1.03 (-2.19; 0.14), 0.083    |
| Adj. mean diff. (95% CI), p- value | CHF 5993 vs. Foster + Tiotropium |                               |                               | 1.76 (0.35; 3.17), 0.014      | 1.76 (0.35; 3.17), 0.014      | 1.76 (0.35; 3.17), 0.014      |

<div style=\"page-break-after: always\"></div>

|                               | Foster + Tiotropium vs. Tiotropium   |                               |                               | -2.79 (-4.21; -1.37), <0.001   | -2.79 (-4.21; -1.37), <0.001   | -2.79 (-4.21; -1.37), <0.001   |
|-------------------------------|--------------------------------------|-------------------------------|-------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Change from baseline: Week 52 | Change from baseline: Week 52        | Change from baseline: Week 52 | Change from baseline: Week 52 | Change from baseline: Week 52  | Change from baseline: Week 52  | Change from baseline: Week 52  |
| n                             | n                                    | 559                           | 532                           | 899                            | 860                            | 463                            |
| Adjusted mean (95% CI)        | Adjusted mean (95% CI)               | -5.12 (-6.18; -4.06)          | -3.43 (-4.51; -2.35)          | -5.74 (-6.60; -4.88)           | -4.14 (-5.01; -3.27)           | -7.32 (-8.51; -6.12)           |
| p-value                       | p-value                              | ˂ 0.001                       | ˂ 0.001                       | <0.001                         | <0.001                         | <0.001                         |
| Adj. (95% value               | CHF 5993 vs. Foster                  | -1.69 (-3.20; -0.17), 0.029   | -1.69 (-3.20; -0.17), 0.029   | -                              | -                              | -                              |
| Adj. (95% value               | CHF 5993 vs. Tiotropium              |                               |                               | -1.60 (-2.82; -0.38), 0.010    | -1.60 (-2.82; -0.38), 0.010    | -1.60 (-2.82; -0.38), 0.010    |
| Adj. (95% value               | CHF 5993 vs. Foster + Tiotropium     |                               |                               | 1.57 (0.10; 3.05), 0.036       | 1.57 (0.10; 3.05), 0.036       | 1.57 (0.10; 3.05), 0.036       |
| Adj. (95% value               | Foster + Tiotropium vs. Tiotropium   |                               |                               | -3.18 (-4.66; -1.69), <0.001   | -3.18 (-4.66; -1.69), <0.001   | -3.18 (-4.66; -1.69), <0.001   |

## · SGRQ response at Weeks 26 and 52

The percentage of patients who were SGRQ responders at Weeks 26 and 52 was statistically significantly greater with CHF 5993 than with Foster (study TRIPLE 5) and Tiotropium (study TRIPLE 6) (Table below). The difference between CHF 5993 and Foster + Tiotropium in study TRIPLE 6 was statistically significant at Week 26 (in favour of Foster + Tiotropium), but no difference between treatments was found at Week 52.

## Table 16 SGRQ responders at Week 26 and Week 52, ITT population - Study TRIPLE 5 and Study TRIPLE 6

|                               |                                    | Study TRIPLE 5                | Study TRIPLE 5                | Study TRIPLE 6            | Study TRIPLE 6            | Study TRIPLE 6            |
|-------------------------------|------------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|---------------------------|
|                               |                                    | CHF 5993 N=687                | Foster N=680                  | CHF 5993 N=1077           | Tiotropium N=1074         | Foster + Tiotropium N=538 |
| Week 26                       | Week 26                            | Week 26                       | Week 26                       | Week 26                   | Week 26                   | Week 26                   |
| Responder, n (%)              | Responder, n (%)                   | 321 (46.7)                    | 246 (36.2)                    | 508 (47.2)                | 438 (40.8)                | 276 (51.3)                |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster                | 1.521 (1.211; 1.911), ˂ 0.001 | 1.521 (1.211; 1.911), ˂ 0.001 |                           |                           |                           |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Tiotropium            |                               |                               | 1.32 (1.10; 1.57), 0.002  | 1.32 (1.10; 1.57), 0.002  | 1.32 (1.10; 1.57), 0.002  |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster + Tiotropium   |                               |                               | 0.81 (0.65; 1.00), 0.049  | 0.81 (0.65; 1.00), 0.049  | 0.81 (0.65; 1.00), 0.049  |
| Odds ratio (95% CI), p- value | Foster + Tiotropium vs. Tiotropium |                               |                               | 1.63 (1.32; 2.02), <0.001 | 1.63 (1.32; 2.02), <0.001 | 1.63 (1.32; 2.02), <0.001 |
| Week 52                       | Week 52                            | Week 52                       | Week 52                       | Week 52                   | Week 52                   | Week 52                   |
| Responder, n (%)              |                                    | 297 (43.2)                    | 244 (35.9)                    | 494 (45.9)                | 423 (39.4)                | 254 (47.2)                |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster                | 1.327 (1.060; 1.661), 0.014   | 1.327 (1.060; 1.661), 0.014   |                           |                           |                           |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Tiotropium            |                               |                               | 1.33 (1.11; 1.59), 0.002  | 1.33 (1.11; 1.59), 0.002  | 1.33 (1.11; 1.59), 0.002  |
| Odds ratio (95% CI), p- value | CHF 5993 vs. Foster + Tiotropium   |                               |                               | 0.91 (0.73; 1 .13), 0.373 | 0.91 (0.73; 1 .13), 0.373 | 0.91 (0.73; 1 .13), 0.373 |
| Odds ratio (95% CI), p- value | Foster + Tiotropium vs. Tiotropium |                               |                               | 1.47 (1.18; 1.83), <0.001 | 1.47 (1.18; 1.83), <0.001 | 1.47 (1.18; 1.83), <0.001 |

- Change from baseline in the percentage of days without rescue medication and average use of rescue medication (puffs/day) over time and averaged over the entire treatment period

At baseline (run-in period), rescue use was lower in patients in study TRIPLE 5 than study TRIPLE 6; in study TRIPLE 5 the percentage of days without rescue medication use was 33.22% and 33.88% in the CHF 5993 and Foster  groups,  respectively  while  in  study  TRIPLE  6  this  percentage  ranged  from  20.47%  to  21.90%

<div style=\"page-break-after: always\"></div>

across groups (Table below). Similarly, the average use of rescue medication was lower in study TRIPLE 5 (2.32 and 2.38 puffs/day, in the CHF 5993 and Foster groups, respectively) than study TRIPLE 6 (ranging from 2.55 to 2.70 puffs/day across groups).

There was a greater improvement in rescue medication use (i.e. increase in percentage of rescue free days and decrease in average use) from baseline over the entire treatment period with CHF 5993 compared with both Foster (study TRIPLE 5) and with Tiotropium (study TRIPLE 6). These differences between treatments only reached statistical significance in study TRIPLE 6 (CHF 5993 vs. Tiotropium), where patients were more reliant on rescue medication during the run-in period. In study TRIPLE 6, no differences between CHF 5993 and Foster + Tiotropium were found. Of note, in study TRIPLE 5 the difference between CHF 5993 and Foster did reach statistical significance (in favour of CHF 5993) for all periods up to Week 12 for the percentage of rescue free days and for all periods up to Week 26 for the average rescue medication use. In patients treated with  CHF  5993,  the  greater  improvement  seen  in  patients  in  study  TRIPLE  6  resulted  in  similar  rescue medication  use  in  both  studies  over  the  randomised  treatment  period  (percentage  of  rescue  free  days 37.91% in study TRIPLE 5 and 34.64% in study TRIPLE 6 and average rescue medication use 2.18 puffs/day and 2.16 puffs/day, respectively).

Table  17  Change  from  baseline  in  rescue  medication  use  over  the  entire  treatment  period,  ITT population - Study TRIPLE 5 and Study TRIPLE 6

|                                                                |                                                                | Study TRIPLE 5                                                 | Study TRIPLE 5                                                 | Study TRIPLE 6                                                 | Study TRIPLE 6                                                 | Study TRIPLE 6                                                 |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                |                                                                | CHF 5993 N=687                                                 | Foster N=680                                                   | CHF 5993 N=1077                                                | Tiotropium N=1074                                              | Foster + Tiotropium N=538                                      |
| Percentage of days without rescue medication                   | Percentage of days without rescue medication                   | Percentage of days without rescue medication                   | Percentage of days without rescue medication                   | Percentage of days without rescue medication                   | Percentage of days without rescue medication                   | Percentage of days without rescue medication                   |
| Baseline                                                       | n                                                              | 653                                                            | 645                                                            | 1040                                                           | 1021                                                           | 514                                                            |
| Baseline                                                       | Mean (SD)                                                      | 33.22 (39.23)                                                  | 33.88 (39.17)                                                  | 20.47 (33.45)                                                  | 21.28 (34.01)                                                  | 21.90 (34.72)                                                  |
| Change from baseline: average over the entire treatment period | Change from baseline: average over the entire treatment period | Change from baseline: average over the entire treatment period | Change from baseline: average over the entire treatment period | Change from baseline: average over the entire treatment period | Change from baseline: average over the entire treatment period | Change from baseline: average over the entire treatment period |
| n                                                              | n                                                              | 650                                                            | 640                                                            | 1038                                                           | 1015                                                           | 513                                                            |
| Adjusted mean (95% CI)                                         | Adjusted mean (95% CI)                                         | 5.01 (3.05; 6.98)                                              | 2.36 (0.37; 4.35)                                              | 13.91 (12.04; 15.79)                                           | 5.19 (3.28; 7.10)                                              | 14.75 (12.08; 17.41)                                           |
| p-value                                                        | p-value                                                        | ˂ 0.001                                                        | 0.020                                                          | <0.001                                                         | <0.001                                                         | <0.001                                                         |
| Adj. mean diff. (95% CI), p- value                             | CHF 5993 vs. Foster                                            | 2.65 (-0.14; 5.45), 0.063                                      | 2.65 (-0.14; 5.45), 0.063                                      | -                                                              | -                                                              | -                                                              |
| Adj. mean diff. (95% CI), p- value                             | CHF 5993 vs. Tiotropium                                        |                                                                |                                                                | 8.72 (6.05; 11.40), <0.001                                     | 8.72 (6.05; 11.40), <0.001                                     | 8.72 (6.05; 11.40), <0.001                                     |
| Adj. mean diff. (95% CI), p- value                             | CHF 5993 vs. Foster + Tiotropium                               |                                                                |                                                                | -0.83 (-4.09; 2.42), 0.616                                     | -0.83 (-4.09; 2.42), 0.616                                     | -0.83 (-4.09; 2.42), 0.616                                     |
| Adj. mean diff. (95% CI), p- value                             | Foster + Tiotropium vs. Tiotropium                             |                                                                |                                                                | 9.56 (6.28; 12.83), <0.001                                     | 9.56 (6.28; 12.83), <0.001                                     | 9.56 (6.28; 12.83), <0.001                                     |
| Average use of rescue medication (puffs/day)                   | Average use of rescue medication (puffs/day)                   | Average use of rescue medication (puffs/day)                   | Average use of rescue medication (puffs/day)                   | Average use of rescue medication (puffs/day)                   | Average use of rescue medication (puffs/day)                   | Average use of rescue medication (puffs/day)                   |
| Baseline                                                       | n                                                              | 653                                                            | 645                                                            | 1040                                                           | 1021                                                           | 514                                                            |
| Baseline                                                       | Mean (SD)                                                      | 2.32 (2.11)                                                    | 2.38 (2.30)                                                    | 2.64 (2.24)                                                    | 2.70 (2.40)                                                    | 2.55 (2.18)                                                    |
| Change from baseline: average over entire treatment period     | Change from baseline: average over entire treatment period     | Change from baseline: average over entire treatment period     | Change from baseline: average over entire treatment period     | Change from baseline: average over entire treatment period     | Change from baseline: average over entire treatment period     | Change from baseline: average over entire treatment period     |
| n                                                              | n                                                              | 650                                                            | 640                                                            | 1038                                                           | 1015                                                           | 513                                                            |
| Adjusted mean (95% CI)                                         | Adjusted mean (95% CI)                                         | -0.15 (-0.26; -0.04)                                           | 0.00 (-0.11; 0.12)                                             | -0.48 (-0.58; -0.38)                                           | 0.10 (-0.01; 0.20)                                             | -0.54 (-0.68; -0.40)                                           |
| p-value                                                        | p-value                                                        | 0.009                                                          | 0.958                                                          | <0.001                                                         | 0.063                                                          | <0.001                                                         |
| Adj. mean diff. (95% CI), p- value                             | CHF 5993 vs. Foster                                            | -0.15 (-0.31; 0.01), 0.062                                     | -0.15 (-0.31; 0.01), 0.062                                     | -                                                              | -                                                              | -                                                              |
| Adj. mean diff. (95% CI), p- value                             | CHF 5993 vs. Tiotropium                                        |                                                                |                                                                | -0.57 (-0.72; -0.43), <0.001                                   | -0.57 (-0.72; -0.43), <0.001                                   | -0.57 (-0.72; -0.43), <0.001                                   |
| Adj. mean diff. (95% CI), p- value                             | CHF 5993 vs. Foster + Tiotropium                               |                                                                |                                                                | 0.06 (-0.11; 0.23), 0.495                                      | 0.06 (-0.11; 0.23), 0.495                                      | 0.06 (-0.11; 0.23), 0.495                                      |
| Adj. mean diff. (95% CI), p- value                             | Foster + Tiotropium vs. Tiotropium                             |                                                                |                                                                | -0.63 (-0.81; -0.46), <0.001                                   | -0.63 (-0.81; -0.46), <0.001                                   | -0.63 (-0.81; -0.46), <0.001                                   |

<div style=\"page-break-after: always\"></div>

## Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 18 Summary of efficacy for trial TRIPLE 5

| Title: A 52-week, double-blind, randomised, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI in patients with Chronic Obstructive Pulmonary Disease.   | Title: A 52-week, double-blind, randomised, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI in patients with Chronic Obstructive Pulmonary Disease.   | Title: A 52-week, double-blind, randomised, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI in patients with Chronic Obstructive Pulmonary Disease.   | Title: A 52-week, double-blind, randomised, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI in patients with Chronic Obstructive Pulmonary Disease.   | Title: A 52-week, double-blind, randomised, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI in patients with Chronic Obstructive Pulmonary Disease.   | Title: A 52-week, double-blind, randomised, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI in patients with Chronic Obstructive Pulmonary Disease.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                                                        | CCD-1207-PR-0091, EUDRACT No. 2013 - 001057 - 27                                                                                                                                                                                                                                                                                                                                                                                        | CCD-1207-PR-0091, EUDRACT No. 2013 - 001057 - 27                                                                                                                                                                                                                                                                                                                                                                                        | CCD-1207-PR-0091, EUDRACT No. 2013 - 001057 - 27                                                                                                                                                                                                                                                                                                                                                                                        | CCD-1207-PR-0091, EUDRACT No. 2013 - 001057 - 27                                                                                                                                                                                                                                                                                                                                                                                        | CCD-1207-PR-0091, EUDRACT No. 2013 - 001057 - 27                                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                  | Phase III, randomised, double blind, active controlled, 2 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                | Phase III, randomised, double blind, active controlled, 2 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                | Phase III, randomised, double blind, active controlled, 2 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                | Phase III, randomised, double blind, active controlled, 2 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                | Phase III, randomised, double blind, active controlled, 2 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                          | 52 week 2 weeks not applicable                                                                                                                                                                                                                                                                                                                                                                                                          | 52 week 2 weeks not applicable                                                                                                                                                                                                                                                                                                                                                                                                          | 52 week 2 weeks not applicable                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                       | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                           | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                           | CHF 5993 pMDI 2 puffs bid (400 µg BDP / 24 µg FF / 50 µg GB / day), 52 weeks, n=687, randomized                                                                                                                                                                                                                                                                                                                                         | CHF 5993 pMDI 2 puffs bid (400 µg BDP / 24 µg FF / 50 µg GB / day), 52 weeks, n=687, randomized                                                                                                                                                                                                                                                                                                                                         | CHF 5993 pMDI 2 puffs bid (400 µg BDP / 24 µg FF / 50 µg GB / day), 52 weeks, n=687, randomized                                                                                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                       | Foster pMDI                                                                                                                                                                                                                                                                                                                                                                                                                             | Foster pMDI                                                                                                                                                                                                                                                                                                                                                                                                                             | Foster pMDI 2 puffs bid (400 µg BDP / 24 µg FF / day), 52 weeks, n=681, randomized                                                                                                                                                                                                                                                                                                                                                      | Foster pMDI 2 puffs bid (400 µg BDP / 24 µg FF / day), 52 weeks, n=681, randomized                                                                                                                                                                                                                                                                                                                                                      | Foster pMDI 2 puffs bid (400 µg BDP / 24 µg FF / day), 52 weeks, n=681, randomized                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                               | Co-Primary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                    | Pre-dose FEV1                                                                                                                                                                                                                                                                                                                                                                                                                           | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                               | Co-Primary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                    | 2-hour post- dose FEV1                                                                                                                                                                                                                                                                                                                                                                                                                  | Change from baseline in 2-hour post-dose FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in 2-hour post-dose FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in 2-hour post-dose FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                               | Co-Primary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                    | TDI                                                                                                                                                                                                                                                                                                                                                                                                                                     | TDI focal score at Week 26                                                                                                                                                                                                                                                                                                                                                                                                              | TDI focal score at Week 26                                                                                                                                                                                                                                                                                                                                                                                                              | TDI focal score at Week 26                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                      | TDI                                                                                                                                                                                                                                                                                                                                                                                                                                     | TDI focal score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                              | TDI focal score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                              | TDI focal score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                      | SGRQ                                                                                                                                                                                                                                                                                                                                                                                                                                    | Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score and domain scores at week 52                                                                                                                                                                                                                                                                                                                    | Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score and domain scores at week 52                                                                                                                                                                                                                                                                                                                    | Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score and domain scores at week 52                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                      | COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                  | Moderate and severe COPD exacerbation rate over 52 weeks of treatment;                                                                                                                                                                                                                                                                                                                                                                  | Moderate and severe COPD exacerbation rate over 52 weeks of treatment;                                                                                                                                                                                                                                                                                                                                                                  | Moderate and severe COPD exacerbation rate over 52 weeks of treatment;                                                                                                                                                                                                                                                                                                                                                                  |
| Database lock                                                                                                                                                                                                                                                                                                                                                                                                                           | 15 March 2016                                                                                                                                                                                                                                                                                                                                                                                                                           | 15 March 2016                                                                                                                                                                                                                                                                                                                                                                                                                           | 15 March 2016                                                                                                                                                                                                                                                                                                                                                                                                                           | 15 March 2016                                                                                                                                                                                                                                                                                                                                                                                                                           | 15 March 2016                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis population and time point description                                                                                                                                                                                                                                                                                                                                                                                          | Intent to treat, week 26                                                                                                                                                                                                                                                                                                                                                                                                                | Intent to treat, week 26                                                                                                                                                                                                                                                                                                                                                                                                                | Intent to treat, week 26                                                                                                                                                                                                                                                                                                                                                                                                                | Intent to treat, week 26                                                                                                                                                                                                                                                                                                                                                                                                                | Intent to treat, week 26                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                         | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                         | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                         | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                         | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                           | Foster pMDI                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                         | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                | Change from baseline in pre-dose morning FEV1 at Week 26                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                         | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                       | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                       | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                       | 642                                                                                                                                                                                                                                                                                                                                                                                                                                     | 616                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                         | Adjusted mean (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                  | Adjusted mean (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                  | Adjusted mean (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.082 (0.062; 0.102)                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.001 (-0.019; 0.021)                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                         | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                 | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                 | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                 | ˂ 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.922                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Effect estimate per comparison                  | Adjusted mean difference (95% CI) [L] p-value            | 0.081 (0.052; 0.109)                                     | 0.081 (0.052; 0.109)                                     |
|-------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                 | Change from baseline in 2-hour post-dose FEV1 at Week 26 | Change from baseline in 2-hour post-dose FEV1 at Week 26 | Change from baseline in 2-hour post-dose FEV1 at Week 26 |
| Descriptive statistics and estimate variability | Number of subject                                        | 631                                                      | 609                                                      |
| Descriptive statistics and estimate variability | Adjusted mean (95% CI) [L]                               | 0.261 (0.240; 0.283)                                     | 0.145 (0.123; 0.166)                                     |
| Descriptive statistics and estimate variability | p-value                                                  | ˂ 0.001                                                  | ˂ 0.001                                                  |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI) [L]                    | 0.117 (0.086; 0.147)                                     | 0.117 (0.086; 0.147)                                     |
| Effect estimate per comparison                  | p-value                                                  | ˂ 0.001                                                  | ˂ 0.001                                                  |
|                                                 | TDI focal score at Week 26                               | TDI focal score at Week 26                               | TDI focal score at Week 26                               |
| Descriptive statistics and estimate variability | Number of subject                                        | 642                                                      | 619                                                      |
| Descriptive statistics and estimate variability | Adjusted mean (95% CI)                                   | 1.71 (1.50; 1.92)                                        | 1.50 (1.29; 1.71)                                        |
| Descriptive statistics and estimate variability | p-value                                                  | ˂ 0.001                                                  | ˂ 0.001                                                  |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI)                        | 0.21 (-0.08; 0.51)                                       | 0.21 (-0.08; 0.51)                                       |
| Effect estimate per comparison                  | p-value                                                  | 0.160                                                    | 0.160                                                    |
| Analysis population and time point description  | Intent to treat, week 52                                 | Intent to treat, week 52                                 | Intent to treat, week 52                                 |
|                                                 | Treatment group                                          | CHF 5993 pMDI                                            | Foster pMDI                                              |
|                                                 | TDI focal score at Week 52                               | TDI focal score at Week 52                               | TDI focal score at Week 52                               |
| Descriptive statistics and estimate variability | Number of subject                                        | 608                                                      | 579                                                      |
| Descriptive statistics and estimate variability | Adjusted mean (95% CI)                                   | 2.03 (1.81; 2.25)                                        | 1.81 (1.59; 2.04)                                        |
| Descriptive statistics and estimate variability | p-value                                                  | ˂ 0.001                                                  | ˂ 0.001                                                  |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI)                        | 0.21 (-0.10; 0.53)                                       | 0.21 (-0.10; 0.53)                                       |
| Effect estimate per comparison                  | p-value                                                  | 0.186                                                    | 0.186                                                    |
|                                                 | Change from baseline in SGRQ total score at Week 52      | Change from baseline in SGRQ total score at Week 52      | Change from baseline in SGRQ total score at Week 52      |
| Descriptive statistics and estimate variability | Number of subject                                        | 559                                                      | 532                                                      |
| Descriptive statistics and estimate variability | Adjusted mean (95% CI)                                   | -5.12 (-6.18; -4.06)                                     | -3.43 (-4.51; -2.35)                                     |
| Descriptive statistics and estimate variability | p-value                                                  | ˂ 0.001                                                  | ˂ 0.001                                                  |
| Effect estimate per comparison                  | Adjusted mean difference (95% CI)                        | -1.69 (-3.20; -0.17)                                     | -1.69 (-3.20; -0.17)                                     |
| Effect estimate per comparison                  | p-value                                                  | 0.029                                                    | 0.029                                                    |
|                                                 | Moderate and severe COPD exacerbation rate               | Moderate and severe COPD exacerbation rate               | Moderate and severe COPD exacerbation rate               |
| Descriptive statistics and estimate variability | Number of subject                                        | 687                                                      | 680                                                      |
| Descriptive statistics and estimate variability | Adjusted Exacerbation Rate per Patient per Year (95% CI) | 0.410 (0.358; 0.469)                                     | 0.530 (0.468; 0.600)                                     |
| Effect estimate per comparison                  | Adjusted rate ratio (95% CI)                             | 0.773 (0.647; 0.924)                                     | 0.773 (0.647; 0.924)                                     |
| Effect estimate per comparison                  | p-value                                                  | 0.005                                                    | 0.005                                                    |

<div style=\"page-break-after: always\"></div>

| Notes   | CHF 5993 was superior to Foster for both pre-dose FEV1 (adjusted mean difference 0·081 L [95% CI 0.052-0.109]; p<0·001) and 2-h post-dose FEV1 (adjusted mean difference 0.117 [0.086-0.147]; p<0·001) at week 26. TDI focal score improved at week 26 in both groups; the mean difference between treatments (0.21 units [95% CI -0·08 to 0·51]) was not statistically significant .   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Table 19 Summary of efficacy for trial TRIPLE 6

| Title: A 52-week, double blind, double dummy, randomised, multinational, multicentre, 3-arm parallel group, active controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease   | Title: A 52-week, double blind, double dummy, randomised, multinational, multicentre, 3-arm parallel group, active controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease   | Title: A 52-week, double blind, double dummy, randomised, multinational, multicentre, 3-arm parallel group, active controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease   | Title: A 52-week, double blind, double dummy, randomised, multinational, multicentre, 3-arm parallel group, active controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease   | Title: A 52-week, double blind, double dummy, randomised, multinational, multicentre, 3-arm parallel group, active controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease   | Title: A 52-week, double blind, double dummy, randomised, multinational, multicentre, 3-arm parallel group, active controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus Glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | CCD-1208-PR-0090, EUDRACT No. 2013-000063-91                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CCD-1208-PR-0090, EUDRACT No. 2013-000063-91                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CCD-1208-PR-0090, EUDRACT No. 2013-000063-91                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CCD-1208-PR-0090, EUDRACT No. 2013-000063-91                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CCD-1208-PR-0090, EUDRACT No. 2013-000063-91                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase III, randomised, double blind, active controlled, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                                                                  | Phase III, randomised, double blind, active controlled, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                                                                  | Phase III, randomised, double blind, active controlled, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                                                                  | Phase III, randomised, double blind, active controlled, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                                                                  | Phase III, randomised, double blind, active controlled, 3 arm parallel group, multicentre, multinational                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 52 weeks 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 52 weeks 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 52 weeks 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Superiority vs. tiotropium, non-inferiority vs. Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                  | Superiority vs. tiotropium, non-inferiority vs. Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                  | Superiority vs. tiotropium, non-inferiority vs. Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                  | Superiority vs. tiotropium, non-inferiority vs. Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                  | Superiority vs. tiotropium, non-inferiority vs. Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | CHF 5993 pMDI 2 puffs bid (400 µg BDP / 24 µg FF / 50 µg GB / day), 52 weeks, n=1078, randomized                                                                                                                                                                                                                                                                                                                                                                                                          | CHF 5993 pMDI 2 puffs bid (400 µg BDP / 24 µg FF / 50 µg GB / day), 52 weeks, n=1078, randomized                                                                                                                                                                                                                                                                                                                                                                                                          | CHF 5993 pMDI 2 puffs bid (400 µg BDP / 24 µg FF / 50 µg GB / day), 52 weeks, n=1078, randomized                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Tiotropium 1 capsule od (18 µg / day), 52 weeks,                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Tiotropium 1 capsule od (18 µg / day), 52 weeks,                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Tiotropium 1 capsule od (18 µg / day), 52 weeks,                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Foster pMDI + tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | n=1075, randomized Foster pMDI 2 puffs bid + Tiotropium 1 capsule od (400 µg BDP / 24 µg FF + Tiotropium 18 µg / day), 52 weeks, n=538, randomized                                                                                                                                                                                                                                                                                                                                                        | n=1075, randomized Foster pMDI 2 puffs bid + Tiotropium 1 capsule od (400 µg BDP / 24 µg FF + Tiotropium 18 µg / day), 52 weeks, n=538, randomized                                                                                                                                                                                                                                                                                                                                                        | n=1075, randomized Foster pMDI 2 puffs bid + Tiotropium 1 capsule od (400 µg BDP / 24 µg FF + Tiotropium 18 µg / day), 52 weeks, n=538, randomized                                                                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Moderate and severe COPD exacerbation rate over 52 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                     | Moderate and severe COPD exacerbation rate over 52 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                     | Moderate and severe COPD exacerbation rate over 52 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pre dose FEV1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Change from baseline in pre dose morning FEV1 at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Change from baseline in pre dose morning FEV1 at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Change from baseline in pre dose morning FEV1 at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Time to first COPD exacerbation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Time to first moderate or severe COPD exacerbation                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Time to first moderate or severe COPD exacerbation                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Time to first moderate or severe COPD exacerbation                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | SGRQ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score and domain scores at week 52                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score and domain scores at week 52                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score and domain scores at week 52                                                                                                                                                                                                                                                                                                                                                                                      |
| Database lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10-May-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10-May-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10-May-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10-May-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10-May-2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis population and time point description                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Intent to treat, week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Intent to treat, week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Intent to treat, week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Intent to treat, week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Intent to treat, week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Moderate and severe COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Moderate and severe COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Moderate and severe COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Moderate and severe COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Moderate and severe COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Moderate and severe COPD exacerbation rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Foster pMDI + Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1077                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1077                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1074                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 538                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Total follow up time (years)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1026.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1026.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 976.68                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 515.19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Number (%) of Patients with Exacerbations                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 351 (32.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 351 (32.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 383 (35.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 167 (31.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                              | Number of Exacerbations                                      | 485                                                          | 569                                                          | 569                                                          | 244                                                          |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                                              | Exacerbation Rate per Patient per Year                       | 0.472                                                        | 0.583                                                        | 0.583                                                        | 0.474                                                        |
|                                                              | Adjusted Exacerbation Rate per Patient per Year              | 0.457                                                        | 0.571                                                        | 0.571                                                        | 0.452                                                        |
| Effect estimate per comparison                               | Comparison groups                                            | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 |
|                                                              |                                                              | Adj. rate ratio (95% CI)                                     | Adj. rate ratio (95% CI)                                     | 0.801 (0.693; 0.925)                                         | 0.801 (0.693; 0.925)                                         |
|                                                              |                                                              | p-value                                                      | p-value                                                      | 0.003                                                        | 0.003                                                        |
|                                                              | Comparison groups                                            | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   |
|                                                              |                                                              | Adj. rate ratio (95% CI)                                     | Adj. rate ratio (95% CI)                                     | 1.013 (0.846; 1.214)                                         | 1.013 (0.846; 1.214)                                         |
|                                                              |                                                              | p-value                                                      | p-value                                                      | 0.887                                                        | 0.887                                                        |
|                                                              | Comparison groups                                            | Foster pMDI + Tiotropium vs. Tiotropium                      | Foster pMDI + Tiotropium vs. Tiotropium                      | Foster pMDI + Tiotropium vs. Tiotropium                      | Foster pMDI + Tiotropium vs. Tiotropium                      |
|                                                              |                                                              | Adj. rate ratio (95% CI)                                     | Adj. rate ratio (95% CI)                                     | 0.790 (0.661; 0.944)                                         | 0.790 (0.661; 0.944)                                         |
|                                                              |                                                              | p-value                                                      | p-value                                                      | 0.010                                                        | 0.010                                                        |
| Change from baseline in pre-dose morning FEV1 (L) at Week 52 | Change from baseline in pre-dose morning FEV1 (L) at Week 52 | Change from baseline in pre-dose morning FEV1 (L) at Week 52 | Change from baseline in pre-dose morning FEV1 (L) at Week 52 | Change from baseline in pre-dose morning FEV1 (L) at Week 52 | Change from baseline in pre-dose morning FEV1 (L) at Week 52 |
| Descriptive statistics and estimate variability              | Treatment group                                              | CHF 5993 pMDI                                                | Tiotropium                                                   | Tiotropium                                                   | Foster pMDI + Tiotropium                                     |
|                                                              | Number of subject                                            | 985                                                          | 921                                                          | 921                                                          | 495                                                          |
|                                                              | Adj. mean (95% CI)                                           | 0.082 (0.065; 0.100)                                         | 0.021 (0.003; 0.039)                                         | 0.021 (0.003; 0.039)                                         | 0.085 (0.061; 0.110)                                         |
|                                                              | p-value                                                      | <0.001                                                       | 0.019                                                        | 0.019                                                        | <0.001                                                       |
| Effect estimate per comparison                               | Comparison groups                                            | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 |
|                                                              |                                                              | Adj. mean difference (95% CI)                                | Adj. mean difference (95% CI)                                | 0.061 (0.037; 0.086)                                         | 0.061 (0.037; 0.086)                                         |
|                                                              |                                                              | p-value                                                      | p-value                                                      | <0.001                                                       | <0.001                                                       |
|                                                              | Comparison groups                                            | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   |
|                                                              |                                                              | Adj. mean difference (95% CI)                                | Adj. mean difference (95% CI)                                | -0.003 ( -0.033 ; 0.027)                                     | -0.003 ( -0.033 ; 0.027)                                     |
|                                                              |                                                              | p-value                                                      | p-value                                                      | 0.852                                                        | 0.852                                                        |
|                                                              | Comparison groups                                            | Foster pMDI + Tiotropium vs. Tiotropium                      | Foster pMDI + Tiotropium vs. Tiotropium                      | Foster pMDI + Tiotropium vs. Tiotropium                      | Foster pMDI + Tiotropium vs. Tiotropium                      |
|                                                              |                                                              | Adj. mean difference (95% CI)                                | Adj. mean difference (95% CI)                                | 0.064 (0.034; 0.094)                                         | 0.064 (0.034; 0.094)                                         |
|                                                              |                                                              | p-value                                                      | p-value                                                      | <0.001                                                       | <0.001                                                       |
| Time to first moderate or severe COPD exacerbation           | Time to first moderate or severe COPD exacerbation           | Time to first moderate or severe COPD exacerbation           | Time to first moderate or severe COPD exacerbation           | Time to first moderate or severe COPD exacerbation           | Time to first moderate or severe COPD exacerbation           |
| Effect estimate per comparison                               | Treatment group                                              | CHF 5993 pMDI                                                | Tiotropium                                                   | Tiotropium                                                   | Foster pMDI + Tiotropium                                     |
|                                                              | Number of subject                                            | 1077                                                         | 1074                                                         | 1074                                                         | 538                                                          |
|                                                              | Comparison groups                                            | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 | CHF 5993 pMDI vs. Tiotropium                                 |
|                                                              |                                                              | Hazard ratio (95% CI)                                        | Hazard ratio (95% CI)                                        | 0.836 (0.723; 0.966)                                         | 0.836 (0.723; 0.966)                                         |
|                                                              |                                                              | p-value                                                      | p-value                                                      | 0.015                                                        | 0.015                                                        |
|                                                              | Comparison groups                                            | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                   |
|                                                              |                                                              | Hazard ratio (95% CI)                                        | Hazard ratio (95% CI)                                        | 1.055 (0.877; 1.269)                                         | 1.055 (0.877; 1.269)                                         |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.569                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Foster pMDI + Tiotropium vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Foster pMDI + Tiotropium vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Foster pMDI + Tiotropium vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Hazard ratio (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Hazard ratio (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.792 (0.661; 0.951)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                 | Change from baseline in the SGRQ total score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Change from baseline in the SGRQ total score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Change from baseline in the SGRQ total score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Change from baseline in the SGRQ total score at Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | CHF 5993 pMDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Foster pMDI + Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 899                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 860                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 463                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                 | Adj. mean (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | -5.74 (-6.60; -4.88)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -4.14 (-5.01; -3.27)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -7.32 (-8.51; -6.12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                 | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | CHF 5993 pMDI vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CHF 5993 pMDI vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CHF 5993 pMDI vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Adj. mean difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Adj. mean difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -1.60 (-2.82; -0.38)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.010                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | CHF 5993 pMDI vs. Foster pMDI + Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Adj. mean difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1.57 (0.10; 3.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1.57 (0.10; 3.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.036                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Foster pMDI + Tiotropium vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Foster pMDI + Tiotropium vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Foster pMDI + Tiotropium vs. Tiotropium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Adj. mean difference (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -3.18 (-4.66; -1.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -3.18 (-4.66; -1.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Notes                                           | The superiority of CHF 5993 pMDI over Tiotropium was demonstrated in terms of the moderate and severe COPD exacerbation rate over 52 weeks of treatment (primary endpoint). The adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and the adjusted rate was 0.801 (95% CI 0.693; 0.925; p=0.003). These results indicated a 20% reduction in the rate of moderate/severe COPD exacerbations with CHF 5993 pMDI compared to Tiotropium. Superiority of CHF 5993 pMDI over Tiotropium in terms of the change from baseline in pre-dose morning FEV1 at Week 52 (key secondary endpoint) was demonstrated as the adjusted mean difference between treatments was 0.061 L (95% CI 0.037; 0.086; p < 0.001). Non-inferiority of CHF 5993 pMDI relative to CHF | The superiority of CHF 5993 pMDI over Tiotropium was demonstrated in terms of the moderate and severe COPD exacerbation rate over 52 weeks of treatment (primary endpoint). The adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and the adjusted rate was 0.801 (95% CI 0.693; 0.925; p=0.003). These results indicated a 20% reduction in the rate of moderate/severe COPD exacerbations with CHF 5993 pMDI compared to Tiotropium. Superiority of CHF 5993 pMDI over Tiotropium in terms of the change from baseline in pre-dose morning FEV1 at Week 52 (key secondary endpoint) was demonstrated as the adjusted mean difference between treatments was 0.061 L (95% CI 0.037; 0.086; p < 0.001). Non-inferiority of CHF 5993 pMDI relative to CHF | The superiority of CHF 5993 pMDI over Tiotropium was demonstrated in terms of the moderate and severe COPD exacerbation rate over 52 weeks of treatment (primary endpoint). The adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and the adjusted rate was 0.801 (95% CI 0.693; 0.925; p=0.003). These results indicated a 20% reduction in the rate of moderate/severe COPD exacerbations with CHF 5993 pMDI compared to Tiotropium. Superiority of CHF 5993 pMDI over Tiotropium in terms of the change from baseline in pre-dose morning FEV1 at Week 52 (key secondary endpoint) was demonstrated as the adjusted mean difference between treatments was 0.061 L (95% CI 0.037; 0.086; p < 0.001). Non-inferiority of CHF 5993 pMDI relative to CHF | The superiority of CHF 5993 pMDI over Tiotropium was demonstrated in terms of the moderate and severe COPD exacerbation rate over 52 weeks of treatment (primary endpoint). The adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and the adjusted rate was 0.801 (95% CI 0.693; 0.925; p=0.003). These results indicated a 20% reduction in the rate of moderate/severe COPD exacerbations with CHF 5993 pMDI compared to Tiotropium. Superiority of CHF 5993 pMDI over Tiotropium in terms of the change from baseline in pre-dose morning FEV1 at Week 52 (key secondary endpoint) was demonstrated as the adjusted mean difference between treatments was 0.061 L (95% CI 0.037; 0.086; p < 0.001). Non-inferiority of CHF 5993 pMDI relative to CHF |

## Clinical studies in special populations

Specific efficacy studies in special populations have not been conducted.

Table 20 Number of subjects by study and age group in the clinical development program of CHF 5993 pMDI

| Trial             | Age 65-74 years   | Age 75-84 years   | Age 85+ years   |
|-------------------|-------------------|-------------------|-----------------|
| Controlled trials | 1601/4763         | 422/4763          | 5/4763          |
| Glyco 1           | 0/20              | 0/20              | 0/20            |

<div style=\"page-break-after: always\"></div>

| Glyco 2 (Part 1)      | 3/27     | 0/27     | 0/27   |
|-----------------------|----------|----------|--------|
| Glyco 2 (Part 2)      | 5/38     | 0/38     | 0/38   |
| CARSAF                | 63/191   | 9/191    | 0/191  |
| Triple 1              | 1/44     | 0/44     | 0/44   |
| Triple 2              | 2/44     | 0/44     | 0/44   |
| Triple 3              | 64/178   | 9/178    | 0/178  |
| Triple 4              | 16/36    | 0/36     | 0/36   |
| Triple 5              | 503/1368 | 124/1368 | 2/1368 |
| Triple 6              | 915/2691 | 273/2691 | 3/2691 |
| Triple 9              | 29/100   | 7/100    | 0/100  |
| Triple 12             | 0/26     | 0/26     | 0/26   |
| Non-controlled trials | 0/42     | 0/42     | 0/42   |
| Triple 10             | 0/42     | 0/42     | 0/42   |

Data are presented as number of subjects in the age group / total number of subjects.

Sufficient numbers of patients aged ≥65 years were included in the two pivotal Phase III studies (46% and 44.3%) to be reassured that efficacy and safety seen in the total population can be extrapolated to the older age group.

As COPD is a disease that is not seen in children a class waiver from the European Paediatric Regulation (Regulation [EC] Number 1901/2006) has been granted for the condition COPD.

## Supportive study(ies)

None

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

Efficacy  data  obtained from six clinical studies has  been provided: three Phase II, one Phase  IIb and  two Phase III studies.

Studies GLYCO 2 and TRIPLE 3 were dose finding studies which assessed the efficacy and safety of different GB doses alone or in combination with BDP/FF. Study TRIPLE 9 further investigated the long-term efficacy and safety of GB in the target population at the selected dose. Study CARSAF assessed cardiac safety and effects on lung function parameters of a free combination of BDP/FF + two doses of GB compared to BDP/FF alone in patients with moderate to severe COPD.

Studies TRIPLE 5 and TRIPLE 6 were the pivotal efficacy and safety studies for CHF 5993 pMDI.

Overall, the proposed daily dosing for the LAMA component (i.e. 50 µg GB) seems to be the optimal dose when combined with 400µg BDP and 24µg FF.

<div style=\"page-break-after: always\"></div>

Of note, the proposed dose of GB has been chosen based on the two dose-finding studies of short duration (GLYCO 2 [8 days] and TRIPLE 3 [7 days]). Treatment durations of 6-12 weeks are recommended by the COPD guideline (EMA/CHMP/483572/2012-corr1). However, the results of study TRIPLE 9 provide additional evidence of the clinical efficacy of the selected GB 50 µg daily dose (used as a single agent) in a 4-weeks trial, thereby showing that the effect of GB in terms of bronchodilation is sustained over a longer period of time in the target population.

The design and methodology of both pivotal studies are appropriate for the objectives. The patient population selected  for  both  pivotal  studies  include  Group  B  and  D  patients  according  to  GOLD  classification,  update 2017.  In  both  pivotal  studies,  patients  with  severe  and  very  severe  airflow  limitation  of  FEV1  &lt;  50% predicted  normal  were  included.  The  patient  populations  were  comparable  in  terms  of  demography,  lung function  and  symptoms. In both studies just over half the patients were aged &lt; 65 years, approximately three quarters were male, and a large majority were Caucasian. Most patients were taking combination COPD therapy at study entry; approximately three quarters were taking ICS + LABA combinations. The patients enrolled  were  representative  of  the  target  population  for  the  proposed  therapeutic  indication.  Postbronchodilator FEV1 was 1.11 and 1.12 L in studies Triple 5 and Triple 6 respectively (36.5% and 36.6% predicted normal).

According to the recommendations from the CHMP guideline on the investigation of medicinal products for the treatment of COPD, measurement of lung function parameters alone is considered to be insufficient in the assessment of therapeutic effect. If lung function is selected as a primary endpoint, additional evidence of efficacy must be demonstrated through the use of a co-primary endpoint, which should either be a symptombased endpoint or a patient-related endpoint. The guideline also states that number of exacerbations may be acceptable as single primary endpoint.

In study TRIPLE 5, the chosen co-primary endpoints of pre-dose FEV1, 2-hour post-dose FEV1 and TDI focal score to explore the contribution of GB are considered to be appropriate and in line with the CHMP COPD guideline. Also in study TRIPLE 6, the chosen primary endpoint moderate and severe COPD exacerbation rate as well as the key secondary endpoint (pre-dose FEV1) to compare CHF 5993 pMDI with Tiotropium and also with Foster pMDI plus Tiotropium are considered to be appropriate and in line with the CHMP COPD guideline.

Studies TRIPLE 5 and TRIPLE 6 were studies of 52 week duration, suitable to measure the exacerbation rate as they cover all seasons.

Appropriate and robust randomisation methods have been used. All study treatments taken during the trial period of both pivotal studies were administered in a double-blind manner. Appropriate measures were taken to ensure integrity of the blinding in both pivotal studies.

The statistical methods used in both pivotal studies are acceptable.

## Efficacy data and additional analyses

## Study TRIPLE 5

At week 26, CHF 5993 improved pre-dose FEV1 by 0.081 L (95% CI 0.052-0.109; p&lt;0.001) and 2-h postdose FEV1 by 0.117 L (0.086-0.147; p&lt;0.001) compared with Foster. Mean TDI focal scores at week 26 were 1.71 for CHF 5993 and 1.50 for Foster, with a difference of 0.21 (95% CI -0.08 to 0.51; p=0.160).

Although there is no consensus statement on what constitutes a minimally important difference for pre-dose FEV1  for  subjects  with  airflow  obstruction,  some  published  literature  suggests  a  threshold  of  100mL  for

<div style=\"page-break-after: always\"></div>

clinical  trials  ( Donohue  JF  2005 )  may  be  appropriate,  or  that  changes  of  5-10%  from  baseline  can  be considered  clinically  meaningful  as  well  ( Cazzola  M  et  al.  2008 ).  The  literature  also  acknowledges  that  a threshold for meaningful change is more meaningful for severe and very severe patients than for patients with  mild  to  moderate  disease.  Considering  the  severity  of  the  condition  of  the  target  population,  an improvement over baseline in pre-dose FEV1 of 81ml for CHF 5993 pMDI compared to Foster is considered to be a meaningful benefit for this more severe COPD group.

According to the pre-specified success criterion the study failed due to the lack of a significant result for the third primary endpoint TDI focal score at Week 26, although a significant result was obtained in the other two primary endpoints, according to the pre-specified hierarchical procedure.

Subgroup  analyses  of  the  three  co-primary  endpoints  were  broadly  consistent  with  the  ITT  analyses.  An exception  was  for  the  subgroup  with  very  severe  airflow  limitation.  In  these  patients,  pre-dose  FEV1 assessment did not differ significantly between treatment groups.

The sensitivity analyses with respect to missing data imputation yielded similar results confirming the results of the primary analyses. Consistency of the estimated effect was found for the vast majority of the countries.

Increases  in  TDI  focal  score  were  observed  in  both  groups  at  all  visits,  with  a  statistically  significant difference between treatments favouring CHF 5993 at the two earliest visits (weeks 4 and 12). More than 50% of  patients  in  each  group  reported  clinically  relevant  improvements  ( ≥ 1  unit)  in  TDI  focal  score  at weeks 26 and 52; at week 26, patients were significantly more likely to respond to CHF 5993 than Foster.

For SGRQ total score, clinically relevant improvements from baseline (decrease ≥ 4 units) occurred for the CHF 5993 group at all visits from week 12 onwards, with statistically significant differences between the two groups at weeks 4, 12, and 52 (mean treatment difference at week 52 of -1.69 [95% CI -3.20 to -0.17]; p=0.029).

The use of rescue medication in puffs per day was significantly lower with CHF 5993 than with Foster, up to week 26; patients in the CHF 5993 group had a significantly greater percentage of days with no rescue use than those in the Foster, group up to week 12.

The percentage of patients who had moderate-to severe exacerbations was lower with CHF 5993 (31%) than with Foster (35%). The adjusted annual rate of moderate-to-severe exacerbations was 0.41 for the CHF 5993 group and 0.53 for the Foster, group, with a rate ratio of 0.77 (95% CI 0.65-0.92; p=0.005), indicating a significant 23% reduction in the rate with CHF 5993. Subgroup analyses were broadly consistent with the ITT analysis. Furthermore, CHF 5993 significantly prolonged the time to first moderate-to-severe exacerbation compared with Foster (hazard ratio 0.80 [95% CI 0.67-0.97]; p=0.020).

## Study TRIPLE 6

In study TRIPLE 6, the triple combination product has demonstrated superiority over Tiotropium in terms of the  moderate  and  severe  COPD  exacerbation  rate  over  52  weeks  of  treatment  (primary  endpoint).  The adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and the adjusted rate ratio was 0.801 (95% CI 0.693 - 0.925; p=0.003). These results indicated a 20%  reduction  in  the  rate  of  moderate/severe  COPD  exacerbations  with  CHF  5993  pMDI  compared  to Tiotropium. 20% reduction of rate of moderate/severe exacerbations is suggested to be minimal clinically important difference in COPD patients ( Calverley PM et al. 2005 ).

The sensitivity analyses with respect to missing data imputation yielded similar results confirming the results of the primary analyses. Consistency of the estimated effect was found for the vast majority of the countries.

<div style=\"page-break-after: always\"></div>

The adjusted mean change in pre-dose morning FEV1 from baseline to Week 52 (key secondary endpoint) was  a  statistically  significant  increase  with  all  three  treatments.  Superiority  of  CHF  5993  pMDI  over Tiotropium in terms of the change from baseline in pre-dose morning FEV1 at Week 52 was demonstrated as the adjusted mean difference between treatments was 0.061 L (95% CI 0.037 - 0.086, p &lt; 0.001). Noninferiority of CHF 5993 pMDI relative to Foster pMDI + Tiotropium was also demonstrated as the adjusted mean difference between treatments was -0.003 L (95% CI -0.033 - 0.027), with a lower confidence limit well  above  the  pre-defined  non-inferiority  margin  of  -0.050  L.  The  difference  between  CHF  1535  pMDI  + Tiotropium  and  Tiotropium  was  of  a  similar  magnitude  to  the  difference  between  CHF  5993  pMDI  and Tiotropium.

The superior clinical efficacy of CHF 5993 pMDI compared to Tiotropium was further supported by consistent findings on other relevant parameters, including SGRQ and use of rescue medication. For these parameters, CHF 5993 pMDI and CHF 1535 pMDI + Tiotropium generally showed a similar effect.

## 2.5.4. Conclusions on clinical efficacy

Study  TRIPLE  5,  triple  therapy  with  BDP/FF/GB  (CHF  5993)  had  a  statistically  significant  and  clinically relevant superior effect on pre-dose and 2-h post-dose FEV1 at week 26 than BDP/FF (Foster).

TDI focal score, the third co-primary endpoint, had a clinically relevant improvement with both treatments, but the mean difference between treatments in TDI focal score at week 26 was not statistically significant.

Nevertheless,  the  responder  analysis  indicates  a  benefit  for  CHF  5993  compared  with  Foster  on  TDI symptoms for a greater proportion  of  patients.  In  addition,  significant  differences  favouring  CHF  5993  for SGRQ total score were also found at several timepoints (weeks 4, 12, and 52). Results were supported by the SGRQ responder analysis. Also, the observed 23% reduction in the exacerbation rate is above the minimum clinically important difference.

Study  TRIPLE  6,  CHF  5993  had  a  statistically  significant  superior  effect  on  moderate  and  severe  COPD exacerbation rate over 52 weeks than Tiotropium. The observed 20% reduction in the exacerbation rate is above the minimum clinically important difference. Superiority of CHF 5993 pMDI over Tiotropium and noninferiority  relative  to  Foster  pMDI  +  Tiotropium  in  terms  pre-dose  morning  FEV1  at  Week  52  was  also demonstrated.

The superior clinical efficacy of CHF 5993 pMDI compared to Tiotropium was further supported by consistent findings on other relevant parameters, including SGRQ and use of rescue medication. For these parameters, CHF 5993 pMDI and Foster pMDI + Tiotropium generally showed a similar effect.

Overall, CHF 5993 pMDI has shown benefits in reduction in exacerbation frequency and in improvement in lung function in two large Phase III studies.

## 2.6. Clinical safety

In studies conducted in healthy subjects or subjects with renal impairment, single doses of BDP 400 μg and FF 24 μg (corresponding to the target daily dose of CHF 5993 pMDI, two inhalations twice daily [bid]) were administered, while for GB, a supra therapeutic dose equal to 100 μg was administered to allow a better characterisation of the PK profile of this component. However, safety data from these five PK studies did not reveal any new adverse effects or any marked changes in severity, duration or frequency of adverse effects.

<div style=\"page-break-after: always\"></div>

An integrated analysis was performed by pooling the individual data from the CHF 5993 treatment in studies TRIPLE  5  and  TRIPLE  6.  These  integrated  data  comprise  the  majority  of  the  safety  information  and  are presented in the following sections.

## Patient exposure

In study TRIPLE 5, mean exposure was 341.3 days (range 6-395 days) in the CHF 5993 group and 334.5 days (3-409 days) in the Foster group.

In study TRIPLE 6, mean exposure was 347.4 days (range 3-402 days) in the CHF 5993 group, 330.6 days (1-403 days) in the Tiotropium group and 349.6 days (4-399 days) in the Foster + Tiotropium group.

The  exposure  is  in  line  with  recommendations  of  ICH  E1.  Given  also  the  fact  that  there  is  already  postmarketing experience with Foster the safety database is considered to be adequate.

## Adverse events

## · Common Adverse Events and Adverse Drug Reactions

In study TRIPLE 5, TEAEs were experienced by 368 (53.6%) patients reported with 927 TEAEs in the CHF 5993  pMDI  group  and  379  (55.7%)  patients  reported  with  928  TEAEs  in  the  Foster  pMDI  group.  Those reported  in ≥ 2%  of  patients  in  either  treatment  group  were:  COPD  exacerbation,  nasopharyngitis, pneumonia, hypertension, headache and respiratory tract infection viral. The majority of TEAEs were mild or moderate in intensity and resolved by the end of the study.

Overall,  the  incidence  of  ADRs  in  both  treatment  groups  was  very  low.  Treatment-emergent  ADRs  were experienced  by  26  (3.8%)  patients  reported  with  31  ADRs  in  the  CHF  5993  pMDI  group  and  14  (2.1%) patients reported with 15 ADRs in the CHF 1535 pMDI group. The only treatment-emergent ADRs reported in &gt;2 patients in either treatment group were oral candidiasis, muscle spasms and dry mouth.

In particular, cardiovascular events are balanced among the different treatment groups.

In study TRIPLE 6, TEAEs were experienced by 594 (55.2%) patients reported with 1422 TEAEs in the CHF 5993 pMDI group, 622 (57.8%) patients reported with 1514 TEAEs in the Tiotropium group and 309 (57.5%) patients reported with 740 TEAEs in the Foster pMDI + Tiotropium group. Those reported in ≥ 2% of patients in any treatment group were: COPD exacerbation, nasopharyngitis, headache, dyspnoea, pneumonia, cough and respiratory tract infection viral. The majority of TEAEs were mild or moderate in intensity and resolved by the end of the study.

Overall,  the  incidence  of  ADRs  in  all  three  treatment  groups  was  low.  Treatment-emergent  ADRs  were experienced by 25 (2.3%) patients reported with 34 ADRs in the CHF 5993 pMDI group, 33 (3.1%) patients reported with 43 ADRs in the Tiotropium group and 27 (5.0%) patients reported with 38 ADRs in the Foster pMDI + Tiotropium group. A slight imbalance favouring the CHF 5993 pMDI group is observed. However, the numbers are very small and no firm conclusion can be drawn.

Those reported in &gt; 2 patients in any treatment group were dry mouth, muscle spasms, dysphonia, headache and oral candidiasis. All ADRs were mild or moderate in intensity and the majority resolved by the end of the study.

## · Other significant adverse events

<div style=\"page-break-after: always\"></div>

## Pneumonia

In  study  TRIPLE  5,  there  were  25  and  18  treatment-emergent  pneumonias  (including  PTs  of  pneumonia, bronchopneumonia and pneumonia aspiration) reported in 23 (3.3%) patients and 18 (2.6%) patients in the CHF  5993  pMDI  and  CHF  1535  pMDI  groups,  respectively.  Serious  pneumonias  were  experienced  by  15 (2.2%) patients reported with 17 events in the CHF 5993 pMDI group and 7 (1.0%) patients reported with 7 events  in  the  CHF  1535  pMDI  group.  None  were  considered  treatment-related  and  none  were  fatal.  One event  of  pneumonia  led  to  study  drug  discontinuation  in  1  (0.1%)  patient  in  each  treatment  group.  The pneumonia rate per 1,000 patients per year was slightly higher in the CHF 5993 pMDI group than in the CHF 1535 pMDI group (38.9 vs. 28.8).

In study TRIPLE 6, there were 30 events of treatment-emergent pneumonias (including PTs of pneumonia, bronchopneumonia, lobar pneumonia and interstitial lung disease) reported in 28 (2.6%) patients in the CHF 5993 pMDI group, 20 events reported in 19 (1.8%) patients in the Tiotropium group and 13 events reported in  12  (2.2%)  patients  in  the  Foster  pMDI  +  Tiotropium  group.  None  were  considered  treatment-related. Serious pneumonias were experienced by 21 (1.9%) patients reported with 21 events in the CHF 5993 pMDI group, 14 (1.3%) patients reported with 15 events in the Tiotropium group and 9 (1.7%) patients reported with  10  events  in  the  CHF  1535  pMDI  +  Tiotropium  group.  One  event  of  pneumonia  led  to  study  drug discontinuation  in  1  (0.1%)  patient  in  the  CHF  5993  pMDI  group,  4  events  in  4  (0.4%)  patients  in  the Tiotropium group and 1 event in 1 (0.2%) patient in the Foster pMDI + Tiotropium group. All these events of pneumonia that led to study drug discontinuation also led to death. As expected, the pneumonia rate per 1,000 patients per year was lower in the Tiotropium group (20.5) than in the CHF 5993 pMDI group (29.2) or the Foster pMDI + Tiotropium group (25.2).

## Lower Respiratory Tract Infections (LRTI) other than pneumonia

In study TRIPLE 5 the most common LRTI were viral related. These infections may be associated with chronic use of ICS, however, they were observed only in 16 (2.3%) and 10 (1.5%) patients in the CHF 5993 and Foster  pMDI group respectively with only slight differences between treatments that are considered to be non-clinically significant.

In study TRIPLE 6 as well the most common LRTI were viral related with events observed in 15 (1.4%), 15 (1.4%), and 13 (2.4%) patients in the CHF 5993 pMDI, Tiotropium, and Foster pMDI + Tiotropium group respectively.

## Candidiasis

In study TRIPLE 5 a higher percentage of patients in the CHF 5993 pMDI group experienced an event (PT laryngitis fungal, oesophageal candidiasis, oral candidiasis, oral fungal infection and oropharyngeal candidiasis) compared to the Foster pMDI group (2.3% vs. 0.7% respectively).  In study TRIPLE 6 on the other  hand,  less  than  1%  of  patients  overall  experienced  an  event  (PT  candidiasis,  laryngitis  fungal,  oral candidiasis,  oral  fungal  infection  and  oropharyngeal  candidiasis),  with  a  comparable  distribution  among treatments.

## Major Adverse Cardiovascular Events

In studies TRIPLE 5 and TRIPLE 6, a central Adjudication Committee composed of physicians with expertise in the  field  of  cardiology  was  established  in  order  to  perform  careful  and  unbiased  scrutiny  of  potentially relevant adverse events and to perform an evaluation of MACE.

<div style=\"page-break-after: always\"></div>

In  study  TRIPLE  5,  treatment-emergent  MACEs  were  reported  in  15  (2.2%)  patients  in  both  treatment groups. Most of these events were heart failures (6 [0.9%] and 3 [0.4%] patients in the CHF 5993 pMDI and Foster  pMDI  groups,  respectively)  and  acute  myocardial  infarctions  (1  [0.1%]  and  6  [0.9%]  patients, respectively). The MACE rate per 1,000 patients per year was similar in both treatment groups (24.9 and 25.6 in the CHF 5993 pMDI and Foster pMDI groups, respectively).

There was, however, a higher rate of treatment-emergent MACEs in patients using a spacer. The MACE rate per 1,000 patients per year was higher in the CHF 5993 pMDI group than in the CHF 1535 pMDI group for patients using a spacer (81.5 vs. 41.7) while it was slightly lower in the CHF 5993 pMDI group for patients not using a spacer (14.7 vs. 21.8). However, patients using a spacer were older, with a higher prevalence of concomitant  diseases  (in  particular  cardiac  disorders)  and  with  a  more  severe  disease  (in  terms  of exacerbation history, airflow limitation and health related quality of life) than patients not using a spacer.

In study TRIPLE 6, there were 20 events of treatment-emergent MACEs reported in 20 (1.9%) patients in the CHF  5993  pMDI  group,  23  events  reported  in  23  (2.1%)  patients  in  the  Tiotropium  group  and  7  events reported in 7 (1.3%) patients in the Foster pMDI + Tiotropium group. In the CHF 5993 pMDI group, most of these  events  were  either  stroke  (9  [0.8%]  patients),  or  cardiovascular  death  (8  [0.7%]  patients)  and  10 events of treatment-emergent MACEs were fatal. In the Tiotropium group they were either heart failure (8 [0.7%] patients) or cardiovascular death (6 [0.6%] patients) and 12 events of treatment-emergent MACEs were fatal. In the Foster pMDI + Tiotropium group, they were either cardiovascular death, heart failure or stroke  (reported  in  2  [0.4%]  patients  each)  and  2  events  of  treatment-emergent  MACEs  were  fatal.  The MACE rate per 1,000 patients per year was slightly higher in the Tiotropium group (23.5) than in the CHF 5993 pMDI group (19.5) and the Foster pMDI + Tiotropium group (13.6).

In patients using a spacer, no treatment-emergent MACEs were reported in the Foster pMDI + Tiotropium group. The rate was higher in the Tiotropium group (31.6) than in the CHF 5993 pMDI group (20.6).

## Other significant cardiovascular events

In  study  TRIPLE  5  a  similar  percentage  of  patients  in  the  CHF  5993  pMDI  group  experienced  any cardiovascular  event  compared  to  the  Foster  pMDI  group  (11.5%  vs  11.2%  respectively).  A  rather  low number of conduction defects (which represent a typical effect associated mainly with LABA and a key safety concern) was observed overall, with only two events of QT prolongation in the CHF 5993 group (one of which was  assessed  as  drug  related)  as  opposed  to  none  in  the  CHF1535  pMDI  group.  The  absence  of  any treatment-related trend was confirmed also in study TRIPLE 6 where the percentage of patients experiencing any cardiovascular event was equally distributed among treatments (9.7%, 10.1% and 10.4% with CHF 5993 pMDI,  Tiotropium  and  Foster  pMDI  +  Tiotropium  respectively).  Notably,  in  this  study  no  events  of  QT prolongation were observed in the CHF5993 pMDI group as well as in the Foster pMDI + Tiotropium group, whereas two events were observed in the Tiotropium only group.

## Vital Signs

In study TRIPLE 5, the mean changes in pre-dose and 10-minute post-dose SBP and DBP were minimal and similar in both treatment groups.

In study TRIPLE 6, the mean changes in pre-dose and 10-minute post-dose SBP and DBP were minimal and similar  in  all  the  treatment  groups.  Serious  TEAEs  of  hypertension  (1  TEAE  in  1  [0.1%]  patient)  and hypertensive crisis (2 TEAEs in 2 [0.2%] patients) were reported with CHF 5993. Of these TEAEs, 1 event (PT: hypertensive crisis) in 1 (0.1%) patient led to study medication discontinuation. All of these TEAEs were moderate in severity and had resolved by the end of the study.

<div style=\"page-break-after: always\"></div>

## Tremor

In study TRIPLE 5 only one event of tremor was observed in the Foster pMDI group and none in the CHF 5993 pMDI group, whereas in study TRIPLE 6 one event was observed in the Tiotropium group, one in the Foster pMDI + Tiotropium group and none in the CHF 5993 pMDI group.

## Muscle spasms

In study TRIPLE 5, 1.2 % of patients in the CHF 5993 pMDI group experienced an event compared to 0.6% in the Foster pMDI group.

In study TRIPLE 6 less than 1% of patients overall had an event with a comparable distribution between the CHF 5993 pMDI and the Foster pMDI + Tiotropium group, whereas a lower percentage of patients in the Tiotropium group experienced an event.

## Urinary retention

In study TRIPLE 5 urinary retention and associated events were observed in less than 1% in the CHF 5993 pMDI and Foster pMDI groups. In study TRIPLE 6 one event was observed in the CHF 5993 pMDI group while no events were observed in the Tiotropium and Foster pMDI + Tiotropium group.

## Ocular effects

In  study  TRIPLE  5  ocular  effects  were  rather  few  and  experienced  by  less  than  1%  of  all  patients  with  a higher incidence in the Foster pMDI group compared to CHF 5993 pMDI.

In  study  TRIPLE  6,  ocular  effects  were  observed  in  less  than  1%  of  all  patients  with  a  slightly  higher percentage  of  patients  experiencing  such  effects  in  the  Tiotropium  and  Foster  pMDI  +  Tiotropium  group compared to the CHF 5993 pMDI group.

## Dry mouth

In both studies, dry mouth was experienced by less than 1% of patients in the CHF 5993 group without any notable difference in the distribution among treatment groups.

## Constipation

In both studies, a rather small number of events were observed with an equal distribution among treatments and affecting less than 1% of patients overall.

## Serious adverse events and deaths

In  study TRIPLE 5, here were 15 TEAEs leading to death reported in 15 (2.2%) patients in the CHF 5993 pMDI group and 17 TEAEs leading to death reported in 16 (2.4%) patients in the Foster pMDI group. No consistent patterns or imbalances were noted across treatment groups when examining the primary causes of  death.  The  most common TEAEs leading to death were from the Cardiac Disorders SOC, with 5 events reported in 5 (0.7%) patients in the CHF 5993 pMDI group and 7 events reported in 7 (1.0%) patients in the Foster pMDI group. COPD exacerbation led to death in 2 (0.3%) patients in the CHF 5993 pMDI group and in 4  (0.6%)  patients  in  the  CHF  1535  pMDI  group.  Cardiac  disorders  and  COPD  exacerbation  are  categories expected in patients with severe and very severe COPD.

There  were  180  serious  TEAEs  reported  in  106  (15.4%)  patients  in  the  CHF  5993  pMDI  group  and  162 serious TEAEs reported in 123 (18.1%) patients in the Foster pMDI group. Consistent with the population

<div style=\"page-break-after: always\"></div>

under investigation, the most frequently observed SAEs were COPD exacerbation and Pneumonia. There was only one serious treatment-emergent ADR of atrial fibrillation (AF) reported in 1 (0.1%) patient in the CHF 5993 pMDI group, which was also the only ADR considered severe. This event resolved in 15 days and did not cause study drug discontinuation.

In study TRIPLE 6, there were 23 TEAEs leading to death reported in 20 (1.9%) patients in the CHF 5993 pMDI group, 35 TEAEs leading to death reported in 29 (2.7%) patients in the Tiotropium group and 8 TEAEs leading to death reported in 8 (1.5%) patients in the Foster pMDI + Tiotropium group. No consistent patterns or imbalances were noted across treatment groups when examining the primary causes of death. The most common TEAEs leading to death were from the Cardiac Disorders SOC, with 9 events reported in 8 (0.7%) patients in the CHF 5993 pMDI group, 15 events reported in 14 (1.3%) patients in the Tiotropium group and 2 events reported in 2 (0.4%) patients in the Foster pMDI + Tiotropium group. COPD exacerbation led to death in 5 (0.5%) patients in the CHF 5993 pMDI group, 4 (0.4%) patients in the Tiotropium group and 1 (0.2%) patient in  the  CHF  1535  pMDI  +  Tiotropium  group.  Cardiac  disorders  and  COPD  exacerbation  are categories expected in patients with severe and very severe COPD.

There were 201 serious TEAEs reported in 140 (13.0%) patients in the CHF 5993 pMDI group, 230 serious TEAEs  reported  in  164  (15.2%)  patients  in  the  Tiotropium  group  and  88  serious  TEAEs  reported  in  68 (12.7%)  patients  in  the  CHF  1535  pMDI  +  Tiotropium  group.  Consistent  with  the  population  under investigation, the most frequently observed SAEs were COPD exacerbation and Pneumonia. There was only one  serious  treatment-emergent  ADR  of  angina  pectoris,  reported  in  1  (0.1%)  patient  in  the  Tiotropium group.

## Laboratory findings

In both pivotal studies, the majority of patients did not show changes of clinical concern in terms of changes in haematology and biochemistry parameters.

## Safety in special populations

Table 21 TEAEs stratified by age group in patients treated with CHF 5993 pMDI, Safety population - Studies Triple 5 and Triple 6 (integrated analysis)

| TEAEs                                              | Age <65 years (N=984)   | Age 65-74 years (N=601)   | Age 75-84 years (N=176)   | Age 85+ years (N=3)   |
|----------------------------------------------------|-------------------------|---------------------------|---------------------------|-----------------------|
| Total AEs                                          | 523 (53.2%)             | 338 (56.2%)               | 100 (56.8%)               | 1 (33.3%)             |
| Serious AEs - Total                                | 122 (12.4%)             | 100 (16.6%)               | 24 (13.6%)                | 0 (0.0%)              |
| - Fatal                                            | 17 (1.7%)               | 16 (2.7%)                 | 2 (1.1%)                  | 0 (0.0%)              |
| - Hospitalization/prolong existing hospitalization | 113 (11.5%)             | 91 (15.1%)                | 23 (13.1%)                | 0 (0.0%)              |
| - Life-threatening                                 | 9 (0.9%)                | 8 (1.3%)                  | 3 (1.7%)                  | 0 (0.0%)              |
| - Disability/incapacity                            | 2 (0.2%)                | 6 (1.0%)                  | 1 (0.6%)                  | 0 (0.0%)              |
| - Other (medically significant)                    | 14 (1.4%)               | 18 (3.0%)                 | 4 (2.3%)                  | 0 (0.0%)              |
| AEs leading to drop-out                            | 26 (2.6%)               | 36 (6.0%)                 | 6 (3.4%)                  | 0 (0.0%)              |
| Psychiatric disorders                              | 8 (0.8%)                | 6 (1.0%)                  | 3 (1.7%)                  | 0 (0.0%)              |

<div style=\"page-break-after: always\"></div>

| Nervous system disorders                                                              | 46 (4.7%)   | 40 (6.7%)   | 14 (8.0%)   | 0 (0.0%)   |
|---------------------------------------------------------------------------------------|-------------|-------------|-------------|------------|
| Accidents and injuries                                                                | 16 (1.6%)   | 17 (2.8%)   | 2 (1.1%)    | 0 (0.0%)   |
| Cardiac disorders                                                                     | 51 (5.2%)   | 47 (7.8%)   | 10 (5.7%)   | 0 (0.0%)   |
| Vascular disorders                                                                    | 40 (4.1%)   | 37 (6.2%)   | 6 (3.4%)    | 0 (0.0%)   |
| Cerebrovascular disorders                                                             | 5 (0.5%)    | 13 (2.2%)   | 1 (0.6%)    | 0 (0.0%)   |
| Infections and infestations                                                           | 179 (18.2%) | 114 (19.0%) | 23 (13.1%)  | 1 (33.3%)  |
| Anticholinergic syndrome                                                              | 16 (1.6%)   | 15 (2.5%)   | 5 (2.8%)    | 0 (0.0%)   |
| Quality of life decreased (PT)                                                        | 0 (0.0%)    | 0 (0.0%)    | 0 (0.0%)    | 0 (0.0%)   |
| Quality of life decreased (selection of PTs)                                          | 26 (2.6%)   | 22 (3.7%)   | 7 (4.0%)    | 0 (0.0%)   |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 20 (2.0%)   | 25 (4.2%)   | 1 (0.6%)    | 0 (0.0%)   |
| Pneumonias                                                                            | 27 (2.7%)   | 20 (3.3%)   | 4 (2.3%)    | 0 (0.0%)   |

Number and percentage of patients with at least one TEAE are presented.

No clear signal of an increased risk with increasing age was found for any of the TEAEs, except for a slightly higher  incidence of  nervous  system  disorders  in  older  patients.  However,  the  majority  of  events  classified under this SOC is represented by headaches. When excluding headaches from the analysis, no clear trend in the  incidence  of  nervous  system  disorders  by  age  is  found  (age  &lt;65  years:  1.7%,  65-74:  4.2%,  75-84: 2.8%, 85+: no events).

## Immunological events

In both pivotal studies, the frequencies for hypersensitivity PV endpoints were low and comparable between treatments.

## Safety related to drug-drug interactions and other interactions

Study TRIPLE 12 was designed as a drug-drug interaction (DDI) study to investigate the effect of cimetidine on the PK profile of CHF 5993 25 µg. PK changes observed in the study did not indicate any clinically relevant DDI.

## Discontinuation due to AES

In study TRIPLE 5, there were 43 and 35 TEAEs leading to study drug discontinuation reported in 35 (5.1%) patients  and  33  (4.9%)  patients  in  the  CHF  5993  pMDI  and  CHF  1535  pMDI  groups,  respectively.  Those reported in &gt;2 patients in either treatment group were COPD exacerbation (5 [0.7%] and 8 [1.2%] patients in the CHF 5993 pMDI and CHF 1535 pMDI groups, respectively) and lung neoplasm malignant (4 [0.6%] and 1 [0.1%] patients in the CHF 5993 pMDI and CHF 1535 pMDI groups, respectively). Overall, the incidences of the treatment discontinuations are balanced across the different treatment groups.

In study TRIPLE 6, there were 41 TEAEs leading to study drug discontinuation reported in 33 (3.1%) patients in the CHF 5993 pMDI group, 71 TEAEs leading to study drug discontinuation reported in 62 (5.8%) patients

<div style=\"page-break-after: always\"></div>

in the Tiotropium group and 15 TEAEs leading to study drug discontinuation reported in 15 (2.8%) patients in the CHF 1535 pMDI + Tiotropium group. Those reported in more than 2 patients in any treatment group were COPD exacerbation, pneumonia, cardiac failure and dyspnoea.

## 2.6.1. Discussion on clinical safety

From the safety database all the adverse reactions reported in clinical trials and post-marketing with the individual components have been included in the Summary of Product Characteristics.

Evaluation of safety in the present application is difficult due to the nature of the study population who were frail, old, with advanced lung disease and often with other significant health and probably social problems.

## Study TRIPLE 5

A similar proportion of patients had treatment-emergent adverse events in the two groups. Most events were mild or moderate in severity. One treatment-related serious adverse event occurred (atrial fibrillation) in a patient in the CHF 5993 group. This event resolved in 15 days and did not cause study drug discontinuation. Treatment-emergent adverse events resulted in death in a similar percentage of patients in the two groups. None of the deaths were assessed to be related to the study treatment.

Mean changes from baseline in blood pressure, heart rate, and Fridericia's corrected QT (QTcF) interval were small and similar in the two groups. The percentages of abnormal QTcF interval absolute values and changes were similar in both treatment groups. In the subgroup of patients with Holter assessments, changes from baseline in 24 h average heart rate to weeks 26 and 52 were minimum and similar in both groups.

Only few patients had pneumonia (about 3%), an event that has been associated with inhaled corticosteroid use in COPD.

None  of  the  subgroup  analyses  (by  age,  cardiovascular  comorbidities,  gender)  highlighted relevant differences in the safety profiles compared with the overall Safety population.

## Study TRIPLE 6

A similar  proportion  of  patients  had  treatment-emergent  adverse  events in  the  three groups.  Most  events were  mild  or  moderate  in  severity.  Treatment-emergent  adverse  events  resulted  in  death  in  a  similar percentage of patients in the three groups. The most common TEAEs leading to death were from the Cardiac Disorders SOC and COPD exacerbation. Both categories are expected in patients with severe and very severe COPD. There was only one serious treatment-emergent ADR of angina pectoris, reported in 1 (0.1%) patient in the Tiotropium group.

Mean changes from baseline in blood pressure, heart rate, and Fridericia's corrected QT (QTcF) interval were small and similar in the three groups.

Only few patients had pneumonia (&lt; 3%), an event that has been associated with inhaled corticosteroid use in COPD. As expected, the pneumonia rate per 1,000 patients per year was lower in the Tiotropium group (20.5) than in the CHF 5993 pMDI group (29.2) or the Foster pMDI + Tiotropium group (25.2).

None of the subgroup analyses (by age, cardiovascular comorbidities, spacer, gender, renal impairment and hepatic impairment) highlighted relevant differences in the safety profiles compared with the overall Safety population.

<div style=\"page-break-after: always\"></div>

In general, in studies TRIPLE 5 and TRIPLE 6 the incidence of pneumonia in the CHF 5993 pMDI group was low and similar to that observed with other non-ICS containing treatments in other recent clinical trials in comparable populations of COPD patients.

## Summary of Product Characteristics

All ADRs reported with CHF 5993 in studies TRIPLE 5 and TRIPLE 6 and those observed in studies TRIPLE 3 and CARSAF with Foster + GB define the safety profile of CHF 5993 and are included in the proposed SmPC, with the exception of benign prostatic hyperplasia, which was observed in a single patient in study TRIPLE 6 and was evaluated as not reasonably explicable by the known pharmacological properties of the product.

For the purpose of compiling the tabulated safety summary in Section 4.8 of the SmPC, the frequency for each of the observed ADRs was calculated based on the overall Safety population (i.e. 2,004 patients treated with the proposed therapeutic dose) in the studies mentioned above. For ADRs which were also observed in the clinical experience with Foster, the assigned frequency is the highest between the one observed in the clinical experience with CHF 5993 pMDI and the one reported in the approved SmPC for Foster. Additional ADRs reported in the Foster SmPC but not observed with CHF 5993 have been included with their respective frequency and were selected based on the known pharmacological properties of the individual components and  the  10-year  post-marketing  experience  with  the  product.  Moreover,  additional  ADRs  reported  in approved SmPC for glycopyrronium single agent were also added.

## 2.6.2. Conclusions on the clinical safety

From the safety data presented there are no particular safety signals that suggest an additive effect when FF and  GB  are  administered  together.  The  main  side  effects  that  have  been  observed  with  CHF  5993  are associated with the known ICS, LAMA and LABA effects. The clinical database is acceptable and considered sufficient.

The clinical safety sections of the SmPC contain appropriate information for each substance and reflect the safety information on the FDC.

## 2.7. Risk Management Plan

Table 22 Summary of the Safety Concerns

| Important Identified Risks   | - Electrocardiogram QT prolonged, tachycardia, tachyarrhythmia - Atrial fibrillation - Increased risk of pneumonia in COPD patients - Risk of increased systemic exposure of Glycopyrronium bromide at therapeutic doses when used in patients with severe renal impairment   |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks    | - Cardio- and cerebrovascular events                                                                                                                                                                                                                                          |
| Missing information          | - Off label use in paediatric population in asthma indication - Use in patients with hepatic impairment - Use in pregnancy and lactation                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Not applicable

Table 23 Summary Table of the Risk Minimisation Measures

| Safety concern                                                                                                                        | Routine risk minimisation measures                            | Additional minimisation measures   | risk   |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|------------------------------------|--------|
| Important Identified Risks                                                                                                            |                                                               |                                    |        |
| Electrocardiogram QT prolonged, tachycardia, tachyarrhythmia                                                                          | Text in SmPC section 4.4, 4.5, 4.8 Prescription only medicine | None                               |        |
| Atrial fibrillation                                                                                                                   | Text in SmPC section 4.4, 4.8 Prescription only medicine      | None                               |        |
| Increased risk of pneumonia in COPD patients                                                                                          | Text in SmPC section 4.4, 4.8 Prescription only medicine      | None                               |        |
| Risk of increased systemic exposure of Glycopyrronium bromide at therapeutic doses when used in patients with severe renal impairment | Text in SmPC section 4.2, 4.4, 5.2 Prescription only medicine | None                               |        |
| Important Potential Risks                                                                                                             |                                                               |                                    |        |
| Cardio-and cerebrovascular events                                                                                                     | Text in SmPC section 4.4, 4.8 Prescription only medicine      | None                               |        |
| Missing Information                                                                                                                   |                                                               |                                    |        |
| Off label use in paediatric population in asthma indication                                                                           | Text in SmPC section 4.2, 5.1 Prescription only medicine      | None                               |        |
| Use in patients with hepatic impairment                                                                                               | Text in SmPC section 4.2, 4.4, 5.2 Prescription only medicine | None                               |        |
| Use in in pregnancy and lactation                                                                                                     | Text in SmPC section 4.6, 5.3 Prescription only medicine      | None                               |        |

## Conclusion

The  CHMP  and  PRAC  considered  that  the  risk  management  plan  version  4.0  (dated  17  May  2017)  is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

CHF  5993  pMDI  is  a  novel  triple  combination  of  an  ICS,  LABA  and  LAMA.  The  product  is  a  fixed  dose combination of BDP, FF and GB and formulated as a HFA solution to be delivered via a pMDI with a nominal dose per actuation of BDP, FF and GB of 100 µg, 6 µg and 12.5 µg, respectively.

The approved indication is:

Maintenance  treatment  in  adult  patients  with  moderate  to  severe  chronic  obstructive  pulmonary  disease (COPD)  who  are  not  adequately  treated  by  a  combination  of  an  inhaled  corticosteroid  and  a  long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

COPD  is  a  progressive  disease  characterised  by  increasing  obstruction  to  airflow  and  the  progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnoea and wheezing.  The  objective  of  pharmacological  treatment  of  is  to  prevent  and  control  symptoms,  reduce  the frequency and severity of exacerbations, and improve general health status and exercise tolerance.

Smoking cessation (including passive smoking) is extremely important. Ideally treatment of COPD would slow its progression but this has never been convincingly demonstrated. Long term domiciliary oxygen has been shown to prolong life but confines the patient to home for protracted periods. In recent years there has been increasing  emphasis  on  physical  training  and  rehabilitation.  Moderate  and  severe  COPD  exacerbations  are generally treated with antibiotics and oral corticosteroids. Maintenance treatment is by combinations of oral and inhaled bronchodilators and anti-inflammatory agents.

## 3.1.2. Available therapies and unmet medical need

Despite the availability of a multiplicity of pharmacological treatments none of them modifies the progress of the disease and none can be considered to have a really major benefit on its most common symptoms of cough, breathlessness, excess sputum production, and thoracic discomfort due to hyperinflation.

ICS/LABA  combination  products  are  considered  key  to  the  symptomatic  management  of  COPD.  The combination  has  been  shown  to  improve  lung  function,  health  status,  and  to  reduce  COPD  exacerbations compared with  either  agent  alone.  LAMAs  have  been  shown  to  improve  lung  function,  relieve  symptoms, increase exercise capacity, improve quality of life, and reduce COPD exacerbations to a greater extent than short-acting  bronchodilators.  As  disease  severity  increases,  COPD  treatment  guidelines  recommend  an

<div style=\"page-break-after: always\"></div>

incremental approach to pharmacological treatment, involving the use of combinations of drug classes with different or complementary mechanisms of action (GOLD 2016).

## 3.1.3. Main clinical studies

The clinical programme of CHF 5993 pMDI in COPD included three Phase II (studies GLYCO 2, TRIPLE 3 and CARSAF), one Phase IIb (study TRIPLE 9) and two Phase III clinical studies (studies TRIPLE 5 and TRIPLE 6). Studies GLYCO 2 and TRIPLE 3 were dose finding studies which assessed the efficacy and safety of different GB doses alone or in combination with BDP/FF. Study TRIPLE 9 further investigated the long-term efficacy and safety of GB in the target population at the selected dose. Studies TRIPLE 5 and TRIPLE 6 were pivotal efficacy and safety studies for the FDC. Study CARSAF focused on the cardiac safety of the combination of GB with BDP/FF, and also provided supportive efficacy data for the combination.

The  Phase  III  clinical  development  programme  in  COPD  included  two  52-week  active-controlled  studies. Study Triple 5 compared CHF 5993 pMDI 100/6/12.5 µg with a fixed combination of BDP and FF 100/6 µg (CHF 1535 pMDI) two inhalations twice daily. Study Triple 6 primarily compared CHF 5993 pMDI 100/6/12.5 µg with tiotropium 18 µg inhalation powder, hard capsule, one inhalation once daily. In addition, effects were compared with an open triple combination made of CHF 1535 pMDI 100/6 µg two inhalations twice daily plus tiotropium 18 µg inhalation powder, hard capsule, one inhalation once daily. Both studies were conducted in patients with a clinical diagnosis of COPD with severe to very severe airflow limitation (FEV1 less than 50% predicted), with symptoms assessed as a COPD Assessment Test (CAT) score of 10 or above, and with at least one COPD exacerbation in the 12 months prior to screening.

The primary objectives of study Triple 5 were to demonstrate the superiority of CHF 5993 pMDI over CHF 1535 pMDI in terms of lung function (change from baseline in pre-dose and 2-hour post-dose morning forced expiratory volume in the 1st second [FEV1] at Week 26) and to demonstrate the superiority of CHF 5993 pMDI over CHF 1535 pMDI in terms of dyspnoea (transition dyspnoea index [TDI] focal score at Week 26). The secondary objectives of this study were to evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient's health status, clinical outcome measures and COPD exacerbations.

The  primary  objective  of  study  Triple  6  was  to  demonstrate  the  superiority  of  CHF  5993  pMDI  over Tiotropium in terms of moderate and severe COPD exacerbation rate over 52 weeks of treatment. The key secondary objectives of the study were to demonstrate the superiority of CHF 5993 pMDI over Tiotropium and the non-inferiority  of  CHF  5993  pMDI  relative to  CHF  1535  pMDI  +Tiotropium  in  terms  of  pulmonary function (change from baseline in pre-dose morning forced expiratory volume in the 1st second [FEV1] at Week 52).

## 3.2. Favourable effects

In study TRIPLE 5, superiority of CHF 5993 over Foster in terms of change from baseline in pre-dose morning FEV1 at Week 26 was demonstrated, with an adjusted mean difference between treatments of 0.081 L (95% CI 0.052; 0.109) (p &lt; 0.001).

In addition, superiority of CHF 5993 over Foster in terms of change from baseline in 2-hour post-dose FEV1 at Week 26 was demonstrated, with an adjusted mean difference between treatments of 0.117 L (95% CI 0.086; 0.147) (p &lt; 0.001).

<div style=\"page-break-after: always\"></div>

The percentage of patients who had moderate-to severe exacerbations was lower with CHF 5993 (31%) than with Foster (35%). The adjusted annual rate of moderate-to-severe exacerbations was 0.41 for the CHF 5993 group and 0.53 for the Foster, group, with a rate ratio of 0.77 (95% CI 0.65-0.92; p=0.005), indicating a significant 23% reduction in the rate with CHF 5993. The observed 23% reduction in the exacerbation rate is above the minimum clinically important difference. Furthermore, CHF 5993 significantly prolonged the time to first  moderate-to-severe  exacerbation  compared  with  Foster  (hazard  ratio  0.80  [95%  CI  0.67-0.97]; p=0.020).

In  study  TRIPLE  6,  superiority  of  CHF  5993  pMDI  over  Tiotropium  was  demonstrated  in  terms  of  the moderate and severe COPD exacerbation rate over 52 weeks of treatment. The adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and the adjusted rate ratio was 0.801 (95% CI 0.693; 0.925; p=0.003). These results indicated a 20% reduction in the rate of moderate/severe COPD exacerbations with CHF 5993 pMDI compared to Tiotropium. A 20% reduction of rate of moderate/severe exacerbations is suggested to be minimal clinically important difference in COPD patients ( Calverley  PM  et  al.  2005 ).  Superiority  of  CHF  5993  pMDI  over  Tiotropium  in  terms  of  the  change  from baseline  in  pre-dose  morning  FEV1  at  Week  52  was  also  demonstrated  as  the  adjusted  mean  difference between  treatments  was  0.061  L  (95%  CI  0.037;  0.086;  p  &lt;  0.001).  Non-inferiority  of  CHF  5993  pMDI relative to Foster pMDI + Tiotropium was demonstrated as the adjusted mean difference between treatments was -0.003 L (95% CI -0.033; 0.027), with a lower confidence limit well above the pre-defined non-inferiority margin of -0.050 L.

## 3.3. Uncertainties and limitations about favourable effects

In  study  TRIPLE  5,  TDI  focal  score  improved  at  week  26  in  both  groups;  the  mean  difference  between treatments  (0.21  units  [95%  CI  -0.08  to  0.51])  was  not  statistically  significant.  According  to  the  prespecified success criterion study TRIPLE 5 failed due to the lack of a significant result for the third primary endpoint TDI focal score at Week 26, although a significant result was obtained in the other two primary endpoints, according to the pre-specified hierarchical procedure.

CHF 5993 pMDI does no modify the natural history of COPD nor does it have a mortality benefit however benefits on reduction of acute COPD exacerbations, on lung function, and on patient reported symptoms are evident.

## 3.4. Unfavourable effects

In  study  TRIPLE  5,  a  similar  proportion  of  patients  had  treatment-emergent  adverse  events  in  the  two groups.  Most  events  were  mild  or  moderate  in  severity.  Treatment-emergent  adverse  events  resulted  in death in a similar percentage of patients in the two groups.

Mean changes from baseline in blood pressure, heart rate, and Fridericia's corrected QT (QTcF) interval were small and similar in the two groups. The percentages of abnormal QTcF interval absolute values and changes were similar in both treatment groups. In the subgroup of patients with Holter assessments, changes from baseline in 24 h average heart rate to weeks 26 and 52 were minimum and similar in both groups.

Only few patients had pneumonia (about 3%), an event that has been associated with inhaled corticosteroid use in COPD.

<div style=\"page-break-after: always\"></div>

None  of  the  subgroup  analyses  (by  age,  cardiovascular  comorbidities,  gender)  highlighted relevant differences in the safety profiles compared with the overall Safety population.

In study TRIPLE 6, also a similar proportion of patients had treatment-emergent adverse events in the three groups.  Most  events  were  mild  or  moderate  in  severity.  Treatment-emergent  adverse  events  resulted  in death in a similar percentage of patients in the three groups. The most common TEAEs leading to death were from the Cardiac Disorders SOC and COPD exacerbation. Both categories are expected in patients with severe and very severe COPD. There was only one serious treatment-emergent ADR of angina pectoris, reported in 1 (0.1%) patient in the Tiotropium group.

Mean changes from baseline in blood pressure, heart rate, and Fridericia's corrected QT (QTcF) interval were small and similar in the three groups.

Only few patients had pneumonia (&lt; 3%), an event that has been associated with inhaled corticosteroid use in COPD. As expected, the pneumonia rate per 1,000 patients per year was lower in the Tiotropium group (20.5) than in the CHF 5993 pMDI group (29.2) or the Foster pMDI + Tiotropium group (25.2).

None of the subgroup analyses (by age, cardiovascular comorbidities, spacer, gender, renal impairment and hepatic impairment) highlighted relevant differences in the safety profiles compared with the overall Safety population.

The safety profile of the dual FDC Foster pMDI has been previously well characterised and are well known. Regarding the safety of the triple FDC there is no evidence of an additive effect when the GB and Foster are administered  together.  There  is  also  no  evidence  that  the  safety  of  the  triple  FDC  is  worse  than  that  of Tiotropium or Foster plus Tiotropium.

Overall,  the  AE  profile  of  CHF  5993  is  well  understood;  none  of  the  active  substances  is  a  new  active substance and all have been used over periods of at least years individually and in combination in treating COPD patients of various grades of severity. In the present application, 2301 patients have been treated with the triple combination (counting the free and fixed combinations) many of them for 52 weeks. There are no evident new safety signals and the treatment associated unwanted effects are of a frequency and nature to be expected given the nature of the clinical development.

## 3.5. Uncertainties and limitations about unfavourable effects

There are no remaining uncertainties and limitations that have an impact on the benefit-risk balance (see section 3.7. Benefit-risk assessment and discussion.

## 3.6. Effects Table

<div style=\"page-break-after: always\"></div>

Table 24 Effects Table for TRIMBOW, COPD

| Effect                  | Short Description                                                     | Uni t                | CHF 5993 pMDI        | Control                  |                        | Uncertainties/ Strength of evidence                                                                                                                                                                   | Reference s                                                      |
|-------------------------|-----------------------------------------------------------------------|----------------------|----------------------|--------------------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Favourable Effects      | Favourable Effects                                                    | Favourable Effects   | Favourable Effects   | Favourable Effects       | Favourable Effects     | Favourable Effects                                                                                                                                                                                    | Favourable Effects                                               |
| Pre-dose FEV1           | Change from baseline in pre- dose morning FEV1 at Week 26             | L                    | 0.082 (0.062; 0.102) | 0.001 (- 0.019; 0.021) a |                        | Adjusted mean difference 0.081 (95% CI 0.052; 0.109), p-value ˂ 0.001                                                                                                                                 | (1), considered to be a meaningful benefit for this COPD group D |
| Pre-dose FEV1           | Change from baseline in pre- dose morning FEV1 at Week 52             |                      | 0.082 (0.065; 0.100) | 0.021 (0.003; 0.039) b   | 0.085 (0.061; 0.110) c | CHF 5993 vs. Tiotropium: Adjusted mean difference 0.061 (95% CI 0.037; 0.86), p-value ˂ 0.001 CHF 5993 vs. Foster + Tiotropium: Adjusted mean difference -0.003 (95% CI -0.033; 0.027), p-value=0.852 | (2)                                                              |
| 2-hour post-dose FEV1   | Change from baseline in 2- hour post-dose FEV1 at Week 26             | L                    | 0.261 (0.240; 0.283) | 0.145 (0.123; 0.166) a   |                        | Adjusted mean difference (95% CI) 0.117 (0.086; 0.147), p-value ˂ 0.001                                                                                                                               | (1)                                                              |
| TDI                     | TDI focal score at Week 26                                            |                      | 1.71 (1.50; 1.92)    | 1.50 (1.29; 1.71) a      |                        | Adjusted mean difference (95% CI) 0.21 (-0.08; 0.51), p-value = 0.160                                                                                                                                 | (1), TDI fail to show statistically significant benefit          |
| COPD exacerbati on rate | Moderate and severe COPD exacerbation rate over 52 weeks of treatment | (3)                  | 0.410                | 0.530 a                  |                        | Adjusted rate ratio 0.773 (95% CI 0.647; 0.924), p- value = 0.005                                                                                                                                     | (1), rate reduction (23%) is above the MCID                      |
| COPD exacerbati on rate | Moderate and severe COPD exacerbation rate over 52 weeks of treatment |                      | 0.457                | 0.571 b                  | 0.452 c                | CHF 5993 vs. Tiotropium: Adjusted rate ratio 0.801 (95% CI 0.693; 0.925), p-value = 0.003                                                                                                             | (2) rate reduction (20%) is equally to the MCDI                  |
| Unfavourable Effects    | Unfavourable Effects                                                  | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects     | Unfavourable Effects   | Unfavourable Effects                                                                                                                                                                                  | Unfavourable Effects                                             |
| Pneumonia               | pneumonia rate per 1,000 patients per                                 |                      | 38.9                 | 28.8 a                   |                        | ICS-containing treatments are known to increase                                                                                                                                                       | (1)                                                              |
| Pneumonia               | year                                                                  |                      | 29.2                 | 20.5 b                   | 25.2 c                 | the risk of pneumonia in COPD patients.                                                                                                                                                               | (2)                                                              |
| MACE                    | MACE rate per 1,000 patients per year                                 |                      | 24.9                 | 25.6 a                   |                        | There is no evidence of an additive effect when FF and GB are administered together.                                                                                                                  | (1)                                                              |
| MACE                    | MACE rate per 1,000 patients per year                                 |                      | 19.5                 | 23.5 b                   | 13.6 c                 | Slightly higher rate in the Tiotropium group                                                                                                                                                          | (2)                                                              |

<div style=\"page-break-after: always\"></div>

| Class effects of ICS/LABA/L AMA   | Muscle spasms, dry mouth, oral candidiasis, dysphonia, headache, oropharyngeal pain, sinus tachycardia   | Eve nt rate   | The incidence of these treatment emergent adverse events never exceeded 3.8% across treatment arms. No particular pattern or concern emerges with respect to CHF 5993   | (1) (2)   |
|-----------------------------------|----------------------------------------------------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|

Notes: (1) Study TRIPLE 5, (2) Study TRIPLE 6, (3) Exacerbation Rate per Patient per Year a) Foster pMDI; b) Tiotropium; c) Foster plus Tiotropium

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The  triple  combination  product  has  demonstrated  a  statistically  significant  effect  on  the  lung  function parameter pre-dose morning FEV1 (adjusted mean difference 0.081, 95% CI 0.052; 0.109, p-value ˂ 0.001) and  2-hour  post-dose  FEV1  (adjusted  mean  difference  0.117,  95%  CI  0.086;  0.147,  p-value ˂ 0.001)  at week 26 when compared to Foster (study TRIPLE 5). The difference between treatments in the TDI focal score  at  Week  26  did  not  reach  statistical  significance:  the  adjusted  mean  difference  (95%  CI)  between treatments was 0.21 (-0.08; 0.51) (p=0.160).

Although there is no consensus statement on what constitutes a minimally important difference for pre-dose FEV1  for  subjects  with  airflow  obstruction,  some  published  literature  suggests  a  threshold  of  100mL  for clinical  trials  ( Donohue  JF  2005 )  may  be  appropriate,  or  that  changes  of  5-10%  from  baseline  can  be considered  clinically  meaningful  as  well  ( Cazzola  M  et  al.  2008 ).  The  literature  also  acknowledges  that  a threshold for meaningful change is more meaningful for severe and very severe patients than for patients with  mild  to  moderate  disease.  Considering  the  severity  of  the  target  population,  an  improvement  over baseline in pre-dose FEV1 of 81ml for CHF 5993 pMDI compared to Foster is considered to be a meaningful benefit for this more severe COPD group.

A decreased risk of moderate and severe exacerbation considered clinically meaningful was observed at week 52. The percentage of patients who had moderate and severe exacerbations was lower with CHF 5993 (31%) than with Foster (35%). The adjusted annual rate of moderate and severe exacerbations was 0.41 for the CHF 5993 group and 0.53 for the Foster, group, with a rate ratio of 0.77 (95% CI 0.65-0.92; p=0.005), indicating a significant 23% reduction in the rate with CHF 5993.

The triple combination product has also demonstrated superiority over Tiotropium in terms of the moderate and  severe  COPD  exacerbation  rate  over  52  weeks  of  treatment  (primary  endpoint).  The  adjusted exacerbation rate per patient per year was lower with CHF 5993 pMDI (0.457) than with Tiotropium (0.571), and  the  adjusted  rate  ratio  was  0.801  (95%  CI  0.693;  0.925;  p=0.003).  These  results  indicated  a  20% reduction in the rate of moderate/severe COPD exacerbations with CHF 5993 pMDI compared to Tiotropium.

Superiority of CHF 5993 pMDI over Tiotropium in terms of the change from baseline in pre-dose morning FEV1  at  Week  52  (key  secondary  endpoint)  was  demonstrated  as  the  adjusted  mean  difference  between treatments was 0.061 L (95% CI 0.037; 0.086; p &lt; 0.001). Non-inferiority of CHF 5993 pMDI relative to CHF 1535 pMDI + Tiotropium was also demonstrated as the adjusted mean difference between treatments was -

<div style=\"page-break-after: always\"></div>

0.003  L  (95%  CI  -0.033;  0.027),  with  a  lower  confidence  limit  well  above  the  pre-defined  non-inferiority margin of -0.050 L.

The safety profile of the dual FDC Foster pMDI has been previously well characterised and are well known. The most frequently reported adverse reactions with CHF 5993 were oral candidiasis (which occurred in 0.5% of the exposed subjects), which is normally associated with inhaled corticosteroids; muscle spasms (0.6%), which  can  be  attributed  to  the  long-acting  beta2-agonist  component;  and  dry  mouth  (0.5%),  which  is  a typical anticholinergic effect.

ICS-containing treatments are known to increase the risk of pneumonia in COPD patients. This signal was first identified in the TORCH study (Calverley et al 2007). This was a large clinical study of 3 years treatment duration comparing the fluticasone propionate/salmeterol combination with its component parts and placebo in COPD patients. This study was assessed in 2010 for review of the risk of pneumonia in COPD patients by the CHMP Pharmacovigilance Working Party that concluded that the treatment with an ICS, either alone or in combination with a LABA, increases the risk of pneumonia in COPD patients. On 27 April 2015 the European Commission triggered a referral under Article 31 of Directive 2001/83/EC to assess the benefit-risk balance of ICS containing medicinal products indicated in the treatment of COPD. The scientific outcome of the referral confirmed  the  risk  of  pneumonia  and  recommended  introducing  a  warning  in  section  4.4  for  all  ICScontaining  products  intended  for  use  in  COPD  patients.  This  has  been  implemented  for  Trimbow.  The incidence of pneumonia events observed with CHF 5993 in both pivotal studies was low and within the range reported in several previous reported ICS/LABA studies.

Cardiovascular AEs are considered additional important risk for the combination of a LABA and a LAMA. In study TRIPLE 5, the MACE rate per 1,000 patients per year was similar with both CHF 5993 pMDI and Foster pMDI. In study TRIPLE 6, the MACE rate per 1,000 patients per year was slightly higher with Tiotropium than with CHF 5993 pMDI and Foster pMDI + Tiotropium. Also, in other parameters (e.g. ECG, Heart rate, blood pressure) the changes were similar in the treatment groups.

Overall, there is also no evidence that the safety of the triple FDC is worse than that of Foster, Tiotropium or Foster plus Tiotropium.

## 3.7.2. Balance of benefits and risks

Reduction of acute COPD exacerbations is probably the most important benefit expected from pharmacological therapy. Patients experiencing  a  moderate to  severe  acute  exacerbation generally  do  not fully return to their status pre-exacerbation; and therefore exacerbations can be thought of as punctuating the  patient's  deterioration.  There  is  little  doubt  that  the  fixed  and  free  triple  combination  reduces exacerbations  to  a  greater  extent  than  the  fixed  dose  double  combination  and  both  to  approximately  the same extent which is helpful in validating the finding.

Lung function particularly FEV1 is considered an important prognostic factor and FEV1 can be considered the 'best understood' because it has been widely studied for several decades. It is considered to be a predictor of mortality on an epidemiological basis but, paradoxically, in clinical trials improvement in lung function does not reduce mortality (though the TORCH study came close). In the present development there is reasonable evidence that triple therapy is more beneficial on lung function than double therapy.

Symptomatic benefit is the most difficult to measure as it depends on an arbitrary scoring systems which must be validated against more objective measures in many clinical studies and over many years and is the most variable likely to 'fail' in studies but in the present development there is evidence of benefit of triple

<div style=\"page-break-after: always\"></div>

therapy as indicated by SGRQ total score and it reaches the threshold for clinical relevance which is generally considered to be a mean reduction of four or more points.

As regards safety, all-cause mortality in the integrated analysis ranged from 1.5% to 2.7% across treatment arms and mortality attributed to COPD from 0.2% to 0.6%. For reference, in the TORCH study where patients had a similar degree of baseline lung function impairment, the 52 week all-cause mortality rates in the triple therapy arm was approximately 3%.

The rate of pneumonia was probably within variability and the non-steroid tiotropium alone arm did not seem to have a convincing advantage in the rate of pneumonia; however the overall development was not powered to show that. The Applicant has taken the approach of presuming that CHF 5993 has a causal association with pneumonia in COPD patients.

The known class associated adverse events and serious adverse events of the active substances were of a frequency  and  nature  to  be  expected  and  can  all  be  considered  reversible  with  change  or  modification  of treatment.

## 3.7.3. Additional considerations on the benefit-risk balance

The CHMP discussed whether to replace 'maintenance treatment' by 'symptomatic treatment and prevention of  exacerbation'  would  be  considered  adequate.  It  was  the  CHMP  view  that  the  term  'maintenance treatment'  reflects  more  adequately  the  use  of  long-acting  therapies  in  COPD.  The  latter  part  of  the indication (who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist) reflects that there is currently no comparison with an authorised LAMA+LABA combination. The applicant agreed to amend the proposed indication in view of CHMP recommendation.

## 3.8. Conclusions

The overall B/R of Trimbow is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Trimbow is favourable in the following indication:

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

<div style=\"page-break-after: always\"></div>

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the  agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.